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Abstract
Since the first reports of cytogenetic abnormalities in ALL, repeated small and large 
scale studies have shown that cytogenetic abnormalities detected at presentation 
continue to be the most important predictor o f outcome in ALL, at presentation, on 
relapse and even in the context o f more intensive treatment modalities.
The accuracy of diagnosis is much improved by the additional application of 
molecular techniques including FISH, which is the technique I used to more 
accurately define the cytogenetic abnormalities in a series o f 176 adult patients with 
ALL.
I have studied the incidence of and clinical features associated with three important 
structural abnormalities, namely BCRJABL, MLL and ETV6/AML1 abnormalities, as 
well as alterations in chromosome number and showed that FISH with commercial 
probes provides a simple and accurate method for the detection of these 
abnormalities in presentation samples. FISH detected cytogenetically silent 
abnormalities in twenty-four of the 176 patients. In addition to the patients positive 
for rearranged genes, I uncovered a rare case o f Philadelphia negative BCR/ABL 
ALL with aberrant insertion ofABL  into a morphologically normal chromosome 9q.
I went on to study in detail twenty-nine cases with indeterminate cytogenetics, and 
was able to further characterize the karyotype in fifteen of these. I have shown the 
applicability o f sequential FISH a technique developed in our laboratory, in 
identifying underlying complex chromosomal abnormalities, even when metaphase 
number and morphology is very poor. In a number of cases the additional findings 
appear to influence clinical outcome.
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Finally by assessing the total cytogenetic information, as well as a number of clinical 
variables at presentation I developed a simple method of risk stratification for adult 
patients with ALL which distinguishes three subgroups, including a population 
accounting for 32% of 159 patients studied who appear to have significantly better 
outcomes when treated according to the UKALL XII protocol.
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Chapter I 
Introduction
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I: 1 Overview
Although a rare disease, acute lymphoblastic leukaemia (ALL) is still fatal within 
three years in over two thirds of adults presenting today (Wetzler 1999).
This is despite tremendous improvements in recent years in our understanding of the 
biology of the disease and the development of treatment protocols that offer cure 
rates in up to 70% of children with this disease (Hann 2000). The success story of 
treating children with ALL has not thus far been transported effectively to the older 
generation of patients.
Increasingly it is becoming recognised that individualised treatment protocols are 
necessary (Finiewicz and Larson 1999; Uckun 1999; Faderl 2000), which take into 
consideration a number of well defined prognostic factors in tailoring treatments for 
individual patients or patient groups with similar features. Novel methods of 
treatment are replacing the often-exhaustive three-year marathon of chemotherapy 
treatment that fails in so many adult patients.
It has been known for some time that one of the most significant predictors of 
outcome in ALL in both children and adults is the presence and type of 
chromosomal abnormalities within the leukaemic blasts at presentation, these 
provide a mode for prognostically classifying patients (Seeker-Walker 1978; 
Williams 1986; Pui 1987; Crist, W. 1990; Jackson 1990; Shurtleff 1995; Chessels 
1997; Heerema 1999), as well as forming the cornerstone for design of molecular 
studies into the pathogenesis of this most heterogeneous of malignant diseases.
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Chromosomal abnormalities can also provide unique markers for the malignant cell 
clones allowing the identification of residual disease, as well as relapse during 
follow up of these patients (Seeker-Walker 1989; Abshire 1992; Chucrallah 1995). 
Unfortunately the routine culture o f bone marrow cells from ALL patients at 
presentation does not always yield an informative cytogenetic result, with 8-45% of 
samples failing to provide any analysable metaphases (Fenaux 1989; Jackson 1990; 
Seeker-Walker 1990; Harris 1992; Schiffer 1992; Wetzler 1999), and others 
showing only normal metaphases. Thus there has been increasing emphasis in recent 
years on molecular techniques to complement cytogenetics in the diagnostic workup 
of these patients, both to detect known chromosomal markers of the disease and to 
search for new alterations that may be associated with subgroups with specific 
clinical or biological features.
The aim of this project was to evaluate the molecular technique of fluorescence in 
situ hybridisation (FISH) to complement conventional cytogenetic studies for 
improved analysis of adult patients presenting with ALL.
I: 2 Aims of the study
I: The aim o f this study was to develop a multiplex FISH protocol available for
the study o f all adult patients with ALL. To detect the currently known 
prognostically significant chromosomal abnormalities, and allow the study of 
individual cases in greater detail to accurately characterise ill defined karyotypes and 
reveal cryptic chromosomal rearrangements.
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The protocol included:
1. The use of specific probes to test for abnormalities associated with poor risk 
disease
a. BCR/ABL (breakpoint cluster region/Ableson) fusion resulting from 
t(9;22)(q34;ql 1), the best-described translocation in poor outcome adult 
ALL.
b. MLL (mixed lineage leukaemia / myeloid lymphoid leukaemia) gene 
rearrangement, including translocations and other abnormalities involving 
1 lq23, identifying another well-known poor risk group o f patients.
2. Specific probes to test for ETV6 (TEL)/AML 1 (ETS variant gene 6 /Acute myeloid 
leukaemia 1 gene) fusion resulting from cryptic translocation t( 12;21 )(p 13;q22). 
This recently described translocation appears to be associated with late relapse in 
children.
3. The use of centromere specific probes, in patients with failed cytogenetic results, 
or normal or ill-defined karyotypes to test for hidden numerical abnormalities. 
Hyperdiploidy (51-65) without t(9;22) is associated with an improved overall 
outcome, whereas hypodiploidy and triploidy/tetraploidy, although exceedingly rare, 
are associated with very poor outcome in adult ALL.
In addition to this combined approach of screening for specific gene rearrangements 
and numerical changes, in selected patients further FISH studies using chromosome 
painting probes were also undertaken to define karyotypic abnormalities and identify 
marker chromosomes.
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II: Compare the accuracy of FISH versus cytogenetics in defining chromosomal
abnormalities.
Ill: Evaluate accurate definition of karyotypes in terms of patients’ classification
into subgroups.
IV: To examine any associations between FISH /cytogenetic findings and patient
outcomes.
1 :3 Acute leukaemia epidem iology and aetiology
1:3:1 Definition
Leukaemias are a group of malignancies of immature haematopoietic cells. They 
arise following the somatic mutation in one single haematopoietic stem cell, the 
progeny of which form a clone of leukaemic cells.
At the time of diagnosis, the normal marrow population has usually been completely 
replaced by the leukaemic clone and there has been haematogenous dissemination to 
a variety of extramedullary sites.
Leukaemias are classified initially on the basis o f the rate of cell division and thus 
disease progression, into:
1 Acute leukaemia; which if untreated usually causes death in weeks or months. The 
diagnosis o f acute leukaemia requires that blasts constitute at least 30% of either 
total nucleated cells or non-erythroid cells in the bone marrow. This diagnostic 
criterion helps distinguish the acute leukaemias from both chronic forms of 
leukaemia and most lymphomas.
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2 Chronic leukaemia; which even without treatment may be asymptomatic for 
several months or years, and causes death in months or years.
I: 3:2 Aetiology o f leukaemia
Despite extensive research the aetiology of leukaemia is still largely unknown 
(Sandler 1992). There have been dramatic changes over time in leukaemia mortality 
and incidence. Mortality from leukaemia increased substantially between the 1920s 
and about 1960 (Sandler 1992; Miller 1993), probably due to the combined effect of 
the reduced incidences and improved survival rates o f other diseases, improvements 
in diagnostic accuracy of leukaemia, and possibly the effects o f some new 
environmental hazards. Since the mid-1970s, there has been an overall slight 
decrease in leukaemia incidence (Miller 1993).
A number of environmental agents have been implicated in the induction o f certain 
types of leukaemia. These include ionising radiation, chemical carcinogens (mainly 
alkylating agents used to treat other malignancies) and benzene (Sandler and 
Collman 1987). In addition, acute leukemia may develop due to host susceptibility in 
some genetic disorders including Down’s syndrome and ataxia telangiectasia (Pui 
1995; Takeuchi 1998). There is evidence that certain polymorphisms in 
methyltetrahydrofolate reductase [a gene involved in folate metabolism] may 
modulate the risk of developing ALL (Skibola 2002). Studies in twin have shown 
that childhood acute lymphoblastic leukaemia is frequently initiated by a 
chromosomal translocation event in utero followed by a postnatal promoter event 
(Weimels 1999). Acute leukaemias may also supervene as blast transformation in 
pre-existing myeloproliferative disorders.
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A/ Radiation
X-rays and other ionising rays were first identified as agents associated with the 
induction of leukaemia in the early cohorts of radiologists, and the survivors o f the 
atomic bomb explosions in Hiroshima and Nagasaki. People exposed at a younger 
age or closer to the hypocentre o f the bomb had shorter latent periods for the 
development of leukaemia. Acute myeloid leukaemia (AML) and chronic myeloid 
leukaemia (CML) were the predominant types although cases o f ALL were also 
reported. There are abundant case reports of patients treated with irradiation for 
other malignancies mainly Hodgkin’s disease and carcinoma of the breast, or benign 
conditions such as ankylosing spondylitis, developing leukaemia, mainly AML, but 
an increase in all leukaemia types except chronic lymphoid leukaemia (CLL) are 
generally reported following radiation exposure (Inskip 1993). Evidence for a 
leukaemogenic effect o f low dose irradiation e.g. exposure to diagnostic X-rays or 
radioisotopes at diagnostic levels has not been substantiated except in infants whose 
mothers were exposed to X-rays during pregnancy (Sandler 1992).
A number of surveys in the UK have suggested a clustering o f cases of childhood 
ALL in the vicinity of nuclear installations, these studies are difficult to interpret 
because of the small numbers of cases expected in these populations (Sandler 1992) 
and other studies demonstrated no increase in leukaemia incidence among nuclear 
workers (Jablon and Boice 1993).
The role o f non-ionising radiation especially electro-magnetic fields is also under 
debate. Not all studies in cohorts of workers exposed to electro-magnetic fields have 
demonstrated increased risk (Bates 1991; Sahl 1993). These studies also failed to
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isolate electro-magnetic fields as the causal agents, because the workers were often 
also exposed to solvents and other agents. Studies of residential exposure have 
suggested a possible leukaemia risk associated with electro-magnetic fields (Bates 
1991; Savitz 1993).
B/ Chemicals
Two types of chemicals are involved in leukamogenesis, benzene and other 
petroleum derivatives, and chemotherapeutic agents.
Benzene related haematological changes were described as early as 1897, and the 
first case of benzene-associated leukaemia was reported in 1928 (Austin 1988). Most 
reports of haematological changes due to benzene come from groups exposed well 
before the current occupational standards, and there have been reports of leukaemia 
in workers first hired in the mid 1970s. In an increasing number of cases alkylating 
agents have been directly implicated in the induction of secondary AML, the 
resulting leukaemia sometimes evolved slowly with myelodysplastic changes and a 
significantly high incidence of chromosomal abnormalities, particularly involving 
chromosomes 5 and 7. The cumulative dose o f alkylating agents and patient age are 
the main determinants for developing AML, the risk increases from one year after 
the start o f treatment and rises steeply in the first 1-2 years levelling off at 7 years. 
The nitrosureas and epipodophylotoxins have been associated with subsequent AML 
after a relatively short latency period o f 1-5 years. They often have cytogenetic 
abnormalities involving chromosome band 1 lq23 and the MLL gene (Seeker-Walker 
1998).
In addition there have been at least ten published studies on smoking and leukaemia.
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Almost all have demonstrated small but statistically significant increase in ALL risk 
in smokers older than 60 years (Sandler 1993).
I: 3:3 Epidemiology o f  acute lymphoblastic leukaemia 
There are no major differences in incidence according to geographical area or 
between urban industrialised and rural areas. Some sociocultural factors appear to 
influence the incidence of CD 10 (cluster o f differentiation 10) positive form o f ALL 
known as common ALL (cALL), which is less frequent than T-ALL in African 
countries and in poorer sections of the community in the United States o f America 
e.g. blacks or Spanish (Hoelzer and Gokbuget 2000).
The highest incidence of ALL is seen in children aged 2-5 years, with a modest 
secondary increase in frequency beginning at about 50 years of age. The annual 
incidence in children 15 years or younger in the United States is reported as 3 cases 
per 100,000 for whites, but no more than 1.4 cases per 100,000 for blacks (Young 
1986). Between 1984 and 1986 ALL occurred in the United Kingdom at ages 0-84 
years at an overall rate of 1.3 per 100,000, with a peak incidence between 0-4 years 
o f age at 5.1 per 100,000, diminishing thereafter and becoming rare between the 
ages o f 25 and 44 with a slight rise between the age of 75-80 (1.8 per 100,000) 
(McKinney 1989).
More males than females present with ALL, the sex ratio at all ages is 1.4:1.0 
(McKinney 1989).
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I: 4 Methods of Classifying Acute Leukaemia
Acute leukaemia comprises a heterogeneous group of conditions differing in 
aetiology, pathogenesis, natural history, and prognosis. The classification into 
subgroups enables an improved understanding of the leukaemic process and the 
increased likelihood o f causative factors being recognised.
The precursor cell in which the leukamic transformation occurs may be lymphoid, or 
myeloid in origin or a cell that is capable o f differentiating into both lymphoid and 
myeloid lineages. Based on the origin o f the cells with leukaemic transformation, 
leukaemia can be classified into lymphoid and myeloid types.
It is also customary to divide patients with acute leukaemia in to two main age 
groups; childhood acute leukaemia (<15 years) and adult acute leukaemia (>15 
years). The main difference between childhood and adult disease is that ALL 
constitutes over 80% of childhood cases, whilst AML constitutes around 80% of 
adult cases, some other age subgroups are often considered separately, adults aged 
>60 years, because their response to treatment protocols for acute leukaemia is 
inferior and because these patients are often not included in the more radical 
approaches using autologous or allogeneic transplantation, adolescents or young 
adults aged 15-21 as a subgroup may be important in ALL as it lies biologically 
between childhood and adult ALL. These patients tend however to have better 
responses when treated according to protocols akin to those used for high risk 
childhood disease (Nachman 1993). ALL in infants (less than 1 year of age) is also 
increasingly being treated according to protocols that are more intensive but shorter 
in duration than those for older children. (Isoyama 2002)
26
The ideal classification of acute leukaemia must be biologically relevant, 
reproducible, and widely applicable. Rapid categorization should be possible so that 
therapeutic decisions can be based on the results o f the classification. A method of 
classification that does not change over time also allows comparisons to be made 
between different groups of patients or different treatment modalities.
There are currently three important methods of classifying the acute leukaemias, 
morphology, immunophenotype, and cytogenetics.
I: 4:1 Morphological classification
The first step in classifying an acute leukaemia is the division o f cases into acute 
myeloid leukaemia, and acute lymphobastic leukaemia.
The importance o f this first step o f categorization is paramount, since the natural 
history differs considerably between the two conditions and the modes of treatment 
are sufficiently different for an incorrect diagnosis to adversely affect prognosis.
The first step in distinguishing these two types is based on the morphology o f the 
cells.
The morphologic classification most commonly employed is the French-American- 
British (FAB) (Bennett 1976), which is dependent on morphological features of blast 
cells when stained with a Romanowsky and cytochemical stains. The FAB 
classification allows the morphological recognition of most cases of AML from the 
presence o f myeloperoxidase positive Auer rods, or monocyte-associated esterases 
in blast cells, with the exception o f AML subtype MO with negative cytochemistry 
by light microscopy.
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The FAB classification classifies lymphoid blasts into three subtypes:
LI morphology:
The blasts are small and uniform, with scanty moderately basophilic cytoplasm; 
nuclei are regular in shape with inconspicuous nucleoli.
L2 morphology:
The blasts are large and non-uniform, with variable amounts of basophilic 
cytoplasm; nuclei are irregular in shape with prominent nucleoli.
L3 morphology:
The blasts are large and uniform; with moderately abundant amounts of deeply 
basophilic cytoplasm with prominent vacuoles nuclei are regular in shape with 
prominent nucleoli.
In childhood ALL, the distribution of cases between LI, L2 and L3 is 85%: 14%: 
1 %.
Most adult patients have L2 type with L I : L2: L3 ratio of 31%: 60%: 9%. 
Morphologic or cytochemical features in ALL are more subjective than in AML and 
have not been on the whole useful in subdividing ALL, with the exception o f the 
rare L3 or Burkitt subtype of ALL. This type lends itself well to morphological 
identification and, as patients with this disease require different treatment to others, 
morphological examination remains of importance to detect these rare cases.
However in the remaining >90% of cases the contemporary diagnostic work-up o f 
ALL relies most heavily on immunophenotyping and cytogenetics.
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I: 4:2 Immunophenotypic classification
The ability to classify ALL by lineage commitment and degree o f maturation 
features displayed by the leukaemic blasts (immunophenotyping) began in 1975 
(Greaves 1975; Sen and Borella 1975), the blasts are classified according to the 
presence or absence o f specific nuclear or surface markers that identify them as 
being arrested at a certain stage in B or T lymphocyte development. The leukaemia 
is classified according to this cell type and nomenclature is based on the closest 
known normal B or T cell progenitor.
Characterisation of leukaemic blasts by immunophenotyping is now usually 
undertaken with a flow cytometer and a panel of specific monoclonal antibodies that 
identify cell surface antigens and cell markers with a specific CD designation (Foon
1990).
The development of new fluorochrome reagents for cell labelling and sensitive, 
reliable flow cytometers, capable of measuring several different cellular properties 
simultaneously, has greatly improved the precision o f the procedure (Greaves 1981). 
The list of leukocyte differentiation antigens and the monoclonal antibodies that 
recognize them has grown rapidly. At the 7th International Workshop on Leukocyte 
Differentiation Antigens (Zola 2003), 246 CD groups were designated, but only a 
few markers have lineage specificity. By this mode of classification lymphoid blast 
cell types fall broadly into two categories: B cells and T cells. (Table 1.1)
The earliest indication of lineage commitment is rearrangement of immunoglobulin 
genes of B-cell leukaemia, with expression of cytoplasmic followed by surface 
immunoglobulin heavy chain (Korsmeyer 1983; Ha 1985), and antigen receptor
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genes of T-cell leukemia (Tawa 1985).
Testing with a variety of monoclonal antibodies specific for antigens is used to 
define the level o f maturation achieved by the blasts from the most primitive or most 
aberrant pre-pre-B or null cells to mature B cells as shown in Table 1.1. B-lineage 
ALL accounts for 75-80% of cases, with cALL being the most common in childhood 
(60-70%), while pro-B ALL is rare in children, but occurs more frequently in adults 
(20-40%).
T-ALL comprises 13-20% of childhood ALL cases and up to 25% in adults (Foa 
1985; Kalwinsky 1985). T-ALL blasts are subdivided according to maturity into pre- 
T, intermediate, late and mature T subtypes as presented in Table 1.2. 
Immunophenotypic analysis is critical to confirm a morphological diagnosis of ALL, 
and to sub-classify cases into precursor-B and precursor-T lineage types. However, 
the distinctions between and the terminology for the different subtypes o f these two 
main groups are not universally agreed upon. In fact due to the lack of conformity 
and the questionable significance o f further sub-classification, the World Health 
Organisation (WHO) classification scheme which incorporates cytology, histology 
and genetic abnormalities in the classification of haematopoeitic malignancies 
simply classifies cases as precursor-B and precursor-T ALL without additional 
categorization, and classifies the Burkitt’s Leukaemia and Burkitfs lymphoma 
together as mature B-cell neoplasia (Jaffe 2001). For purposes o f treatment planning, 
the only critical distinction is between mature B-cell and B-cell precursor ALL. On 
the other hand a specific immunophenotype identified at diagnosis might be useful 
for evaluating residual disease by flow cytometry after treatment.
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Table 1.1 Immunophenotype in B-ALL
Normal counterpart Leukaemic blast type CD19 CD10 clg sig
Pre-pre B/Pro-B Pro-B/Null + - - -
Early pre-B c-ALL + + - -
Late pre-B cell Pre-B ALL + +/- + -
Mature B cell B-cell ALL (Burkitt type) + - + +
clg ^Cytoplasmic Immunoglobulin slg= surface Immunoglobulin
Table 1.2 Immunophenotype in T-ALL
Normal counterpart Leukaemic blast 
type
CD7 CD2 CD4 cCD3 CD8 TCR
a p
Bone marrow Prothymocyte Pre-T + - - - - -
Thymic cortex thymocyte Intermediate T + + + + + -
Thymic medulla thymocyte Late T + 4* +/- + -/+ +
Peripheral blood T cell Mature T + + +/- + -/+ +
cCd3=cytoplasmic CD3 TCR=T-cell receptor gene
I: 4:3 Cytogenetic classification
Leukaemia arises from a hematopoietic progenitor cell that has sustained specific 
genetic damage, leading to malignant transformation and growth. Thus, genetic 
classification o f ALL should yield more useful information than that obtained with 
other systems.
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Classification o f patients with ALL by chromosomal abnormalities was originally 
based on counting the chromosomes and arranging them into seven categories, A-G. 
This form of classification was shown to be prognostically important in 1978, when 
it was found that hyperdiploidy (>50 chromosomes) in childhood ALL carried a 
better prognosis (Seeker-Walker 1978). Later it was shown that the presence o f an 
abnormally short chromosome 22 called the Philadelphia (Ph) chromosome, which 
resulted from the translocation t(9;22)(q34;ql 1) was associated with a poor outcome 
in ALL (Seeker-Walker 1982). With improved preparation and chromosome 
banding techniques it became possible to classify leukaemic blasts according to 
chromosomal abnormalities. Currently by standard karyotyping, more than 80% of 
ALL cases show clonal chromosomal abnormalities, half of which are translocations 
(Secker-Walker 1990; Schiffer 1992; Seeker-Walker 1997; Harrison and Foroni 
2002).
The cytogenetic analysis of leukaemic blast cells has become an indispensable tool 
in diagnosis and risk assessment o f ALL, and can be used to pinpoint chromosomal 
sites for the molecular cloning of proto-oncogenes.
A: Numerical chromosomal changes
Cytogenetic changes are classified according to number of chromosomes:
Near haploid; 23-29 chromosomes
Low hypodiploid; 30-39 chromosomes
High hypodiploid; 40-45 chromosomes
Normal; 46 chromosomes, without structural abnormalities
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Pseudodiploid; 46 chromosomes, with either structural abnormalities, or gains o f
chromosomes compensated by losses of other chromosomes
Low hyperdiploidy; 47-50 chromosomes
High hyperdiploid; 51 -65 chromosomes
Near triploid; 66-80 chromosomes
Near tetraploid with >85 Chromosomes
Numerical chromosomal changes were the first cytogenetic anomaly to be described 
in leukaemia. And to date, after the description of numerous structural abnormalities, 
the presence o f an abnormal chromosome count remains an important classification 
tool in ALL.
Losses of chromosomes are generally associated with deteriorating outcome, near 
haploid karyotypes are rare in both adults and children, with an incidence o f less 
than 3%, and are associated with median survival o f 11 months (Gibbons 1991; 
Seeker-Walker 1997; Heerema 1999; Harrison 2004). Poor outcome is also 
associated with hypodiploidy with 44 chromosomes or less in childhood ALL 
(Heerema 1999), and with loss of chromosome 7 in adults (Wetzler 1999).
In contrast high hyperdiploidy (modal numbers of 50-68 chromosomes) is associated 
with good risk ALL, a disease characterized by specific age groups, two to nine year 
olds in children, and below 18 years in adults, leukocyte counts o f <10x109/I, female 
sex, and c-ALL immunophenotype (Walters 1990; Seeker-Walker 1997). In 
children, where high hyperdiploidy occurs in over one third of cases it is associated 
with 5-year survival rates of 72%-80% (Pui 1989; Jackson 1990; van der Plas 1992; 
Raimondi 1996; Heerema 2000). In adults high hyperdiploidy accounts for
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approximately 10% of cases. When not associated with other structural 
abnormalities, such as translocation t(9;22), it predicts a better outcome with three- 
year event free survival (EFS) rates of 59% (Seeker-Walker 1997).
Within hyperdiploid clones chromosomal gains are restricted to certain 
chromosomes, in low hyperdiploidy the chromosomes most frequently acquired are 
chromosomes 21 (42%), X (22%), 10 (13%), 8 (11%), 6 (9%) and 16 in (7%), in 
high hyperdiploidy those most frequently gained are chromosomes 21 (100%), X 
(95%), 6 (86%), 18 (78%), 4 (75%), 17(65%), and 10 in (61%) (Moorman 1996). 
Within the ploidy groups, gain or loss of specific chromosomes plays an important 
role in predicting outcome. Early studies found the combination of trisomies for 
chromosomes 4 and 10 in high hyperdiploidy predicted the best prognosis in 
children (Harris 1992), more recently the presence of trisomies for chromosomes 4 
and 18 in high hyperdiplody has been found to predict five year survival of 96% 
(Moorman 2003). Whereas trisomy 5 confers a poorer outcome within this group of 
patients (Heerema 2000). Trisomy 8 has been associated with poor outcome in 
adults (Wetzler 1999).
Numerical changes can be associated with structural changes including 
t(4;ll)(q21;q23), t(8; 14)(q23;q32), and t(9;22)(q34:ql 1). One fifth of adults with 
Philadelphia chromosome positive ALL have hyperdiploid clones (Crist, W. 1990; 
Seeker-Walker 1997). The influence of co-existing structural abnormalities remains 
unclear. Childhood ALL studies show conflicting results: Van der Plas et al showed 
better prognosis in the absence of structural abnormalities (van der Plas 1992), 
Raimondi showed the reverse (Raimondi 1996). In adults from Medical Research
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Council United Kingdom Acute Lymphoblastic Xa trial (MRC UKALLXa) the 
better outcome with high hyperdiploidy was only seen in those patients without 
structural abnormalities (Seeker-Walker 1997).
The effect o f low hyperdiploidy (47-50) chromosomes which occurs in 11% of 
children and adults (Fletcher 1989; van der Plas 1992; Harbott 1993; Raimondi 
1993; Kobayashi 1994) is less clear, but appears to predict slightly better outcomes 
in adults (Seeker-Walker 1997).
B: Structural chromosomal abnormalities:
B-precursor ALL
Non-random chromosomal rearrangements are common in ALL: Table 1:3 lists the 
most common. Some of these have clinical significance, including: 
i: The translocation t(9;22)(q34;ql 1), giving rise to the Philadelphia chromosome. 
The Ph chromosome is the cytogenetic hallmark o f CML (Nowell 1960), later 
described in childhood (van Biervliet 1975) and adult ALL (Propp and Lizzi 1970). 
It occurs in 5% of children and 20-35% of adults with ALL (Ribeiro 1987; Secker- 
Walker 1991; Westbrook 1992). ALL patients carrying the Ph translocation present 
with white blood cell counts (WBC) which range from 3 to >100xl09/l. Higher 
WBC are found in childhood Ph positive ALL than in other childhood patients 
(Crist, W. 1990). This difference is not consistently seen in adults (Seeker-Walker
1991).
The incidence o f Ph positive ALL increases with age from approximately 2% in 
children <15 years of age (Seeker-Walker 1990) to 10% at 15-20 years, 19% at
35
21-30 years, 24% at 31-50 years, and up to 44% in those over 50 years old at the 
time of presentation (Seeker-Walker 1991).
Blast cell immunophenotype shows that the vast majority o f Ph positive cases have 
B-lineage blasts. In children, 74% show cALL, a further 16% have a pre-B 
phenotype and only 10% have blasts with positive markers for T-ALL (Ribeiro 
1987; Crist, W. 1990). Similarly in adult series, the overwhelming majority o f Ph 
positive ALL show either cALL or pre-B phenotypes (Seeker-Walker 1991; Secker- 
Walker 1997).
Patients with Ph positive ALL, particularly adults, have a dismal prognosis when 
treated with standard chemotherapy, and are treated according to high-risk treatment 
protocols, (Bloomfield 1986; Maurer 1991; Seeker-Walker 1991; Gotz 1992; 
Westbrook 1992; Rieder 1993; Annino 1994; Secker-Walker 1997).
More recently, Imatinib (Gleevec, STI-571), a relatively specific BCR-ABL tyrosine 
kinase inhibitor, has shown marked therapeutic benefit in CML (Druker 2001) and 
in the short term, at least, in Ph positive ALL (Ottmann and Hoelzer 2002; 
Wassmann 2002; Wassmann 2003). It has been incorporated into treatment regimens 
for this subgroup of patients, including patients entered to the UKALL XII trial, and 
the new childhood ALL trial ALL2003.
However even within this group of patients there seems to be some heterogeneity, 
for example the additional finding of monosomy 7 or abnormalities involving the 
short arm of chromosome 9 in Ph positive ALL are associated with low remission 
rates of extremely short duration (Rieder 1991; Russo 1991; Rieder 1996; Heerema 
2004). In contrast the finding of hyperdiploidy in Ph positive disease is associated
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with higher rates o f remission and an overall improvement in survival (Rieder 1996).
ii: 1 lq23 abnormalities
A second group of significant chromosomal abnormalities are structural 
rearrangements of chromosome 11 at band q23. Rearrangements include deletions, 
duplications, inversions and reciprocal translocations (Seeker-Walker 1998). Most o f 
these abnormalities involve the MLL gene at 1 lq23. As a group they account for 5- 
10% of acquired chromosomal rearrangements in children and adults with ALL, 
AML, poorly differentiated or biphenotypic leukaemias and myelodysplastic 
syndromes (Mitelman 2004). They occur in 70% of acute leukaemias in neonates 
and up to 85% of secondary leukemia resulting from exposure to topoisomerase II 
inhibitors such as the epipodophyllotoxins. Most of these are AML (Reaman 1985; 
Chen 1993; Rubnitz 1994; Seeker-Walker 1998; Rowley and Olney 2002), but there 
have been approximately 50 cases o f therapy related ALL reported (Andersen 2001). 
The largest series of 1 lq23 abnormalities was reviewed by the European Union (EU) 
Concerted Action Workshop on 1 lq23 Abnormalities in 1998. This showed that the 
majority of patients exhibited reciprocal translocations joining 1 lq23 with as many 
as 30 cytogenetically distinguishable partner loci. The most common partners were 
found to be 4q21 in t(4; 11 )(q21 ;q23) translocation, and 9p21~22 in t(9; 11) 
accounting for 40% and 27% of translocations respectively (Johansson 1998; 
Swansbury 1998). Another frequently encountered rearrangement was t(l 1; 19) 
involving the p i3 band of chromosome 19 which accounted for 12% of the 
translocations (Moorman 1998). Additions, duplications, and inversions accounted 
for 16% of 1 lq23 abnormalities (Harrison 1998).
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The translocation, t(4;l I)(q21;q23), is specifically associated with a Null cell 
immunophenotype (Pui 1992). Blasts may also have myelomonocytic characteristics 
(Hagemeijer 1987). Another feature is their association with a WBC > 100x109/l, 
seen particularly in infants and older patients.
The adverse prognostic significance of llq23 rearrangements has been noted for 
some time (Raimondi 1989; Rubnitz 1997; Pui 2003). Patients tend to enter 
remission with the same frequency, but relapse more frequently and have shorter 
remission durations than patients without llq23  abnormalities. Children with B- 
precursor ALL and t(4; 11) t(9 ;ll) , or t( 11; 19) have 5 year EFS of 11% compared 
with 74% for patients without llq23  abnormalities (Pui 1991; Rubnitz 1997). Pui 
stratified paediatric patients with t(4; 11) positive ALL by age and found 
significantly shorter EFS in children under 1 year o f age and over 10 years old, but 
not for children between the ages of 1 and 10. Taking all age groups represented in 
the EU 1 lq23 Workshop, a similar difference was found, with 3-year EFS rates o f 
almost 75% in the 2-9 year olds, dropping to 40% in 10-39 years old, and those less 
than 2 years of age. The worst outcome was seen in patients over 40 years of age, in 
whom the 3-year EFS was only 14%. There is some evidence that overall survival 
(OS) can be improved in these patients by more intense therapy, including 
allogeneic transplantation in first remission (Ludwig 1998). Other abnormalities of 
1 lq23 in ALL have different outcome, for example it seems that outcome is related 
to MLL involvement rather than cytogenetic evidence o f 11 q23 deletions in ALL 
(Harbott 1998).
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iii: t( 1; 19)(q23;p 13)
Another translocation in pre-B ALL is the t(l;19)(q23;pl3), o f which there are two 
forms a balanced t( 1; 19)(q23;p 13) and an unbalanced form der(19)t(l;19). The 
translocation was first described in 1984 (Carroll 1984; Michael 1984), occurring in 
2-9% of children with ALL (GFCH 1993; Harbott 1993; Pui 1994; Seeker-Walker 
1997) and 2% of adults (GFCH 1996; Seeker-Walker 1997). Blasts express 
cytoplasmic immunoglobulin in a high percentage o f cells (Carroll 1984). The 
prognostic implications of this abnormality are not entirely clear. Initially it was 
identified as a major adverse feature in pre-B ALL (Crist, W. M. 1990). Further 
studies from St Jude’s hospital showed that the more intensive treatments, now used 
as standard therapy improved the survival rates o f children with pre-B ALL with any 
translocation and t( 1; 19) in particular (Raimondi 1990). In one large study it was 
shown that the unbalanced form was associated with a better prognosis than the 
balanced form (Secker-Walker 1992). The small number o f adults with either form 
treated within the MRC UKALL Xa trial (1985-1992), had an EFS of 54% at three 
years, and not statistically significantly different from the group as a whole.
iv:t(12;21)
The most common structural cytogenetic abnormality found in children with ALL is 
the t( 12;21 )(p 13;q22) involving the TEL-AML1 (ETV6-RUNX1) . This translocation is 
invisible by conventional cytogenetic analysis, because the rearrangement does not 
alter the banding pattern of the involved chromosomes. When analysed by FISH or 
polymerase chain reaction (PCR) the t(12;21) is found in 16-32% of paediatric B- 
lineage ALL cases but in only 3-7% of adult cases (Faderl 1998; Harrison 2001;
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Jabbar Al-Obaidi 2002). Clinically the majority o f such patients present with a 
precursor-B-phenotype at 3-6 years of age. These patients have an excellent 
prognosis with EFS approaching 90% with the best results obtained with regimens 
using intensive L-asparaginase treatment (Borkhardt 1997; Rubnitz 1997). Although 
late relapses some occurring after more than 10 years have been reported (Harbott
1997), it is possible that in some o f these cases the TEL / AML clone persists in long 
term remission (Endo 2003), and that subsequent relapses occurs due to the 
acquisition o f further genetic alteration such as deletion o f the second TEL (Zuna 
2004).
Mature B-cell ALL
B-cell leukaemia is found in 1% to 3% of childhood and adult ALL, usually 
characterized by FAB L3 cellular morphology (Bennett 1976), the presence of 
monoclonal Ig on the surface o f malignant cells (Flandrin 1975) and extramedullary 
diseases (Patte 1986; Sullivan 1990).
Over 80% of mature B-cell ALL have one or other o f the three translocations 
consistently found in Burkitt’s lymphoma t(8;14)(q24;q32) (80%), t(2;8)(pl2;q24) 
(6%) or t(8;22)(q24;ql 1) (14%) (Komblau 1991). Although Burkitt lymphoma 
associated with 8q24 translocations were once associated with a poor prognosis, 
multiple studies now show improved outcome in both children and adults with the 
use of short term chemotherapy, using high doses of an antimetabolite 
(methotrexate) and alkylating agents (cyclophosphamide, ifosfamide) (Hoelzer 
1996; Lee 2001).
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T-cell ALL
In T-cell ALL, the frequency of chromosomal rearrangement is low at 44%. This 
may be a reflection of small abnormal clones that are difficult to detect, or the 
presence of cryptic abnormalities. The most common abnormalities involve the 
TAL-1 (T-cell acute leukaemia 1) gene on chromosome lp32. Other common 
abnormalities involve breakpoints at 14q 11, 7q32 or 7pl5 (Raimondi 1988), the sites 
of the T-cell receptor alpha/delta [TCRA/TCRD], beta (TCRB) and gamma (TCRG) 
genes respectively. The recently described recurrent cryptic translocation 
t(5;14)(q35;q32), which is seen in 16-22% of childhood and adolescent T-ALL, 
results in overexpression of the HOXIIL2 gene (Bernard 2001). There is no apparent 
relationship between particular translocations and the stage of thymocyte 
differentiation of leukaemic blasts. In general chromosomal abnormalities have been 
found to correlate with a poor outcome in T-cell ALL (Pui 1990) but insufficient 
cases have been studied to determine the unique impact of specific rearrangements.
There are some important associations among the three methods of classifying the 
acute leukaemias, which prompted the integration of morphology with immunology 
and karyotype o f the neoplastic cells. This classification became known as the MIC 
(morphologic, immunologic, and cytogenetic) classification 1986 (MIC 1986) as 
summarised in Table 1.4.
O f note is that the L3 morphology is consistently associated with the B-cell 
leukaemia immunophenotype, surface immunoglobulin and the t(8; 14) translocation 
or one of its variants.
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The t(4;l I)(q21;q23) translocation is frequently associated with blast cells of mixed 
lymphoid and myeloid antigenic markers and associates with pro-B ALL, the 
t( 1; 19)(q23;p 13) and t( 12;21 )(p 13 ;q22) associate with pre-B ALL,. The 
t(9;22)(q34;ql 1) blasts are more usually cALL. The t(l l;14)(pl3;ql 1) associates 
with T-cell ALL. Hyperdiploidy is more common in children with early pre-B ALL, 
translocations are less common in this group. Pre-B ALL is less likely to include 
hyperdiploidy and translocations are a more frequent finding.
The LI or L2 morphology has no consistent correlation.
Table 1.3 Recurrent chromosomal abnormalities in ALL
Frequency DFS
% in ALL__________ at 3-Syr
Children Adults Children Adults
8q24 translocations Mature B MYC, IGH/IGKJIGL 2 3-5 75-85 60
t(4; 11 )(q21 ;q23) Pro-B MLL.AF4 70 3-6 9mo 7 mo
(infants) (MS) (MS)
t( 1; 19)(q23;p 13) Pre-B E2A.PBX1 5-6 1-3 70-80 10-50
t(9;22)(q34;ql 1) B-lineage BCR,ABL 3-4 25-30 20-40 <10
t( 12;21 )(p 13 ;q22) B-lineage ETV6,AML1 20-25 1-3 85-90 10-50
14q 11, 7q35, 7pl4-15 T-lineage TCR rearrangements 10 <5 65-75 60
del 9p B o rT p i 6INK4ap i 4arf,p 1 5[NK4B 9 12 <10 40
del 6p B o rT 32 3 >70 ?
<46 Chromosomes B o rT 7 4-5 25-40 10
51 -65 Chromosomes B o rT 25 2-5 80-90 40-50
DFS=disease free survival mo=months MS=median survival TCR=T-cell receptor
42
Table 1.4 The MIC classification of ALL
Disease category Morphology
FAB
Immunology Karyotype
B-lineage ALL
Early B-precursor ALL L1,L2 TdT+,CD 19+,CD 10- t(4; 11), t(9;22)
Common ALL L1,L2 TdT+,CD19+,CD10+ 6q-,near haploid,t or del(12p), t(9;22)
Pre-B ALL LI TdT+,CD 19+,CyIg t( 1; 19), t(9;22)
B-cell ALL L3 TdT-,CD19+,SmIg t(8;14), t(2;8), t(8;22),
T-lineage ALL
Early T-precursor ALL L1,L2 TdT+,CD2-, CD7+ t or del(9p)
T-cell ALL L1,L2 TdT+, CD2+, CD7+ t( 11; 14), 6q-
TdT= Terminal deoxynucleotidyl transferase
I: 5 Molecular Genetic Events in the Pathogenesis of
ALL
The observation that chromosomal gains or losses as well as structural abnormalities 
can identify subgroups of ALL that differ in their response to chemotherapy 
prompted several studies to identify biological explanations for these differences. 
The favourable prognosis of hyperdiploidy has been attributed to the low leukaemic 
cell burden associated with this cytogenetic feature, a tendency to accumulate an 
increased amount of methotrexate polyglutamates, an increased sensitivity to 
anti metabolites, and a marked propensity for spontaneous apoptosis (Belkov 1999; 
Ito 1999). For the most part, biological explanations for the prognostic impact of 
other genetic abnormalities remain uncertain.
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There are two mechanisms by which chromosomal translocations contribute to ALL 
pathogenesis
1:5:1 Chimeric proteins
The best-studied examples of chromosomal translocation leading to chimeric protein 
formation are:
i: t(9;22)(q34;ql 1) BCRJABL
This translocation results from the fusion of the BCR gene at 22ql 1 to the ABL gene 
at 9q34. This results in the generation of a protein composed of the 5’ part of the 
BCR and the 3’ part of the ABL. Fusion of BCR to ABL results in activation o f ABL, 
a non-receptor tyrosine kinase whose activity is normally very tightly regulated 
(Davis 1985).
The sites of breakpoint within ABL are variable within a 300 kilo base (kb) segment 
of intron 1 at the 5’ end of the gene, in BCR the breakpoints are more restricted.
In CML and some cases of ALL the BCR breakpoint is localized to a 5.8 kb region -  
the major breakpoint cluster region- (M-bcr) spanning 5 exons bl to b5, usually 
resulting in a hybrid BCR-ABL mRNA molecule with a b3a2 and/or b2a2 junction, 
encoding a new protein of 210 kilo daltons. In 90% of childhood ALL and 50% of 
adult ALL the BCR breakpoint is 5’ to M-bcr, within a 200kb span referred to as the 
-minor breakpoint cluster region- (m-bcr) between two e2’ and e2 exons, the 
resultant mRNA codes for a 185 to 190 kilo dalton fusion protein.
The precise mechanism by which BCR-ABL chimeric protein transforms cells 
remains elusive. What is known is that it can transform haematopoeitic cells so that 
their growth and survival in vitro becomes independent of cytokines (Gishizky and
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Witte 1992). The BCR-ABL chimeric protein can also protect haemopoietic cells 
from apoptosis in response to cytokine withdrawal and DNA damage by 
chemotherapy and radiotherapy (Evans 1993; Nishii 1996). Biochemical studies of 
leukemogenesis indicate that the BCR-ABL protein is a constitutively active 
tyrosine kinase confined to the cytoplasm, whereas the wild type ABL shuttles 
between the nucleus and cytoplasm (Van Etten 1989). As a consequence o f 
increased tyrosine kinase activity, the BCR-ABL protein can phosphorylate several 
substrates, thereby activating multiple signal transduction cascades, affecting the 
growth and differentiation o f cells.
ii: 1 lq23 MLL translocations
Breakpoints at 1 lq23 disrupt the 100 kb MLL gene between exons 5 and 11 (Djabali 
1992; Tkachuk 1992). MLL has partial homology to the Drosophila transcription 
factor trithorax, which is thought to regulate a number o f homeotic genes in the fly. 
It remains unknown how dysregulated MLL function contributes to leukomogenesis 
in humans.
Reciprocal translocations result in the replacement of MLL coding sequences 3’ to 
the breakpoint by the translocation partner. The derivative chromosome 11, which is 
universally transcribed by the leukaemic clone (Rowley 1992; Johansson 1998) 
retains the MLL promoter as well as amino terminal MLL coding sequences up to 
exon 5-11, depending on the exact breakpoint.
MLL is among the most promiscuous oncogenes in human leukemia, with over 30 
MLL fusion partners now cloned. Despite this heterogeneity, each translocation
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results in the production of a characteristic hybrid protein with an MLL amino 
terminus and a carboxyl terminus, the later encoded by the gene at the partner locus. 
Fusion transcripts from both reciprocal derivative chromosomes are usually found in 
leukaemic cells. However clustering of breakpoints found in various 11 q23 
rearrangements, heterogeneity of breakpoints in the 1 lq23 fusion partners, and loss 
of the translocated MLL region telomeric to 1 lq23 have led to the hypothesis that the 
derived chromosome 11 [der(ll)] fusion product, which is encoded by the 5’ 
portion of the MLL gene, represents the biologically more relevant potential 
oncogenic fusion protein (Chen 1991; Cimino 1992; Rowley 1992; Chen 1993). 
Using highly sensitive reverse transcriptase polymerase chain reaction (RT- PCR) 
techniques to detect mRNA in peripheral blood and bone marrow MLL fusion and 
duplication transcripts can be detected in the absence o f a demonstrable 11 q23 
rearrangement with or without cytogenetically detectable t(4; 11) or other structural 
chromosomal aberrations involving llq23 (Chen 1993; Griesinger 1994; Rubnitz 
1994; Rambaldi 1996; Rubnitz 1996; Borkhardt 2002).
iii t(12;21)(pl3;q22) TEL/AML1
One of the more recent additions to the list of chromosomal translocations associated 
with ALL is the t(12;21)(pl3;q22). Abnormalities of the short arm of chromosome 
12 (12p) are a frequent finding in haematological malignancies (UKCCG 1992). The 
translocation was first detected by Romana in 1994 when FISH studies in cases o f 
ALL with abnormalities of 12p detected a cryptic translocation involving the short 
arm of chromosome 12 and the long arm of chromosome 21, t( 12;21 )(p 13 ;q22) 
(Romana 1994). This translocation was subsequently demonstrated to involve the
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Ets-related transcription factor TEL (ETV6) gene at 12 p l3 and the transcription 
factor AML1 (CBFA2) gene at 21q22 (Romana 1995). The TEL gene, like MLL, is 
frequently rearranged in a variety of hematopoietic malignancies through 
chromosomal translocation.
This abnormality is the most common translocation in childhood ALL occurring in 
25% of B-lineage ALL (Shurtleff 1995; McLean 1996; Borkhardt 1997), with a 
lower incidence (1-3%) in young adults (Aguiar 1996; Raynaud 1996).
O f interest, is the finding that all positive cases of both children and adults tested by 
RT-PCR, showed the ETV6/AML1 transcript, but only a proportion showed the 
reciprocal one (Shurtleff 1995; Aguiar 1996). This indicated that ETV6/AML1 was 
the important product in leukaemogenesis. Driven by the ETV6 promoter, the 
ETV6/AML1 chimeric protein includes the first 336 amino acids of ETV6 and nearly 
the entire coding sequence of AML1. The DNA-binding Ets domain of ETV6 is lost 
in the fusion, suggesting that ETV6/AML1 does not de-regulate genes normally 
regulated by ETV6.
Deletions of the homologous ETV6 allele have been reported in the majority of cases 
with the t(12;21) translocation. This occurred either in all or a proportion of the 
positive nuclei, and were sometimes intragenic (Raynaud 1996; Romana 1996). The 
consequence o f this biallelic alteration of the ETV6 gene is complete loss of wild- 
type ETV6 function in the leukemic cells. Such a two-hit mechanism is indirectly 
suggestive of a tumour suppressor function for ETV6, although there is no 
experimental evidence to support this hypothesis. ^TFd-deficient mice have an 
embryonic lethal phenotype, making them unsuitable for testing the hypothesis that
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ETV6 loss of function alone is leukaemogenic. It has been proposed that the extent 
of deletion of the second ETV6 allele and the presence or absence of other 
chromosomal abnormalities may identify subgroups o f ETV6/AML1 positive patients 
with different outcomes (Raynaud 1996; Martineau and Greaves 1998).
iv t( 1; 19)(q23 ;p 13) PBX1/E2A (pre-B-cell leukemia transcription factor 1)
The molecular consequence of the t( 1; 19) is to juxtapose the E2A gene at 19p 13 with 
PBX1 gene at lq23. The E2A protein is one o f the helix-loop-helix family of 
transcription factors, PBX1 protein utilizes a homodomain for DNA binding. The 
t( 1; 19) translocation results in the generation of a chimeric fusion protein consisting 
of the N-terminal transcriptional activation domain o f the E2A fused to the C 
terminus o f PBX1, which contains the DNA-binding homodomain (Mellentin 1989; 
Nourse 1990).
1:5:2 Gene over-expression
Gene overexpression through chromosomal translocation is a common event in 
ALL.
i c-MYC over-expression
Mature B-cell ALLs usually show one or other o f three translocations consistently 
found in Burkitt’s lymphoma t(8;14)(q24;q32) in 80% of cases, t(2;8)(pl2;q24) in 
6%, or t(8;22)(q24;ql 1) in 14%. Chromosomes 14, 2, and 22 carry the genes coding 
for immunoglobulin heavy chain, and light chain kappa and lambda genes 
respectively. The oncogene c-MYC (myelocytomatosis viral oncogene) is normally 
located at chromosome 8q24. As a result o f each translocation, the coding regions
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for c-MYC gene are brought into close proximity with one o f the immunoglobulin 
genes (Dalla-Favera 1982; Taub 1982; Croce 1983; Erikson 1983; Hollis 1984; Taub 
1984). The enhanced expression of c-MYC is believed to result from MYC coming 
under the control of these highly active genes and being switched on inappropriately, 
the over expression of c-MYC mediates cellular transformation by disrupting the 
normal transcriptional programme regulating proliferation, differentiation and cell 
death in lymphoid cells.
ii TCRA/D and TALI over-expression
Most chromosomal translocations associated with T-ALL result in the juxtaposition 
of transcription factor genes into one of the four T-cell antigen receptor loci 
resulting in their de-regulated expression. In these translocations the TCR gene 
becomes juxtaposed with other chromosomal sites at the location o f putative 
oncogenes, which then become up regulated. One o f the most common 
translocations is the t( 10; 14)(q24;q32) bringing the homeobox gene HOX11 on 
chromosome 10q24 in close proximity to the TCRA/D on chromosome 14q32.
The TAL-1 gene located on chromosome lp32 is translocated to the T-cell receptor 
delta locus at 14qll in the t( 1; 14)(q32;q 11) translocation seen in 3% of T-ALL 
leading to the overproduction of the the helix-loop-helix type transcription TAL-1 
protein not expressed in normal T-cells (Huang 1995; Stock 1995), more commonly 
the aberrations o f the TALI gene, comprise intrachromosomal submicroscopic 
deletions resulting in the approximation of the TAL-1 coding region and the SIL 
promoting region, with increased expression of TAL-1 (Apian 1992).
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1:6 Risk-Adapted Therapies in ALL
1:6:1 Principles o f  ALL Therapy
The aims o f ALL treatment regimens are: the rapid restoration of bone marrow 
function by using multiple chemotherapy drugs at acceptable toxicities in order to 
prevent the emergence of resistant subclones, the use of adequate prophylactic 
treatment of sanctuary sites, such as the central nervous system (CNS); and post­
remission consolidation therapies to eliminate minimal (undetectable) residual 
disease (MRD). Post-remission therapy has traditionally been categorized as 
intensification or consolidation treatment, and is followed by prolonged maintenance 
therapy.
For late intensification therapy, many approaches have been used, including bone 
marrow transplantation (BMT). Although allogeneic BMT may be essential to cure 
patients with specific high-risk subsets of ALL, or those who relapse after initial 
treatment (Chao 1991; Barrett 1992; Annino 1994; Forrest 1998) clinical trials do 
not support its use in first complete remission (CR) for adults with ALL and good- 
risk or standard-risk features (Horowitz 1991; Zhang 1995). As yet, autologous 
transplantation has not been proven to be more effective than chemotherapy in ALL 
(Fiere 1998).
Current treatment strategies in adult ALL result in CR rates o f 70- 90%, but long­
term disease survival in only 25-50% of patients (GFCH 1996; Seeker-Walker 1997; 
Wetzler 1999).
The ability to identify groups of ALL patients with different prognoses, based on the 
biology of the malignant clone and clinical patterns of disease, allow treatment to be
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tailored to individual risk groups. This approach has resulted in dramatic 
improvements in outcome for paediatric patients with ALL and as a result risk- 
adapted strategies based on biological and clinical features are now being applied to 
adults with ALL in an attempt to improve their survival. Notably, significant 
progress has been made in survival for adult patients with mature B-cell ALL with 
the introduction of novel therapeutic approaches for this subset o f patients (Hoelzer 
1996).
1:6:2 Prognostic F actors
In adult ALL the most important prognostic factors are determined at diagnosis, 
several clinical and biological factors influence CR rates, remission durations, and 
survival rates.
In multivariate analyses, patients presenting with WBC counts >30x109/l have 
significantly shorter durations of remission compared with patients with lower 
leukocyte counts (Kantarjian 1990; Cuttner 1991; Linker 1991; Larson 1995). 
Advancing age decreases both CR rate and disease-free survival in almost all adult 
ALL treatment studies. Age of >60 years is associated with a particularly poor 
prognosis (Marcus 1986; Kantarjian 1990; Chessells 1998).
Minor factors, or those that have had some significance with certain treatment 
regimens, are the percentage of circulating blast cells; the degree of bone marrow 
involvement; the presence of hepatomegaly, splenomegaly, or lymphadenopathy; 
lactate dehydrogenase levels; and CNS involvement at presentation.
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Karyotype is well accepted as an independent prognostic factor in children, and in 
multivariate analyses of risk factors in adult ALL, karyotype was identified as the 
most important factor for DFS (Seeker-Walker 1997; Faderl 1998; Wetzler 1999).
In general, adult patients with a normal karyotype have improved survival over those 
with a cytogenetic abnormality. Patients with t(9;22), t(4; 11), and t(8; 14) [or variant 
translocations, t(2;8) or t(8;22)] in mature B-cell ALL appear to have better 
outcomes when treatment approaches other than standard induction, intensification / 
consolidation and maintenance are used (Seeker-Walker 1991; Faderl 1998; Wetzler 
1999). Recently, two other cytogenetic abnormalities, -7 and or +8, have been 
associated with adverse outcomes in adult ALL patients treated with standard multi­
agent chemotherapy approaches (Wetzler 1999). In contrast, these studies indicated 
that patients with a t(l 0; 14) and other abnormalities involving chromosome band 
14ql 1-13, who typically have T-cell ALL, have an excellent prognosis when treated 
with conventional combination chemotherapy regimens.
In Ph positive ALL to date, allogeneic BMT is the only post remission therapy 
associated with improved long term DFS for about 30% of these patients (Barrett 
1992; Miyamura 1992; Annino 1994).
For patients with an HLA-matched donor, allogeneic BMT in first CR is currently 
the treatment o f choice. Since these patients relapse quickly and are usually resistant 
to salvage therapy, BMT should be performed as soon as remission is achieved.
In young patients without a donor, as well as the many Ph positive patients who are 
>60 years old, where allogeneic BMT is not an option, newer strategies including 
the use of attenuated transplant regimens, with subsequent immunotherapy,
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antisense molecules or specific tyrosine kinase that target products of the BCR/ABL 
fusion gene or its chimeric protein product may be considered for this group of high 
risk patients (de Fabritiis 1998; Ottmann and Hoelzer 2002; Wassmann 2002; 
Wassmann 2003).
Similarly because o f their high risk, pro-B-ALL t(4 ;ll)  patients are often offered 
allogeneic BMT in first CR and this can improve survival up to >60% (Ludwig
1998).
In addition to factors determined at presentation, response to treatment is 
significantly correlated with outcome. Until recently it was evaluated with relatively 
coarse parameters such as time to achievement of CR. Failure to attain CR within 4- 
6 weeks following induction chemotherapy was reported as an adverse prognostic 
factor (Lazzarino 1982; Hoelzer 1988). In the past decade, new highly sensitive 
methods for the detection of MRD (disease undetected by microscopic analysis of 
bone marrow slides), which reached at its best a sensitivity of 1-5 leukaemic cells in 
100 normal cells, have been developed. Methods for MRD detection include 
assessment of leukaemia specific constellation of surface markers by flow cytometry 
(Orfao 1994; Farahat 1998; Weir 1999), detection of fusion genes related to specific 
chromosomal translocations, for example detection of the chimeric BCR-ABL in 
t(9;22) by PCR, and analysis of individual rearrangements of immunoglobulin and 
T-cell receptor genes by PCR (Cole-Sinclair 1993; Stolz 1999; Szczepanski 2002), 
and more recently by real-time PCR (Eckert 2003). MRD analysis by 
immunophenotyping may detect one leukaemic cell in 104 normal cells, and PCR 
based studies can detect one abnormal cell in 106 normal cells.
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Results of MRD evaluation in adult ALL shows that after induction, a high MRD 
level >103 was associated with a high risk o f relapse (89%), however even patients 
with low MRD levels <103 had a considerable risk o f relapse (46%) (Brisco 1996; 
Foroni 1997; Mortuza 2002). In retrospective studies, MRD was a significant 
predictor of relapse risk at all time points, but its predictive value was improved at 
later time points (months 6-9). A combination o f time points during the first year 
improved the prognostic model, with 52% of patients with high MRD level (> 104) at 
any point relapsing compared to none of those with low MRD (<104) (Brueggemann 
2001), These findings have been confirmed in a prospective study (Hoelzer 2001). 
Using a combination of these recognised risk factors precursor-B or T-ALL allows 
for stratification of adult patients into three risk groups:
1. Good-Risk Group
This group contains patients with both B and T-lineage disease, who have no 
adverse cytogenetics, are less than 30 years of age, present with WBC counts of 
<30x109/l, and achieve remission in less than four to six weeks. These patients are 
estimated to have a 3-year DFS of 69% (Linker 1997).
2. Intermediate-Risk Group
This group is comprised primarily o f patients with precursor-B ALL <60 years of 
age. It is likely that as yet undefined, biological features are inherent within subsets 
of intermediate-risk patients and account for the heterogeneity in DFS rates of this 
group. The identification of prognostic factors based on disease biology would help 
more accurately identify the higher risk patients within this group, who would
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benefit from dose intensification with allogeneic transplant in first CR. For example, 
the molecular detection and quantification of MRD following early intensification.
3. High-Risk Group:
This group, characterized by patients with B-lineage disease, presenting with WBC 
counts >100xl09/l, and/or adverse cytogenetics, has a dismal prognosis with 
standard treatment approaches, with 3-year DFS estimated between 0 and 20% 
(Linker 1997). Patients >60 years of age are also considered within this group.
It is thus clear that in adult patients presenting with ALL a comprehensive analysis 
of risk factors is needed. This must include chromosomal analysis, by conventional 
cytogenetics where possible or complementary molecular methods.
1:7 Patient selection The MRC Acute Lymphoblastic
Leukaemia Trials
The Medical Research Council Leukaemia Steering Committee was formed by 
interested haematologists, physicians, paediatricians and statisticians in the late 
1950’s, to consider the treatment of children and adults with acute leukaemia, with a 
view to establishing randomized trials. The first randomized trial, comparing steroid 
therapy at high and low dosage in conjunction with 6-mercaptopurine, was published 
in 1963. The Childhood Leukaemia Working Party initiated the UK ALL I trial in 
August 1970, and reported its first results in November 1972. The Working Party on 
Leukaemia in Adults set up multicenter trials in acute and chronic myeloid 
leukaemia, chronic lymphocytic leukaemia, multiple myeloma, and polycythaemia
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rubra vera at about the same time, but adult patients with acute lymphobastic 
leukaemia were enrolled in the childhood trials, UK ALL I through VI. The first 
entirely adult trials UK ALL IX (1985) and UK ALL XII (1993) were open to persons 
over 15 years of age.
UKALL I (1970-1971)
This trial was designed to estimate the effect of prophylactic therapy on the central 
nervous system (Lilleyman and Eden 1986) and included 16 patients over the age o f 
15 years in whom the remission rate was 88%. EFS at 5 years, however, was only 
6%
UKALL 11(1972-1973)
This trial included the addition of L-asparaginase (MRC 1986). O f the 325 patients 
entered in this trial, 23 were older than 15 years. The remission rate for adults was 
70%, EFS at 5 years was 30%, and there were 6 adult survivors at 20 years (26%). 
UKALL 111(1974-1975)
In this trial two methods of administering L-asparaginase and cytosine arabinoside, 
and gaps in 6-mercaptopurine administration were assessed in 392 patients, 
including 37 adults (MRC 1986), in whom the remission rate was 73%, the EFS at 5 
years was 14%, and 6 of 37 adults remained alive at 20 years (16%).
UKALL IV (1975-1978), UKALL V (1976-1979)
One hundred and twenty five o f 362 patients in UKALL IV were adults who 
received intensive maintenance chemotherapy (MRC 1986). The remission rate was 
79%, the EFS at 5 years was 17% and 23 adults survived at 20 years (18.4%). No 
adults were entered into UKALL V.
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UKALL VI (1978-1980) This trial investigated methods o f consolidation therapies. 
One hundred and fifty one of 379 patients were >15 years old. The remission rate 
was 87%, the EFS at 5 years was 25%, and 33 patients were still alive at 20 years 
(22%) (MRC 1985). No adults were entered into UKALL Trial VII.
UKALL VIII (1980-1984)
This trial included randomization at intensification as well as maintenance stages, 
with over 800 patients recruited over 4 years. It reported the single greatest 
improvement in EFS seen in children in the UK up to that date (MRC 1986;Eden 
1991; Eden 2000). No adults were entered in this trial.
UKALL IX (1980-1985)
This trial ran concurrently with the childhood trial UKALL VIII. A total of 266 
patients were entered. The prognostic factors o f increased age and high WBC count 
were identified. The CR rate was 87% and the EFS at 5 years was 26%.
UKALL XA (1985-1992)
This trial was designed to assess the effect on long-term survival o f intensifying 
treatment given during the first four weeks, as reported by the West German Study 
Group (Hoelzer 1988), to which 618 eligible patients were entered. The remission 
rate was 88%. At 5 years the overall DFS was 28%, and there was no difference 
between the three arms of the trial, which contradicted expectations. This was 
attributed to inadequate intensity of consolidation. Compliance with trial protocol 
was a problem in this trial, with a number of patients undergoing transplant 
procedure.
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The current trial UKALL XII (1993-to date)
Allografting and autografting were shown to be successful in some patients in 
UKALL XA. UKALL XII was designed to evaluate the efficacy of BMT in first 
complete remission and of two highly intensive blocks of therapy after remission. 
Entry criteria are the diagnosis of ALL in an adult patient (aged 15-55 years at the 
time of diagnosis), with the exception of the L3 Burkitt type patients, who are 
treated according to a different protocol.
All patients entered to the trial are expected to undergo full diagnostic workup at 
presentation, with morphology, cytochemistry, immunophenotyping and 
cytogenetics as essential requirements. Central review is provided for morphological 
diagnosis, and the Leukaemia Research Fund (LRF) Cytogenetics Group reviews all 
regionally analysed karyotypes centrally. (Harrison 2001). The sheer size of 
participation in this trial (target recruitment at commencement 1000 patients) makes 
this a perfect setting for collecting information on a number of prognostic factors 
including full cytogenetic and MRD studies.
1:8 Method selection Screening for chromosomal
abnormalities in ALL
1:8:1 Molecular analysis in ALL
Since the prognostic significance of certain chromosomal abnormalities had become 
known throughout the 1980s cytogenetic analysis became a requirement for entry o f 
patients to trials of treatment. This commenced officially with the UK ALLX and XA
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trials in children and adults respectively. At that time cytogenetic analysis of 
haematological malignancies was not well established. In the U.K. there was no 
standardisation or co-ordination between laboratories and the cytogenetic results in 
those trials were rather incomplete. In an attempt to improve co-ordination of 
cytogenetic studies in the following trials, UKALLXI and XII for children and 
adults, the LRF in association with Professor Loma Seeker-Walker established a 
cytogenetics group to undertake this role, in collaboration with the United Kingdom 
Cancer Cytogenetics Group (UKCCG) representatives from 30 laboratories carrying 
out cytogenetic analysis in acute leukaemia. Through their efforts the cytogenetic 
results obtained in UKALLXI were much improved (Richards 1998; Hann 2000). 
Cytogenetic analysis of leukaemic blasts in ALL is notoriously difficult. There are a 
number of factors responsible for this: bone marrow aspirates may have low cell 
counts; in some cases the leukaemic blasts do not divide in culture; the morphology 
of chromosomes and the quality of chromosome banding may be poor. Failure to 
yield sufficient analyzable metaphases in 10-30% of cases has been reported in most 
surveys (Fenaux 1989; Seeker-Walker 1990; Schiffer 1992; GFCH 1996; Secker- 
Walker 1997; Wetzler 1999).
In spite of this, cytogenetic analysis remains the best method for a genome wide 
detection of all chromosomal abnormalities. Variant or complex rearrangements of 
established changes can identified, new recurring abnormalities can be discovered, 
for which cytogenetics provides the starting point for molecular characterisation of 
genetic changes. Analysis on an individual cell basis reveals secondary
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chromosomal changes involved in karyotype evolution, which may be important in 
disease progression.
The introduction o f molecular analysis throughout the 1980s assisted in overcoming 
some of the limitations of cytogenetic analysis in ALL. Molecular analysis is highly 
sensitive for the detection of known genetic abnormalities (Griesinger 1994; Fears 
1996; Scurto 1998; Gleissner 2001). It can distinguish lesions that appear identical 
by karyotyping, but in fact involve different genes with different prognostic and 
therapeutic implications. It can also detect submicroscopic changes, which may be 
important in risk assignment (Romana 1994).
The three major molecular techniques applied in the investigation of chromosomally 
mediated genetic change in ALL are: Southern blotting, reverse transcriptase (RT)- 
PCR and FISH. Southern blotting and RT-PCR have the advantage that they can be 
carried out on DNA or RNA prepared from the total cell population of leukemia 
samples and do not require the preparation o f cells in metaphase. Translocations that 
result in breakage within a well-defined region of a gene can be investigated by 
Southern blotting, for example in MLL gene rearrangements, in which there are 
numerous partner genes many of which have not as yet been cloned. RT-PCR is 
widely applicable for the rapid and sensitive detection o f translocations, provided 
both partner genes have been cloned and the breakpoint clusters are small enough to 
design specific primers. It is an excellent method for the detection o f MRD (Gehly 
1991; Lion 1992; Miyamura 1993; Satake 1997; Park 2000). RT-PCR is limited by 
the need for viable cells for RNA extraction and the need for multiple primers in 
multiplex experiments, to allow the reliable detection of translocations with more
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than one breakpoint such as the BCR/ABL translocations and MLL gene 
rearrangements. Insufficient primers give false negative result. On the other hand, 
the exquisite sensitivity of the technique makes contamination with a few cells, or 
even a trace o f DNA a potential source o f false positive results (Bagg and Kallakury 
1999). FISH in interphase and metaphase has a number o f advantages over 
molecular analysis in the detection o f prognostically important chromosomal 
abnormalities. The availability of a wide range of robust probes and refined 
technologies for application and image analysis particularly, when applied in a 
complimentary manner with conventional cytogenetic techniques, means that FISH 
is the best method for the detection of both numerical and structural chromosomal 
abnormalities in ALL, the rapid detection o f which allows the modification of 
treatment modalities offered to patients.
The childhood trial, ALL 97 was established in April 1997. It had a high-risk arm, in 
which patients were treated according to a different protocol. These included 
patients with the translocation, t(9;22), MLL gene rearrangements, and near 
haploidy. In order to ascertain that these patients were assigned to the correct risk 
group, in addition to cytogenetic analysis that was being carried out on >95% of 
patients, material from cytogenetic preparations was additionally used in an 
interphase FISH screening programme to detect these chromosomal abnormalities. 
This also allowed an assessment of the effectiveness of this approach to be 
compared with that of conventional cytogenetics for accuracy o f detection. Testing 
for BCR/ABL, MLL rearrangements and the cytogenetically invisible ETV6/AML1 
were carried out in all cases. Near haploidy was tested for using centromeric probes
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in cases with normal or failed cytogenetic result (Harrison and Foroni 2002).
1:8:2 Fluorescence in-situ hybridization:
FISH relies on the ability of fluorescent molecules to be deposited in chromatin at 
the sites o f specific DNA sequences. The use of the in situ hybridization technique 
began in the late 60s, when Gall and Pradue reported the hybridization of radioactive 
DNA probes for repetitive sequences to mouse and drosophila chromosomes. Harper 
who mapped the insulin gene to chromosome 11 p i5, achieved autoradiographic 
localization of single genes on human chromosomes (Harper 1981). Methods for 
non-isotopic in situ hybridization and detection were soon developed, to overcome 
the difficulties o f the use of radioactive probes. The technique was refined 
throughout the 1980’s until by the mid 1990’s 24 different chromosome painting 
probes specific for each of the somatic chromosome pairs and the sex chromosomes, 
X and Y, could be hybridized simultaneously and detected in different colours using 
specialized filter sets and computer software (Speicher 1996; Harrison 2000; Van 
Limbergen 2002).
The components of the FISH procedure are the probe (DNA or RNA) of interest, 
which can range in size from a single gene to whole chromosomes, and the locus i.e. 
the target sequence, to which the probe hybridizes. In order to microscopically 
visualize the hybridization o f the probe to the target, a fluorescent tag is attached to 
the probe. The probes for the identification o f individual chromosomes, or 
chromosome arms, are often called painting probes or whole chromosome paints 
(wcps). For the detection of deletions or duplications, probes are derived from the 
gene sequence in question or from closely linked markers, the so-called single copy
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gene probes. Also useful are repetitive sequences probes of structural regions of 
chromosomes for example those to alpha satellite regions near centromeres can be 
used to identify and count individual chromosomes. Subtelomeric probes may be 
used to define cryptic translocations. The probe is labelled, either directly by the 
incorporation of a fluorochrome-conjugated nucleotide e.g. fluorescein, or indirectly 
with the incorporation of a reporter molecule e.g. biotin-dUTP or digoxigenin- 
dUTP.
Principles of the FISH method:
Target sequences are prepared, the probe and target sequences are denatured with 
heat and/or formamide, they are then combined and allowed to hybridize. 
Non-specifically bound probe is washed off the target. If the probe was directly 
labelled with a fluorochrome, antifade solution with a counter stain such as 
propidium iodide (PI) or 4 ’6-diamino-2-phenyindionle dihydrochloride (DAPI) is 
applied and the preparation is cover slipped ready for analysis.
Indirectly labelled probes are detected by a reaction that binds a fluorochrome e.g. 
fluorescein-avidin or antidigoxigenin-rhodamine to the probe.
If the target sequence is large, >50kb, the signal is usually visible. Smaller signals 
may need to be amplified by immunocytochemistry. (Fig 1:1)
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Fig 1:1. Principle of FISH
Chapter II 
Materials and Methods
II: 1 Patients and controls
Patient selection:
The work presented here commenced in October 1998. Regional cytogenetics 
laboratories carrying out cytogenetic studies on patients entered to the UKALLXI I 
trial were informed in writing of the commencement o f the study and asked to send 
fixed cell suspensions from cytogenetic preparations from newly diagnosed adult 
patients with ALL. This included trial and non-trial patients.
Respondents sent new and retained samples from 185 patients, or information on 
studies carried out locally in a further 8 patients with adult ALL. Samples were 
blood in 14 cases, bone marrow in 172 cases, and both in 7 cases, of which 178 
samples were from patients entered to UKALLXI I.
Patient samples were assigned unique identification numbers (UIN) (from 1-193). 
These UIN are presented in all tables and images within this work.
Clinical features of all patients are shown in Table II: 1. With the exception of one 
patient, the age range was that of inclusion to the UKALLXII trial i.e. 15-55 years, 
the sex ratio of 1.35:1 male: female was similar to that reported in other adult series. 
Considering the largely retrospective nature o f the study and dependence on 
availability of stored material, the proportion of cases with failed cytogenetics 
(fewer than 20 normal metaphases analysed), at 22% was only slightly higher than 
expected for a multicentre trial.
Nine bone marrow samples were selected as controls from adult patients with a 
normal karyotype and non-malignant haematological disease. These included six
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cases with immune thrombocytopenia, two with iron deficiency anaemia and one 
with immune neutropenia.
For chromosomal enumeration experiments using the Multiprobe®-I (as detailed in 
section 11:4) five bone marrow samples were selected as negative controls, two from 
patients with a normal karyotype and non-malignant haematological disease; one 
with immune thrombocytopenia, and the other with immune neutropenia, and three 
cases from adults with ALL with pseudiploidy, as well as two positive controls from 
patients with ALL and hyperdiploidy.
Table II.l Clinical features of patients in the study.
Age
Mean
(Range)
Sex 
M: F
WBC x l0 9/l 
Median 
(range)
c-ALL
Immunophenotype 
Pre-B T-cell Null Other
Abn
Conventional
Cytogenetics
Norm Fail
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(15-88)
111:82 9
(0.11-930)
82 34 32 3 11 111 39 43
cALL: CDIO+Common ALL Abn :Abnormal clone identified Norm:20 normal metaphases
analysed
II: 2 Cytogenetics
Cytogenetic analysis was carried out on diagnostic samples in the UK regional 
cytogenetic centres. All samples were processed by established short-term culture 
methods (Seeker-Walker 1997). The G-banded slides and karyotypes were reviewed 
by the LRF Cytogenetics group and collected into their database. Karyotypes were 
described according to the International System of Human Cytogenetic
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Nomenclature (Mitelman 2004). The requirement for a classification of “normal 
karyotype” in the UKALLXII trial is complete analysis of 20 metaphases.
II: 3 FISH slide preparation:
Fixed cell suspensions used for conventional cytogenetics were stored at -20°C, and 
re-used for the FISH studies.
Successful FISH is dependent on the quality of the fixed cell suspension available. 
Isolated nuclei without residual cytoplasm or other cellular debris are vitally 
important, since the presence of these debris reduces the intensity of FISH signals 
and increases background staining in both interphase and metaphase studies, but 
more markedly in metaphase FISH studies.
Numerous methods have been described to optimise the quality of FISH 
preparations, utilizing a combination of factors such a temperature gradients, 
positional factors (such as distance between dropper and slide, and placing the slide 
at an angle) and humidity as well as various enzymatic techniques to remove cellular 
debris and cytoplasmic residues. In this study I adopted the following steps for slide 
preparation for FISH.
1-Stored fixed bone marrow/peripheral blood samples were stored at -20°C in 3:1 
Methanol: Acetic acid fixative.
2-The cells were washed and resuspended in fresh fixative solution prior to slide 
preparation.
3-The cell suspension was dropped from a height of about 15cm onto an ice-cold 
slide placed on a rack over boiling water to create the necessary humidity, and
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facilitate spreading and flattening of cells.
4-As the fixative started to evaporate from the edges of the drop; a further drop of 
ice-cold fixative solution was added.
5-The slide was placed in an air current to speed up the evaporation of the fixative.
6-Further flattening and separation o f the interphase cells and chromosomes within 
the metaphases was achieved by placing the slide on a hot plate at 60°C for a few 
minutes to dry completely.
7-Any residual cellular debris or cytoplasm was removed by putting the slides into a 
70% solution of glacial acetic acid, at room temperature for 1-2 minutes, followed 
by rinsing in distilled water for a further 2 minutes.
8-The slides were then aged in 2 x SSC (sodium chloride, sodium citrate) for 30 min 
at 37°C, dehydrated in an ethanol gradient at 70%, 90% and 100% for 2 minutes 
each and air-dried.
II: 4 FISH Probes & Equipment
11:4:1 Probes
Commercially available directly or indirectly labelled probes were used throughout 
the study. Single or dual colour probes were used for the detection of BCR and ABL, 
MLL, ETV6 and AML1 rearrangements. (Vysis, U.K. Oncor, France) Centromeric 
probes (Oncor, France), and a device coated with 24 individual directly labelled 
alpha satellite probes (Chromoprobe Multiprobe®-I, Cytocell UK) were used for 
chromosome enumeration and marker chromosome identification. Confirmation of 
translocations and marker chromosomes was carried out using directly labelled
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whole chromosome painting probes (Cambio, STAR™ FISH, U.K.)
(i) BCR/ABL probes:
The probes used to detect the BCR/ABL fusion o f the t(9;22)(q34;ql 1) 
translocation:
A LSI Dual Colour BCR/ABL probe (Vysis, U.K.)
This dual colour probe contains two probes; the BCR probe extends from between 
BCR exon 13 and 14 (M-bcr exons 2 and 3) in a centromeric direction on 
chromosome 22, approximately 300kb, extending beyond the m-bcr region. The 
BCR probe spans both M-bcr and m-bcr breakpoints, thus detecting breakpoints in 
both regions. The probe for ABL begins between exons 4 and 5 and extends over 
200kb towards the telomere of chromosome 9, spanning the breakpoint region. The 
probes are directly labelled with SpectrumGreen (BCR) and SpectrumOrange 
(ABL).
In a normal cell two red and two green signals are observed. As a result o f the 
translocation the ABL probe becomes juxtaposed to BCR on the der(22) to provide a 
yellow fusion signal in metaphase and interphase cells, in association with one red 
and one green signal.(Fig 11:1) In a nucleus possessing the t(9;22) involving the M- 
bcr, one green (native BCR), one red (native ABL), one red/green (yellow) (fused 
5’BCR/3’ABL) signal are observed. Minor breakpoint (m-bcr) signal patterns appear 
as one red, two green and one fusion signal.
B LSI Dual Colour BCR/ABL ES (Extra signal) probe (Vysis, U.K.)
This probe detects BCR/ABL fusion with increased sensitivity, it contains a BCR 
probe similar to that in the BCR/ABL probe kit, and an ABL probe that extends
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beyond the breakpoint cluster region to include the Argininosuccinate synthetase 
(ASS) gene sequences (ES probe). In BCR/ABL positive cells, in addition to the 
fusion signal, an extra red signal from the residual ASS  area of the derived 
chromosome 9 will be seen, cells without this second signal are negative, thus 
reducing the false positive rate. (Fig 11:2)
(ii) LSI Dual colour TEL/AML1 LS probe (Vysis):
This probe is used to detect the ETV6/AML1 fusion o f t( 12;21 )(p 12;q22) 
translocation. The probe for ETV6 extends from between exon 3-5 towards the 
telomeric end of chromosome 12, covering approximately 350 kb. The probe for 
AML1 extends over 500 kb spanning the entire gene. The probes are directly labelled 
with SpectrumGreen (ETV6) and SpectrumOrange (AML1). Normal cells have two 
red and two green signals, in the interphase nuclei o f ETV6/AML1 positive cells, one 
or more fusion signals are seen representing the fusion gene on the derived 
chromosome 21. Since the AML1 probe spans the breakpoint, the signal splits 
between the derived chromosomes 12 and 21 so that in addition to the fusion signal 
with the ETV6 on the derived chromosome 21, a small extra signal is present on the 
derived chromosome 12. A red signal corresponding to the normal AML1 signal on 
chromosome 21 and a green signal corresponding to the normal ETV6 on 
chromosome 12 are seen. (Fig 11:3).
(iii) MLL probes
These probes were used to detect translocations involving the MLL gene at 11 q23 
A Single colour MLL probe (Oncor)
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This is an indirectly labelled probe, which spans the MLL breakpoint cluster region. 
In cases with a rearrangement o f MLL the probe is split between the derived 
chromosomes, giving three signals in positive interphase cells. (Fig 11:4) Cases with 
three or more signals need further testing using centromeric probes to exclude 
trisomy for chromosome 11. Patients with deletions, duplications, loss or gains of 
one signal will be detected. This probe does not detect breakpoints 3' o f the 
breakpoint cluster region which occur in 20% of cases.
B LSI Dual colour MLL probe (Vysis, U.K.)
This comprises two directly labelled probes, located to 1 lq23, The SpectrumGreen 
labelled probe lies centomeric to MLL and SpectrumOrange probe telomeric to the 
MLL breakpoint. In normal cells there will be two yellow (fused or closely adjacent 
green and red) signals. Cells with an MLL translocation will show one yellow signal 
(on the normal llq23) and separated red and green signals (one on each of the 
derived chromosomes). (Fig 11:5) The probe successfully detects unbalanced 
translocations in which one (usually the red) of the separated signals is lost.
(iv) Centromeric probes:
FISH testing for numerical chromosomal changes was carried out using the 
Multiprobe®-I device. This device allows detection o f 24 centromers in a single 
hybridisation on one slide. (Fig 11:6) The probes used in the Multiprobe®-I kit are 
listed in (Table 11:2).
Alternatively the gains or a loss of individual chromosome was assessed using 
indirectly labelled alpha satellite probes (Oncor) in single or dual colour 
combinations.
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(v) Whole chromosome painting:
Whole chromosome painting probes (wcps) (Star*FISH, Cambio) directly labelled 
with biotin or Cy3 were used.
Table II.2 Probes used in Chromoprobe Multiprobe®-!
Multiprobe template 
square
Chromosome Locus DNA class
1 lqh D1Z1 satellite III
2 2 D2Z2 a-satellite
3 3 D3Z1 a-satellite
4 4 D4Z1 a-satellite
5 1/5/19 D1Z7/D5Z2/D19Z3 a-satellite
6 6 D6Z1 a-satellite
7 7 D7Z1 a-satellite
8 8 D8Z2 a-satellite
9 9qh D9Z3 satellite III
10 10 D10Z1 a-satellite
11 11 D11Z1 a-satellite
12 12 D12Z3 a-satellite
13 13/21 D13Z1/D21Z1 a-satellite
14 14/22 D14Z1/D22Z1 a-satellite
15 15 D15Z4 a-satellite
16 16 D16Z2 a-satellite
17 17 D17Z1 a-satellite
18 18 D18Z1 a-satellite
19 1/5/19 D1Z7/D5Z2/D19Z3 a-satellite
20 20 D20Z1 a-satellite
21 13/21 D13Z1/D21Z1 a-satellite
22 14/22 D14Z1/D22Z1 a-satellite
X X DXZ1 a-satellite
Y Y DYZ1 satellite III
II: 4:2 Equipment
Slides were analysed using a Ziess Axiophot epifluorescence microscope (Ziess, 
Oberkochem, Germany) equipped with a 100W mercury lamp. Images were
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captured using a cooled coupled device (CCD) camera (Photometries) and analysed 
using Mac Probe software (Applied Imaging International Ltd, UK).
II: 5 FISH techniques
II: 5:1 Directly labelled commercial probes
(LSI probes; BCR/ABL, MLL, ETV6/AML1 and directly labelled 
whole chromosome paints)
Method A
1-Denaturation of target DNA was achieved by flooding the selected area o f the 
slide with 40pi of 65% Formamide, slides were heated on a hot plate to 72°C for 
2min, then dehydrated in an ethanol gradient at 70%, 90% and 100% and air dried.
2-Locus specific probes were reconstituted in formamide, in an eppendorf to which 
lpl of probe, 2 pi distilled water and 7 pi o f Hybrisol VII (100% formamide) were 
added. The solution was heated in a water bath to 72°C for 5 minutes, to denature the 
probes.
3-WCP probes were reconstituted by adding 13 pi of Hybrisol VI (65% formamide) 
to each 2 pi of probe, denatured by heating in a water bath to 72°C for 10 minutes, 
re-annealed by incubation at 37°C for a further 30 minutes.
4-The probe was applied to the slide, the hybridization area was covered by a glass 
coverslip, the edges of which were sealed with cow-gum. The slides were hybridized 
overnight in a humid chamber at 37°C. (A plastic slide box kept in an incubator, 
moisture was created by placing wet paper towels under the slides).
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5-Non-specificallv bound probe was removed the next day by washing the slides in a 
0.5XSSC solution, heated to 72°C for 2 minutes, followed by a second wash in a 
mixture of 2XSSC + Tween, at room temperature for a further 2 minutes.
6-Slides were counter stained with DAPT and mounted in antifade solution 
(Vectashield; Vector laboratories, Burlingame, CA, USA).
Method B co-denaturation
In this modified approach target DNA and probe were denatured together. 
Reconstituted probe was applied to the target area, slides and probe were co­
denatured on a hot plate at 72°C for 2 minutes. Cohybridisation and washing steps 
was carried out as described in steps 4-6 above.
II: 5:2 Indirectly labelled probes
(Single colour MLL specific probe and alpha satellite centromeric probes)
1-Denaturation of the target DNA was achieved by flooding the area o f the slide 
with 40pl of 65% Formamide. Slides were heated on a hot plate to 72°C for 2 min, 
then dehydrated through an ethanol gradient at 70%, 90% and 100% and air-dried.
2-The probe was reconstituted by heating to room temperature {MLL) or 
reconstituted with formamide by adding lp l of probe to 15pl o f Hybridsol VI (65% 
formamide) and denatured by heating in a water bath to 72° for 5 minutes (alpha 
satellite centromeric probes).
3-The probe was applied to the target area o f the slide, covered with a glass 
coverslip and sealed with cow-gum. The slides were hybridized overnight in a 
humid chamber at 37°C.
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4-Non-specificallv bound probe was removed the following day by washing slides in 
a 0.5XSSC solution heating to 72°C for 2 minutes, followed by a second wash in a 
mixture of 2XSSC + Tween, at room temperature for a further 2 minutes.
5-Detection o f probe was achieved by flooding the target area with 30pl of 
antidigoxigenin-rhodamine/ antiavidin- Fluorescein isothiocyante (FITC) mixture 
and incubating the slide for 15 minutes at 37°C.
6-Excess fluorochrome bound antibody was removed by washing slides in a mixture 
of 2XSSC + Tween, at room temperature for 2 minutes before counterstaining and 
analysis as described above.
II: 5:3 Multiprobe®-I
1-1-2pl of fixed cells were dropped onto each of the 24 scored squares on the 
customizes slide (Fig 11:6) cell density was adjusted to ensure at least 100 nuclei in 
each square.
2-1 pi of hybridization solution (65% formamide) was added to the probe attached to 
each of the squares of the coverslip device.
3-Alpha satellite probe and target DNA were then co-denatured by placing the slide 
over the coverslip; the whole device (slide and coverslip) was then inverted and 
placed onto a hot plate at 75°C for 2 minutes.
4-The device was hybridized in a humid chamber (a plastic slide box suspended in a 
water bath) at a temperature of 37°C overnight.
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5-The next day the slide was washed in a solution of 0.4XSSC heated to70°C for 2 
minutes, followed by a further wash in a mixture of 2XSSC and Tween at room 
temperature for a further 2 minutes.
6-Slides were then counter stained with propidine iodine and mounted in antifade 
solution (Vectashield; Vector laboratories, Burlingame, CA, USA).
II: 6 Triple testing or Multiplex FISH
The method was adapted to combine the three dual colour probe tests for BCR/ABL, 
MLL, and ETV6/AML1 rearrangements in a single hybridisation step on one slide, in 
a triple or multiplex FISH test. In the presence of good quality cellular sample a 
slide was spotted with three separate drops of suspension, each equivalent to 3pi as 
shown in (Fig 11:7). Probes were reconstituted as described above, with one third o f 
the probe volume added to each test area. The three areas were hybridised under 
separate 13 mm diameter coverslips overnight. Using this modification it was 
possible to greatly reduce the time, volume of sample used and the quantity o f 
probes utilised.
II: 7 Sequential FISH
Material for this group of adult ALL patients was limited and often of poor quality, 
therefore to conserve these valuable cells, we developed a method of serial 
hybridisation o f probes (sequential FISH). Wcp were applied to slides following 
their hybridisation with locus specific probes.
After examination and image capture of all required cells,
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1-The coverslips were removed by immersion in phosphate buffer solution (PBS) at 
room temperature for 15 minutes.
2-The slides were then dehydrated through an ethanol gradient.
3- wcp directly labelled with biotin or Cy3 (Oncor) were used in dual (using one 
biotin and one Cy3 labelled probe) or triple colour (one biotin, one Cy3 and the third 
composed of equal volumes of biotin and Cy3 giving a yellow fluorescence) 
combinations.
Up to five serial hybridisations with wcps for two or three chromosomes at a time 
were carried out. Following each hybridisation slides were washed and dehydrated 
as described above.
4-Images were captured following each sequential hybridisation. The serial digital 
images were superimposed using MacProbe software; each chromosome was 
assigned a different pseudocolour. Thus a complete image o f the metaphase with 
variously coloured chromosomes was created in each case, to enable improved 
interpretation of chromosome abnormalities.
Where metaphases were very limited, in samples with unidentified chromosomes, a 
further modification to this technique, by the application of wcp to interphase nuclei. 
The presence of more than two distinct areas of hybridisation within nuclei 
suggested that translocations involving large segments of the painted chromosome 
were present. Once the number of potential chromosomes involved in translocations 
had been determined, their origins could be confirmed by sequential metaphase 
FISH.
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II: 8 Determination of positive results and cut-off 
values
For locus specific dual-colour FISH probes, 200 nuclei were scored for each test 
wherever possible. A minimum of 100 cells was accepted for a test result to be 
eligible for inclusion in this study. The number and the co-localization of the red and 
green signals were determined for each nucleus. A positive result from co­
localization of the red and green fluorescence was accepted only if  a yellow fusion 
signal (produced by overlapping red and green signals) was observed. Touching red 
and green signals were considered to be negative. The proportion of cells with co­
localized signals was calculated as a percentage of the total number of nuclei 
analysed testing with each probe and for each patient.
To determine the hybridisation efficacy for each probe the nine control samples were 
hybridised individually with each probe as described above. Four hybridisation 
signals, two specific for BCR and two for ABL were found in 96 ± 1.3% of 
interphases examined, two specific for ETV6 and two for AML1 were found in 96.5 
± 2% of interphases examined. Two hybridisation signals were found in 96.7% ± 1.7 
of nuclei tested with the MLL Oncor probe, and in 97.1% ± 2.3 of nuclei tested with 
the MLL Vysis probe. The results indicate high hybridisation efficiency for all three- 
probes.
In normal nuclei two discrete signals for each BCR and ABL , ETV6 and AML1 
should be seen. As a result of close positioning of two signals by chance it is 
possible to detect apparent fusion signals (false positive results) in a small 
proportion of normal nuclei, a mean rate o f fusion signals o f 1.76 ± 0.97% was
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found in the nuclei o f the normal controls tested for ETV6/AML1 fusion, and 1.56 ± 
0.86% in nuclei tested for BCR/ABL Thus the cut-off point for false-positive nuclei 
was set at 4.67% for ETV6/AML1 and 4.1% for BCR/ABL (calculated from the mean 
of the nine control samples plus 3x standard deviation (s.d)).
The single colour MLL probe showed three signals in 1.3 ± 1.4% of nuclei and the 
cut-off point for false positive nuclei was set at 5.5% (mean, plus 3x s.d.). The dual 
colour MLL probe showed a separation of fused dual colour signals in split signal in 
0.69 +/- 0.7% of nuclei and the cut-off point for false positive nuclei was set at 
2.79% (mean, plus 3x s.d.).
For the Chromoprobe Multiprobe®-I, one hundred nuclei were counted for each 
probe. The five control samples were hybridised as described above, hybridisation 
efficiency of individual centromeric probes was hugely variable, the proportion of 
nuclei with strong hybridisation signals ranging from 47-94% as detailed in (Table 
II: 3).
The proportion of nuclei showing disomy was also variable, ranging from 83-98% as 
shown in (Table II: 4). The cut-off points for monosomy (range from 3-30%) and 
trisomy (range from 1.5-29%) calculated from mean +3x s.d. using nuclei with 
abnormal numbers of signal are also shown in this table.
The centromeric probe for chromosome 5 cross-hybridises to chromosome 1 and 19 
making reliable analysis difficult. Less than 50% of normal control samples showed 
the expected six signals, thus further analysis was not carried out using this probe.
In every case a number o f probes failed to provide a satisfactory result, either due to 
insufficient analysable nuclei, poor hybridisation or excessive cross hybridisation.
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Only cases with a minimum of 10 analysable squares were included in this study. 
Probes which failed most frequently were chromosomes 1, 20, 4, 14/22, X, and 
13/21, the proportion o f cases where each probe failed are shown in (Table II: 5).
Table II.3 Hybridization efficiency of probes in Chromoprobe
Multiprobe®-!_____________________________________
Probe for Nuclei with hybridisation
Chromosome (% of nuclei examined)
1 47%
2 88%
3 59%
4 82%
1/5/19 NA
6 83%
7 79%
8 91%
9 90%
10 88%
11 53%
12 85%
13/21 79%
14/22 71%
15 82%
16 88%
17 63%
18 74%
20 58%
X 94%
Y 77%
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Table II.4 Chromoprobe Multiprobe®-! findings in control samples
Probe for Frequency of signals per nucleus %  and cut-off point for norm al reading (mean+3x s.d.)
Chromosome
1 Cut-off 2 Cut-off 3 Cut-off 4 Cut-off 5 Cut-off 6 Cut-off
signal point signals point signals point signals point signals point signals Point
1 3.73±3.16 13.2 95.2+3.3 1.06+0.11 1.4
2 1.3+0.6 3.1 98+1 0.63+0.55 2.3
3 2.33±2.52 9.8 95+1.73 2+1 5 0.66+1.15 4.1
4 4.16±4.25 16.9 94.6+4.9 1.3+0.64 3.2
6 2.66+1.52 7.3 95.7+3.5 1.33+1.53 5.9
7 3.23+0.68 5.3 94.3+0.57 1.63+1.18 5.2
8 1.23+1.36 5.3 98.1+1.65 0.66+1.15 4.1
9 1+2 7 98.5+1.71 0.5+2.59 8.2
10 1.9+2.47 9.3 96.9+2.32 0.59+0.54 2.2
11 5.45+2.9 14.1 92.7+2.8 2.43+0.98 5.4
12 2.28+0.53 3.9 97.1+0.78 1+0.1 2.5
13/21 0.75+1.5 5.2 15+6.37 34.1 83.25+5.5 3.66+3.51 14.1 0.25+0.5 1.75
14/22 0.5+1 3.5 17.3+3.86 28.9 83.5+3.32 1+1 4
15 8.95+4.15 21.4 90.8+3.8 0.7+1.1 3.9
16 3.78+3.82 15.2 95.44+3.7 0.56+0.87 3.2 0.2+0.44 1.5
17 4.97+1.18 8.5 95+2.65 0.6+0.89 3.3 0.2+0.44 1.5
18 3.25+2.06 9.4 97.8+4.15 0.6+0.55 2.24
20 8.3+7.35 30.6 90.05+8.8 1.8+1.27 5.6
X(Female) 1.21+1.35 5.2 98.1+1.74 0.71+1.5 5.2
X(Male) 95.6+1.53 3.5+2.1 9.7
Y 97.25+2.5 3.7+2.1 9.9
Table II.5 Failure rates of individual centromere probes in the Multiprobe-I
Probe for
Chromosome 1 2 3 4 6 7 8 9 10 11 12 13/21 14/22 15 16 17 18 20 X Y
Failed cases
(% of total) 60 0 12.5 48 12.5 10.4 4.2 6.25 10.4 16.7 12.5 33.3 44 16.7 10.4 12.5 12.5 48 37.5 11.4
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LSI ABL
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LSI BCR
Probe map
LSI BCR/ABL Dual colour, single fusion probe 
hybridised to a nucleus with the t(9;22). 
Showing one red, one green and 
one yellow fusion signal pattern (1RIGIF)
Probe image
Fig 11:1 Dual colour BCR/ABL LS probe
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Probe image
Fig 11:2 Dual colour BCR/ABL LS ES probe
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LSI ETV6(TEL)/AML1 Dual colour probe hybridised 
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showing two red and two green signal pattern (2R2G).
Fig 11:3 Dual colour ETV6/AML1 LS probe
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■
 LSI MLL single colour probe hybridised 
to cells with a t(9:11)(p22;q23) showing 
three red signal pattern.
Probe image
Fig 11:4 Single colour MLL probe
86
Ccnttomoro H q23 region Telomere
5 I
•-350  Kb
BCR
5 ? 
5 5
_] L
-190  Kb
LSI MLL Dual Color. Break Apart
Probe map
LSI MLL Dual colour probe hybridised 
to cells with a t(9:l I)(p22;q23) 
showing one red, one green and 
one yellow fusion signal pattern (1 RIG IF).
r *
• I
•  /
Probe image
Fig 11:5 Dual colour MLL LSI probe
Device slide with divisions for 24 tests
Location of probes on device coverslip
Fig 11:6 Chromoprobe Multiprobe®-!
BCR/ABL MLL ETV6/AML1
Fig 11:7 Triple testing o r  .Multiplex FISHO ' 1. C? M.
Chapter III
Interphase FISH for Abnormalities of BCR/ABL, 
MLL and ETV6/AML1 at Diagnosis in Acute 
Lymphoblastic Leukaemia
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Ill: 1 Abstract
The use of FISH with probes for BCR/ABL, MLL, and ETV6/AML1 as a diagnostic 
tool for the accurate detection of the Ph chromosome, 1 lq23 abnormalities, and the 
t(12;21) translocation was evaluated in adult ALL.
A total of 176 adult patients were studied using interphase FISH, metaphase FISH, 
chromosomal analysis (CA) and PCR, for the detection of abnormalities involving 
BCR and ABL.
Interphase FISH detected a Ph translocation in 23 cases (13%), These included the 
first reported case of the insertion of BCR into ABL on an apparently normal 
chromosome 9 seen in an adult patient with ALL. A false positive result was found 
in ten cases. In sixteen of 153 (6.5%) Ph negative patients, gains of BCR and/or ABL 
signals were identified. Overall FISH detected alterations involving the BCR and or 
ABL genes in 22% of patients. Among 47 cases with combined FISH, CA and PCR 
it was possible to investigate discrepancies in results using these different testing 
methods, FISH failed to establish a correct diagnosis in 1/47 (2.1%), PCR in (0%), 
and CA in (0%).
In 14 selected cases, a probe with increased sensitivity for the accurate detection of 
BCR/ABL fusion was evaluated. This dual-colour LSI BCR/ABL ES probe is 
designed to produce an extra signal in Ph positive cases. It reduced the false positive 
rate to 0%, but did not change the rate o f false negativity.
174 patients were studied for the presence of abnormalities involving the MLL gene, 
by cytogenetic analysis, interphase FISH using two probes, a single colour, and a 
dual-colour kit, and whole chromosome painting. Interphase FISH gave a positive
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result in seven patients (4%), detecting MLL gene rearrangement in all five cases 
with a t(4;l I)(q21;q23), one case with t( 11; 19)(q23;p 13), and one case with hidden 
t( 11; 19). Loss of one MLL signal was seen in 2/4 cases with cytogenetic evidence o f 
del(l l)(q23). FISH revealed a false positive result in 9/119 (7.6%) cases tested with 
the single colour probe. The dual-colour probe showed no false positive results in 55 
samples tested.
162 patients were studied using interphase FISH, whole chromosome painting, and 
RT-PCR for abnormalities involving ETV6 and/or AML 1. Interphase FISH detected 
ETV6/AML1 fusion in 7 cases (4.3 %) which included two patients over the age of 
40 years, and showed a 4.5% false positive rate. Losses or gains of ETV6 and/or 
AML1 were identified in 31 o f 155 (20%) negative patients. In total interphase FISH 
detected alterations of the ETV6 and or AML1 genes in 23.5% of cases.
Fifteen cases were tested by both FISH and RT-PCR. Thirteen cases were negative 
by both methods, two cases were positive by FISH; only one o f which was RT-PCR 
positive.
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Ill: 2 Introduction
Abnormalities of ABL, and BCR
The Philadelphia chromosome is found in 20-35% of adults with ALL (Secker- 
Walker 1991; Westbrook 1992). The almost universally poor prognosis of this 
abnormality means that most patients are treated according to high-risk treatment 
protocols, and if applicable they receive an allogeneic BMT (Seeker-Walker 1991; 
Barrett 1992; Miyamura 1992; Rieder 1993; Annino 1994; Secker-Walker 1997). 
For appropriate management, it is vital that these patients are diagnosed early, as 
they tend to have short remissions in the absence of intensive treatment modalities. 
Several series have shown a higher detection rate of BCR/ABL fusion by molecular 
techniques than conventional cytogenetics (Preudhomme 1993; Radich 1994; 
Devaraj 1995; Rieder 1998; Campbell 1999; Mancini 2001). Due to the speed with 
which results can be achieved using commercially available probes on both 
conventionally prepared samples and cytospin preparations (Horton 2000), 
interphase FISH offers potential for use in detecting this important abnormality at 
the time of diagnosis of ALL.
Abnormalities of MLL
Numerous abnormalities involving chromosome band 1 lq23 have been described in 
acute leukaemia (Mitelman 2004), the majority of these are translocations 
(Johansson 1998; Swansbury 1998). Translocations and other abnormalities of 
1 lq23 involving the MLL gene are associated with poor outcome (Pui 1991; Rubnitz 
1994; Harbott 1998). It is important to detect MLL gene rearrangements rapidly and 
accurately in adult patients presenting with ALL, since it is possible that treatment
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modification, with high dose chemotherapy and bone marrow or stem cell rescue, 
may improve outcome (Ludwig 1998). Apart from the classical MLL 
rearrangements, rare or subtle abnormalities o f MLL may be overlooked by CA, also 
due to the large number of partner genes multiplex RT-PCR is required for 
molecular diagnosis. Although Southern blotting has been described as the gold 
standard to detect variant MLL rearrangements. Interphase FISH analysis with 
probes specific for MLL is also independent of chromosomal or gene partners of 
translocations, FISH provides is a rapid and simple test, and has been recommended 
by other groups as a screening method for these abnormalities (Mathew 1999; 
Cuthbert 2000).
Abnormalities of ETV6 and AML1
Since the cryptic translocation, t(12;21)(pl3;q22), was described in childhood ALL 
by Romana et al in 1994 (Romana 1994), it has been the focus of much interest. It is 
found in up to 25% children with B-ALL (Shurtleff 1995; McLean 1996; Borkhardt 
1997). A lower incidence has been reported in young adults, with all reported cases 
being less than 28 years of age (Aguiar 1996; Raynaud 1996; Shih 1996; Kwong and 
Wong 1997; Garcia-Sanz 1999). There are indications from prospective studies that 
t(12;21) is associated with delayed and lower rates o f relapse in childhood ALL 
(Harbott 1997). The low incidence of t(12;21) in adults precludes accurate 
evaluation of prognosis. Thus, it is vital to study this abnormality in large series of 
adult patients with ALL, in order to understand the biology of the disease in older 
patients. Since cytogenetic detection is not possible, alternative methods had to be 
considered. Interphase FISH screening for ETV6/AML1 abnormalities allows the
94
rapid assessment of a large number o f cells in samples lacking metaphases. Unlike 
RT-PCR, the probes will also detect the abnormality when it arises from alternative 
breakpoints within the ETV6 and AML1 loci (O'Connor 1998).
In this chapter the use of interphase FISH for the detection of structural 
chromosomal abnormalities of potential prognostic significance is evaluated, against 
cytogenetic and molecular analysis, as a diagnostic tool for their accurate 
identification.
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Ill: 3 Materials and Methods:
III: 3: 1 Patients and controls:
Diagnostic samples were available from 185 adults with a diagnosis of ALL aged 
15-88 years (median 28.5) presenting between February 1993 and April 2000. They 
included 172 patients entered to the UKALLXII trial and thirteen treated 
independently. In five cases the sample was inappropriate or inadequate. O f the 
remaining samples 180 were tested for BCR and ABL abnormalities and an evaluable 
result was available in 176.
Of the 174 samples successfully tested for MLL abnormalities; a total of 119 
samples were tested using the single colour MLL probe, and 55 using the dual-colour 
MLL probe, and included 162 patients entered to the UKALLXII treatment trial and 
twelve treated independently. 162 samples were successfully tested for ETV6/AML1 
fusion, 153 were from patients entered to UKALLXII and nine from patients treated 
independently. Nine bone marrow samples were used as controls. (Details of 
patients and controls are presented in Chapter 11:1)
III: 3: 2 Probes for FISH:
Cosmid probes:
Commercial probes for BCR/ABL, for MLL and ETV6 and AML1 were used, as 
described in Chapter 11:4:1.
Whole chromosome paint (wcp)
Digoxigenin and biotin labeled wcps, were applied to metaphases: to identify 
additional chromosomal abnormalities and to confirm the partner chromosomes
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involved with llq23. Since the t(12;21) translocation is invisible, wcp 12 and 21 
were used to confirm the presence of this translocation.
Alpha satellite probes:
Multiprobe-I was used for the enumeration of all 24-chromosome centromeres in 
patients with failed or normal cytogenetics, as described in Chapter 11:4.
Individual centromeric probes were used to confirm chromosomal gains and to 
determine the origin of specific marker chromosomes.
Ill: 3: 3 Methods o f analysis 
Cytogenetics:
All cases were investigated by conventional chromosomal analysis as previously 
described in Chapter 11:2.
FISH:
The same fixed cell suspensions as used for conventional chromosomal analysis 
were used for FISH. Slides were prepared as previously described in Chapter 11:3.
All probes were hybridised according to manufacturers’ instructions. (Analysis, 
hybridisation protocols and equipment are detailed in Chapter II).
Interphase FISH
For BCR/ABL, MLL, ETV6/AML1 probes a minimum of 100 nuclei and up to 200 
nuclei where possible were scored for each sample. For centromeric probes and the 
Multiprobe-I 100 nuclei were scored for each probe.
Hybridisation efficiencies and cut-off levels were established for each probe, as 
previously described in Chapter 11:8.
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Metaphase FISH:
Slides previously hybridised with specific probes were used in sequential FISH 
hybridisations with wcps as previously described in Chapter 11:7. This conserved 
scant patient material and provided maximum interpretable information on as many 
probes as possible in the same series o f individual cells.
RT-PCR & Southern Blotting
RT-PCR for BCRJABL was undertaken for patients in the UKALLXII trial, centrally 
by the molecular laboratory at the Hammersmith Hospital on behalf of the MRC 
Adult Leukaemia Working Party.
RT-PCR and Southern blotting for ETV6/AML1 had been carried for some patients 
as part of a previously published study (Aguiar 1996).
Results of RT-PCR testing were available for 47 of the 174 cases analysed by FISH 
for BCR/ABL and 14 of the 159 cases analysed for ETV6/AML1. These results were 
provided by Dr .J. Kaeda, Professor N.C.P.Cross & Professor J.Goldman.
In a further two cases, RT-PCR for ETV6/AML1 was undertaken in the regional 
cytogenetic laboratories (Salisbury and Birmingham) and results were provided for 
comparison.
Immunophenotyping
Immunophenotyping was carried out by referring hospitals. Immunophenotypic 
subgroups of ALL were defined as follows: Null ALL (TdT + ve, CD 19 + ve, CD 10 
- ve), common or pre-B-ALL (TdT + ve, HLADR + ve, CD 19 + ve, CD 10 + ve) or 
T-ALL (TdT + ve, CD 19 - ve, CD2 + ve, CD7 + ve) or ‘other’.
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Ill: 4 Study Results
Cytogenetic analysis o f the 176 cases showed a Ph translocation in 19 cases, a 
t(4; 11 )(q21 ;q23) translocation in five cases and a t(l 1; 19)(q23;p 13) in one case. As 
expected the cryptic t(12;21)(pl 3;q22) translocation was not identified by 
cytogenetic analysis alone.
Details of immunophenotype, cytogenetic analysis, sample available for FISH 
analysis and number of nuclei analysed are presented in Table III: 1.
Ill: 4: 1 BCR/ABL fusion positive cases
Interphase FISH showed a positive result for BCRJABL fusion in 23 of 176 patients. 
The clinical, cytogenetic and interphase FISH findings o f these positive cases are 
presented in Table III: 2. Between 8-97% (mean 67.6 ± 30.2%) of nuclei showed co­
localization of BCR/ABL suggesting the presence of Ph translocation. FISH 
indicated that the breakpoint had occurred in M-BCR in ten patients and in m-BCR 
in the remaining 13. Interphase FISH diagnosis of BCR/ABL rearrangement was 
confirmed by chromosomal analysis (cases 1-18), metaphase FISH and/or PCR 
(cases 2, 5, 7 ,9 , 14 & 19).
Among the 18 cases with cytogenetic evidence o f Ph chromosome, in five the 
t(9;22)(q34;ql 1) was the sole karyotype change (cases 1-6), additional cytogenetic 
findings were found in a further 10 cases, abnormalities of chromosome 7 being the 
most common, in five cases (9, 11-13, & 16).
In two cases the BCR/ABL fusion corresponded to a variant Ph translocation 
described as, t(2;9;22)(pl?2;q34;ql 1) (case 17) and t(l;9;22)(p36;q34;ql 1) (case 
18).
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Five cases had no Ph chromosome by convential cytogenetic analysis, in three (cases 
19-21) conventional cytogenetic analysis failed to produce a cytogenetic result due 
to poor quality metaphases, and in one (cases 22) cytogenetic analysis showed only 
normal metaphases, in case 23 cytogenetic analysis showed no apparent abnormality 
in chromosomes 9 nor 22.
Case 19 was initially reported to have a failed karyotype, with 15 normal 
metaphases. FISH on the same sample showed fusion signals in 80% of nuclei and 
on a derived chromosome 22 in five o f 56 metaphases examined, with additional 
evidence for an m-BCR breakpoint. The sample was re-examined and analysis of an 
additional 10 metaphases revealed one with a classical Philadelphia chromosome.
In case 20 cytogenetic analysis failed, as only a small number o f poor quality 
metaphases were available for examination. Interphase FISH showed the presence of 
fusion signals and the M-BCR breakpoint in 80% of nuclei and metaphase FISH 
confirmed the presence of the BCR/ABL fusion on derived chromosome 22 in two 
poor quality metaphases. Upon review a derived chromosome 22 was found 
suggestive of Philadelphia in one metaphase.
In case 21 hyperdiploid metaphases were observed but the poor chromosome 
morphology precluded accurate enumeration and analysis. Interphase FISH revealed 
one fusion signal in 45% of nuclei and duplication o f the fusion in a further 28% of 
nuclei (Fig III: 1).
In case 22 the sample provided for analysis was peripheral blood. A total of 20 
metaphases showed no chromosomal abnormalities, interphase FISH showed 
BCR/ABL fusion signals in 11-15% of nuclei, but in none of the metaphases.
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In case 23 cytogenetic analysis of bone marrow showed a deletion of the long arm of 
chromosome 13. Interphase FISH showed the presence of fusion signals in over 70% 
of nuclei. Metaphase FISH showed both the ABL genes on apparently normal 
chromosomes 9, one copy of BCR on an apparently normal chromosome 22, the 
second copy of BCR was juxtaposed with the ABL gene on the long arm of 
chromosome 9 (Fig III: 2). RT/PCR confirmed the presence o f BCR/ABL mRNA 
transcript. This is an example of Ph negative BCR/ABL positive ALL and at the time 
was the first case of insertion of BCR into ABL to be recognised in an adult with 
ALL. A similar case has since been reported (Terre 2001). Wcp redefined the 
del(13) as an unbalanced translocation involving chromosomes 13 and 14 producing 
a der(14)ins(13;14). In a small number of metaphases additional further 
translocations involving part of chromosome 9 were also found. Inadequate 
metaphases precluded the complete identification o f all partner chromosomes.
Overall Ph positive patients had a higher median age (36 years), than the group as a 
whole (28 years), as well as a higher median WBC at 17.4x109/l compared to 
9.7x109/l.
Ill: 4: 2 BCR/ABL ES probe in cases with equivocal results 
On comparing results from interphase FISH with those from conventional 
cytogenetics and where available PCR, a number o f cases with interesting findings 
were seen, a number of these cases are presented in Table III.3. These included 
fourteen patients with low rates of BCR/ABL fusion of between 4.5% and 12.3%, 
slightly higher than the cut-off level of positivity (4.1%). Ten patients (with fusion 
rates of between 4.5% and 9%) with the absence o f cytogenetic (in seven) or PCR
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(in four) evidence of a Ph chromosome, were considered as potentially having false 
positive results (cases E-L). In four other patients, conventional cytogenetics showed 
a Ph chromosome while FISH revealed BCR/ABL fusion rates o f between 8% and 
12.3% (cases A-D). In two further cases there was cytogenetic or PCR evidence of a 
Ph chromosome, but FISH results were negative (cases M & N).
In order to study this patient group in more detail further testing was carried out 
using a more sensitive LSI BCR/ABL ES probe (as described in Chapter 11:4).
A total of 14 cases were succesfuly tested with this probe. Details of the findings are 
given in Table III: 3. The cases included the four patients with probable true but low 
level positivity (cases A-D), eight of the ten cases with possible false positive FISH, 
where there was material remaining (cases E-L), and the two cases with possible 
false negative FISH (cases M & N).
The use of this ES probe distinguished between positive cases with low rates of 
fusion (cases A-D) and false positive results (cases E-L). In the positive cases, there 
was clear concordance in fusion rates using both FISH probes, with the exception of 
case B. In this case, cytogenetics showed only normal metaphases, interphase FISH 
showed a low level of BCR/ABL fusion, and testing by Multiprobe-I showed loss of 
one 9 centromere signal in a small proportion o f nuclei. The absence of evaluable 
metaphases precluded further studies, but it is possible that in addition to the 
t(9;22)(q34;ql 1) there was further loss of chromosome 9 material including the ASS 
gene in a proportion of cells.
Although using the ES probe did not allow unambiguous identification of BCR/ABL 
fusion in the two cases with negative FISH by dual colour probe (cases M and N), it
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is of note that in these two cases a small proportion of interphase cells did show the 
extra-signal fusions, compared to the universal absence of any extra-signal fusion 
signals in the eight negative cases. Overall the rate o f false positive results using the 
dual colour probe was 10/153 (6.5%) (confirmed negative with the ES probe), and 
the false negative results 2/153 (1.3%), using the ES probe reduced the false positive 
rate to 0%, but did not change the rate o f false negativity.
Ill: 4: 3 FISH versus cytogenetics and RT-PCR
In a number of cases, FISH, conventional cytogenetics and RT-PCR results were 
available for comparison. This allowed the sensitivity and accuracy of the individual 
techniques to be evaluated.
Results were discrepent between FISH and CA in 4/145 cases (2.75%). Interphase 
FISH detected three additional positive cases. FISH was negative in one case with 
positive cytogenetics. This case was difficult in all aspects, CA showed the majority 
of metaphases to be normal, only one metaphase with poor chromosome 
morphology was abnormal with a questionable t(9;22) and additional abnormalities 
(case N in Table 111:3). The diagnostic sample tested negative by FISH and produced 
equivocal results on PCR, a second sample sent for PCR was positive. Clinically the 
patient relapsed rapidly despite undergoing a transplant procedure and samples at 
relapse showed the Ph chromosome. Interphase FISH was negative in a further case 
with a positive PCR, and failed cytogenetics (case M in Table 111:3). It is difficult to 
determine whether this represents a false negative FISH or a false positive PCR 
result.
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A total of 64/176 patients were tested for the BCR/ABL rearrangement by RT-PCR. 
Five patients demonstrated a rearrangement in m-BCR, four in M-BCR and 55 
patients gave a negative result. The combination of PCR and successful CA 
produced discrepant results in one of 48 cases, with the detection of the Ph negative, 
BCR/ABL case (case 23 in Table 111:2).
In addition to CA, complementary FISH or PCR, improved detection of Ph 
chromosome. However, the combination of two methods seems to be necessary for 
the accurate detection of cases with atypical results.
Ill: 4: 4 MLL rearrangements detected with the combination o f  the 
single colour MLL probe and centromere probe 
In 11/119 samples tested with the single colour {MLL) probe, 30-75% of nuclei 
showed three signals suggesting the presence of MLL rearrangements, and in one 
sample a single MLL signal was seen in 30% of nuclei. Seven of these cases tested 
with chromosome 11 centromeric probe showed that the extra MLL signal resulted 
from a gain of an extra copy of chromosome 11 (to be presented later). Clinical, 
cytogenetic and interphase FISH details of the remaining five cases are shown in 
Table III: 4.
Cytogenetic analysis identified a t(4;l I)(q21;q23) in three cases (24-26), The fourth 
case (27) metaphase FISH showed splitting of the MLL signal between two 
chromosomes, whole chromosome painting identified the presence o f a translocation 
t( 11; 19)(q23 ;p 1 ?). The fifth case (28) had a terminal deletion of chromosome 11 at
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11 q23 by cytogenetics, this was confirmed by FISH showing loss o f one copy o f 
MLL in 30% of nuclei.
In two further cases three MLL signals were seen in 7 and 7.7% of nuclei, no extra 
copies of chromosome 11 were seen by cytogenetic analysis. Further testing, as 
detailed in section III: 4: 6, confirmed these to be false positive results. Using the 
single colour MLL probe in isolation gave a false positive result in 9/119 (7.6%) 
cases, seven of which were due to trisomy 11, a combined approach o f cytogenetics 
and interphase FISH with MLL probe and chromosome 11 centromeric probe 
reduced the false positive rate to 2/119 (1.7%) cases.
Ill: 4: 5 MLL rearrangement detected by the use o f  a dual-colour 
probe
In 46 of the 55 samples tested using the dual colour MLL probe, two MLL fusion 
signals indicative o f two normal copies of chromosome 11 were seen. In these cases 
the number of split signals was below the cut-off point o f 2.79% and ranged from 0- 
2.6% (0.37 ± 0.48%).
In three cases 82-94% of nuclei showed a split MLL signal indicating an MLL gene 
rearrangement. Cytogenetic analysis showed a t(4;l I)(q21;q23) in 2 cases (cases 29 
and 30), a t(l 1; 19)(q23;pl 3) in one (case 31) Details of the findings in these cases 
are shown in Table III: 5.
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Ill: 4: 6 Single versus Dual-colour probe for MLL rearrangements
Comparison of results from the two probes showed that there was a difference in the 
level of false positive results. The single colour probe identifies cases with trisomy 
11 as positive. Thus the dual-colour probe, with a very low false-positive rate is 
more specific. Both probes were sufficiently sensitive to detect all cases identified as 
positive from cytogenetics.
For a direct comparison between the probes, 26 cases were analysed using both 
probes. These included nine normal control samples, six ALL samples without 
t(4; 11) or trisomy 11 on routine cytogenetics, two with cytogenetic evidence of 
del(l l)(q23), three with borderline increase in the number o f MLL signals with the 
single-colour probe, two with hidden trisomy / tetrasomy 11 detected by Multiprobe- 
1, three cases with cytogenetically confirmed t(4;l I)(q21;q23), and one with a 
hidden t(l 1; 19). Abnormal results are presented in Table III: 6.
The dual colour probe allowed clear distinction between false positive results with 
three signals at low levels with the single-colour probe (cases A-C) and cases with 
extra copies of chromosome 11 (cases D and E) from true positive cases (cases F-I). 
The positive cases showed a higher proportion o f positive cells with the dual colour 
probes compared to the single colour probe.
Ill: 4: 7 ETV6/AML1 fusion positive cases
In seven cases 50-100% of nuclei showed co-localization of ETV6 and AML1 
indicating the presence of the t(12;21) translocation. The clinical, cytogenetic and 
interphase FISH findings of the positive cases are presented in Table III: 7. The
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positive interphase FISH results were confirmed on metaphases by the observation 
of the ETV6/AML1 fusion signal on the derived chromosome 21 in all cases. This 
was confirmed by dual application of wcps 12 and 21, showing exchange of material 
between these two translocated chromosomes (cases 33, 35, and 36) (case 33 in Fig 
III: 3) and by RT-PCR (case 38), in the other three cases with complete cytogenetic 
analysis (33, 35, 36) abnormalities of 12p were detected as part of a complex 
karyotype.
The patients ranged in age from 15-50 years and they all showed a c-ALL 
phenotype. The presentation white cell counts were below 10x109/l. in all except one 
patient. Two patients (32 & 35) relapsed at 11 and 24 months and did not achieve a 
second remission. A third (34) developed secondary acute myeloid leukaemia within 
29 months of presentation. The follow-up for the remaining four patients was short, 
ranging from six to 27 months.
In a further seven patients, 4.8-7.2% of nuclei showed co-localization of ETV6 and 
AML1 suggesting the presence of the t( 12;21 )(p 13;q22) translocation in a low 
proportion of cells. In none of the seven cases however was the fusion signal 
observed in metaphase cells, while RT-PCR was negative for the one case tested. In 
view of this lack of confirmation and the low level of fusion signals, these results 
were presumed to be false positive, at an incidence of 4.5% (7/155 cases).
Ill: 4: 8 Additional abnormalities
In addition to the positive results (BCR/ABL fusion, MLL rearrangement, or 
ETV6/AML1 fusion), abnormalities involving gains or losses o f signals were found 
in a total of 44 patients. Six of these showed abnormal signal number in addition to
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the positive results. The abnormal copy of number of MLL, ETV6, and AML1 was 
consistent with the cytogenetic findings of hyperdiploidy in cases 10 (Table III.2), 
33 and 38 (Table III.7) and deletion of llq23  in case 28 (Table III.4). In case 21 
(Table III.2) the additional copies of AML1 were consistent with trisomy/tetrasomy 
21 in a hidden hyperdiploid clone detected by Multiprobe-I. Case 29 (Table III.5) 
showed unexpected loss of ETV6. This deletion was cytogenetically invisible.
The findings in the remaining 38 cases with abnormal numbers of one or more o f 
BCR, ABL, MLL, ETV6, AML1 signals are shown in (Table III: 8). In 20 cases the
FISH results concurred with cytogenetics. In one case (39) with a visible 11 q23
deletion, and seven cases (40-46) with visible abnormalities o f 12p, there was loss of 
one MLL and one ETV6 signal respectively. In eleven cases with extra copies of 
chromosome 21 (cases 45-50, 52-54), chromosome 22 (cases 49 and 51), and
chromosome 11 (cases 50-52) there were concordant gains of AML1, BCR, and
MLL, respectively, while in three cases (53-55) with very incomplete karyotypes, the 
extra signals observed were not unexpected given the numbers of chromosomes 
involved in the underlying hyperdiploidy. In cases 56-59 the extra copies of ABL 
were consistent with cytogenetic findings of a dicentric chromosome 9 or a similar 
chromosomal rearrangement, giving rise to duplication o f 9q.
In six cases with failed or normal cytogenetics (60-65), the numbers of centromeric 
signals for chromosomes 9, 11, 12, 13/21, and 14/22, successfully defined by 
Multiprobe-I, agreed with those for ABL, MLL, ETV6, AML1 and BCR. (These cases 
are discussed in further detail in chapter IV). Thus findings from the sequence 
specific probes can be indicative of numerical chromosomal changes.
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the length of an abnormal marker, which subsequently proved to be composed 
entirely of chromosome 21 material (this case is detailed further in chapter V)(Fig 
111:4).
In summary, 38 (27.5%) ALL patients who were negative for BCR/ABL fusion, MLL 
rearrangement and ETV6/AML1 fusion did not show the expected two copies o f the 
tested genes, although the abnormalities corresponded to the cytogenetic result in 
half the cases; the other 17 cases only came to light by the particular combination o f 
techniques employed.
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Ill: 5 Discussion
Testing for BCR/ABL
Extensive FISH based study has been carried out to detect cases o f Ph positive ALL 
in a large series of adult patients. Initial testing with dual colour probes applied to 
interphase nuclei preparation identified the BCR/ABL rearrangement in all but one of 
the 19 patients shown to have a Ph translocation by cytogenetics. An additional five 
cases, with hidden Ph were identified in which the Ph chromosome was not seen by 
conventional karyotyping due to the poor sample quality, low level o f the 
abnormality, or variant Ph translocation. The probe distinguishes between M-BCR 
and m-BCR breakpoints, and in the six cases with both FISH and RT-PCR results 
there was almost complete concordance in the results obtained.
Ten patients tested with the dual-colour BCR/ABL probe showed fusion signals at a 
low level, suggesting a Ph translocation in a small proportion of cells. Evidence o f a 
true Ph translocation was not achieved from cytogenetics, or PCR in a number of 
these cases, and further testing with the sensitive ES probe kit confirmed that the 
low fusion rate was due to the chance co-localisation o f BCR and ABL in these 
nuclei, rather than a genuine translocation. In three of these ten cases a hyperdiploid 
clone was identified with extra copies of ABL and/or BCR. The false fusion signals 
were identified within these hyperdiploid nuclei only. This type o f association has 
been previously described using the same probe (Rieder 1998). It is probable that 
with the increased numbers of signals increases the likelihood that a chance co­
localisation will occur. Overall the false positive rate with this probe in this series 
was 10/176 (5.6%).
I l l
The use of an ABL probe that extends to and includes sequences from the ASS gene, 
beyond the breakpoint cluster region o f ABL, increases the sensitivity o f the FISH 
test. Dual-fusion or triple signal probes have been applied successfully in diagnosis 
and in the study of minimal residual disease in CML (Sinclair 1997; Buno 1998). 
These probes have not been used extensively in ALL but the same principle applies. 
In this series this probe was used in cases with a suspected false positive result. 
Comparisons were made with normal controls, and cases confirmed to have a low 
level Ph positive clone, as negative and positive controls respectively. In the normal 
and the false positive cases, the rate o f fusion was consistently found to be zero, 
whereas true Ph positive cases the detection o f a fusion was accurate even at a level 
of only 5%. An interesting observation was that in the “false-positive” cases a 
population of cells with closely aligned BCR and ABL signals within their nuclei was 
consistently observed, this may be due to the structural orientation of the sequences 
of these genes preferentially lying in close proximity within the nuclei.
False negative FISH results were obtained in two cases with cytogenetic or PCR 
evidence of a Ph chromosome. The incidence of fusion signals was 1.5% and 3.75% 
in these cases. This phenomenon of low level values, within the normal range for 
controls, has previously been described (Dewald 1993). It is likely to be related to 
the quality of the sample in this study, and may be caused by the gradual depletion 
of positive cells from the regularly re-used cell suspension. In this study, material 
used for FISH were samples provided after completion o f cytogenetic analysis in 
other laboratories. In one of the positive cases the rate o f positivity by FISH dropped 
from 15% to 11% to 5% in successive sampling of the same fixed cell pellet.
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Cytogenetic analysis revealed only one Ph positive metaphase from 20 examined, 
implying low level of positivity, and in the second case examination of the initial 
sample by conventional cytogenetics failed, FISH for BCR/ABL fusion on this 
sample was negative, the sample taken at the same time for RT-PCR was 
inconclusive, a repeat sample sent for RT-PCR only was positive, this implying that 
initial sampling quality was the cause for false negativity of tests.
In general this study has confirmed the efficiency o f dual-colour probes for 
interphase FISH screening of Ph positive ALL. Cases with low levels of positive 
nuclei can be verified by testing with the ES probe. Testing with ES probe reduces 
the rate of false positive results but not necessarily the rate of false negatives.
In the five cases with FISH evidence of a BCR/ABL rearrangement without a Ph 
chromosome a number of events explained the difficulties of cytogenetic analysis. In 
one case this was due to the low proportion of abnormal cells in peripheral blood. 
Several previous studies have clearly shown the superiority of bone marrow over 
blood samples in the initial diagnosis of ALL, especially for karyotyping (Secker- 
Walker 1997). In the second case, despite the high proportion o f abnormal cells 
found by FISH, there appeared to have been a selective growth advantage o f the 
non-malignant cells, since lower proportions of Ph positive metaphases were 
observed than would be expected from the interphase FISH results.
The association o f hyperdiploidy with the presence o f a Ph chromosome is not 
uncommon in adult ALL. It is recognized that chromosome morphology may be 
poor in cases with more than 60 chromosomes, making identification o f structural 
abnormalities difficult. In one of the five cases described here this was so. However
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this case serves to illustrate the powers of FISH, in defining abnormalities in 
metaphases of poor quality.
In only one of the five BCR/ABL positive Ph negative cases was the Ph chromosome 
truly absent. The fusion arose from the insertion o f BCR into ABL on the apparently 
normal chromosome 9. This is a well-described finding in CML, but rarely reported 
in ALL and is believed to be the result o f a two-step event. In the first step a 
classical Ph translocation takes place and this is followed by a second translocation 
between chromosome 9 and 22 that results in the two chromosomes appearing 
morphologically normal but with the fused BCR/ABL genes now located on 9q 
(Nacheva 1994).
In five BCR/ABL positive cases further studies utilising wcp to define chromosomal 
translocations, provided evidence o f involvement of other chromosomes with an 
impact on prognosis (Rieder 1996) these included chromosomes 7, 9p and the 
presence of hidden hyperdiploidy in association with the Ph chromosome in two 
cases.
In addition to detection of BCR/ABL rearrangements the probe identified numerical 
abnormalities by chance findings of abnormal copy number o f BCR and/or ABL in 
17 cases. In three of these case the finding pointed to the presence of a hidden 
hyperdiploid clone, later confirmed by Multiprobe-I system. In a further three cases 
additional signals were not associated with numerical changes, in these cases 
structural abnormalities involving chromosome 9 and/or 22 could not be ruled out. 
This study provides strong support for the important role of FISH in the accurate 
diagnosis of Ph positive ALL. The combination of interphase and metaphase FISH
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with a variety of FISH probes allows the detection of rare cases with variant 
translocation, the accurate identification of BCR breakpoints, provides information 
on proportions of Ph positive and Ph negative cells at presentation and gives a more 
complete picture of associated abnormalities which may be related to prognosis, 
which provides vital information for patient management, as well as scientists 
studying the biology of this disease.
Testing for MLL
In this study two commercially available FISH probes, one single and one dual­
colour, were assessed for detection of MLL rearrangements in a large population of 
adults with ALL. Comparison was made between the two probes and FISH results 
were evaluated against cytogenetic results. Both probes proved to be highly efficient 
in the detection of MLL rearrangement in cases with cytogenetically visible 
translocations involving 1 lq23, as well as one case with a hidden t(l 1;19).
In agreement with previous reports, the five cases with t(4;l I)(q21;q23) in this 
series showed very high presentation WBC (mean 191x109/l) compared to the 
negative cases, and only one expressed the CD 10 (common-ALL antigen).
In this series there were also four cases with cytogenetic evidence of llq23  
deletions. FISH with both probes showed MLL was deleted in two o f these. MLL 
was retained in the other two cases, indicating a breakpoint outside llq23 . The 
distinction between these two groups is o f clinical importance, as it appears that 
patients with 1 lq23 deletions involving the MLL gene do less favourably than those 
without MLL gene loss (Harbott 1998).
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The false positive rate was lower with the dual-colour probe, 0/55 compared to 
9/119 (7.6%) for the single colour probe. This confirmed the higher specificity o f the 
dual-colour probe. The extent of the dual-colour probe, spanning the MLL gene 
beyond the breakpoint cluster region (bcr) and flanking sequences, enables the dual­
colour probe to be able to detect the rare cases with breakpoints 3’ o f the gene, 
which would not be detected by the single colour probe, covering only the bcr 
region. Since the dual-colour probe relies on the separation of different coloured 
signals, rather than number of signals, it is able to detect unbalanced translocations, 
which would appear as normal with the single colour probe.
An observation made on examining four cases with t(4; 11) or t(l 1; 19) was that a 
higher proportion of positive nuclei was found with the dual colour than with the 
single colour probe. This may reflect differing hybridization efficiencies between the 
probes, or be due to difficulties in scoring extra signals. The presence o f two 
separate signals in different colours is easier to count with confidence.
FISH is the method of choice for the rapid screening o f acute leukaemia cells for the 
presence of rearrangements of the MLL gene as it detects all translocation partners, it 
is hoped that with the continued introduction of more sophisticated FISH probes for 
testing, the need for supporting methods of analysis should be reduced.
Testing for ETV6/AML
This study is the first to report o f the use of interphase FISH for the identification of 
ETV6/AML1 fusion in a series of adult patients. It also represents the largest series of 
adult patients in which the incidence of the translocation has been studied. The 
technique has been used for childhood ALL series, in which the results differ
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strikingly from this one in the much higher incidence o f positive cases (Ameye 
2000). RT-PCR, was used in previously reported series o f adult patients (Aguiar 
1996; Raynaud 1996; Shih 1996; Kwongand Wong 1997; Garcia-Sanz 1999).
Seven positive cases were found among 162 adult ALL patients, an incidence of 
4.3%. If known non-B ALL cases are excluded the incidence in our study is 5.1% 
(Jabber Al-Obaidi 2002). This figure is a little higher than those reported for other 
adult series (0-3.3%), which may reflect the larger size of our sample, or result from 
a real geographical variation in incidence (Garcia-Sanz 1999). The most likely 
explanation however, is that FISH may identify cases with alternative breakpoints in 
the gene which are not detected by RT-PCR (O'Connor 1998). In our series RT-PCR 
was performed on 16 cases, but one o f these proved to be positive by FISH and 
negative by RT-PCR. Previously described ETV6/AML1 fusion positive adults were 
aged between 15 and 27 years. Two of our positive cases were older and at 45 and 
50 years respectively, are the oldest ETV6/AML1 fusion positive cases reported. 
Similar to findings in childhood cases, ETV6/AML1 fusion was associated with a 
low white blood count, a common ALL phenotype, cytogenetically identifiable 12p 
abnormalities and in two cases a near triploid/tetraploid clonal karyotype (Romana 
1995; Romana 1996; Raimondi 1999).
The deletion o f the second ETV6 allele, which has been reported to occur frequently 
in children in association with the fusion gene, was only observed in two o f the 
positive adults. Although the occurrence of intragenic deletions or point mutations 
undetectable by FISH techniques cannot be ruled out, outcome could be in some 
way related to the retention of this second allele.
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Due to the infrequency of the t(12;21) translocation in adults, its influence on 
prognosis has yet to be resolved. In this series, two of the ETV6/AML1 fusion 
positive patients relapsed. One with a complex karyotype had retained the second 
copy of the ETV6 allele in the abnormal cells at both diagnosis and relapse. In 
another, cytogenetics had failed, while interphase FISH showed loss o f the second 
copy of the ETV6 gene. A third patient developed secondary acute myeloblastic 
leukaemia within 29 months o f presentation. Firm conclusions on the influence of 
this translocation on outcome await a longer follow-up and larger numbers of 
patients. However it appears unlikely that the t(12;21) translocation is associated 
with a uniformly better outcome in adults.
The commercial AML1 probe used spans the breakpoint on chromosome 21 and is 
designed to give an extra signal on the derived chromosome 12 in positive cases. In 
this study the additional signal was only clearly visible in three of the positive cases 
and then in only some of the positive nuclei. Care must therefore be taken in relying 
on the extra signal for confirmation of positivity. A possible explanation is that there 
has been a partial deletion of the AML1 gene involved in the AML1/ETV6 fusion. In 
our laboratory, specific probes to the exons of the AML1 gene were used together 
with wcps for chromosomes 12 and 21 on some positive childhood cases. They 
showed that the 21 material translocated to the short arm o f chromosome 12 did not 
always include AML1 exons, indicating that they had been deleted (GR Jalali, 
personal communication). This interpretation is supported by similar results obtained 
with probes to the MLL gene (Cherif 1994).
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The sensitivity of dual-colour interphase FISH is limited by the occurrence o f false 
positive results. Studies using similar probes for BCR/ABL fusion showed that 
hyperdiploidy (Rieder 1998) or the small-condensed nuclei characteristic o f T-ALL 
(Chase 1997) may produce higher rates of false positivity. In our series only one 
each of the 16 cases with hyperdiploidy and the 25 cases with T-ALL had slightly 
raised fusion rates. However in all the false positive cases, the proportion o f fusion 
signal positive nuclei was far lower than in the confirmed t(12;21) cases. The cut-off 
points for positivity need to be determined by each investigator independently, but it 
appears that higher cut-off levels for a false positive result are required in the 
presence of extra ETV6 and or AML1 signals, or very small blast nuclei. In cases 
with a low level positive result (< 10%), the t(12;21) status should be verified by 
chromosome painting and/or RT-PCR to confirm a positive finding.
Thirty-one cases negative for ETV6/AML1 fusion did not show expected normal 
pattern of two signals for each of the genes in interphase. There was, however, a 
close agreement in the majority o f these cases between the interphase FISH results 
and those obtained by cytogenetics or by Multiprobe-I system. The case in which 
only one cytogenetic population appeared to be represented at interphase could 
reflect a real chromosomal difference between cells in division and in interphase, a 
feature which we have noted in our laboratory in some cases o f hyperdiploidy.
In four cases the result obtained with the ETV6 probe was the only indication that 
there had been deletion of the gene. This reflects the common association between 
ALL and abnormalities of 12p (Baccichet and Sinnett 1997). This we have also
119
shown in our laboratory, 3/30 cases o f ALL negative for ETV6/AML1 fusion showed 
deletions of ETV6, which were not suspected from the cytogenetics. Extra copies of 
chromosome 21 are also a recurrent feature of ALL (Moorman 1996). The finding of 
additional copies of AML1 was the first clue to the presence o f hidden 
hyperdiploidy, confirmed by Multiprobe-I in seven patients. In three other cases 
discordant results between cytogenetics and interphase FISH led to the discovery of 
AML1 amplification; which has been described in both childhood and adult ALL (Le 
Coniat 1995; Najfeld 1998; Niini 2000). In one of these cases which has been 
published (Harewood 2003) the extra signals were found on a quadruplicated 
chromosome 21, a finding previously reported in a child (Baialardo 1996).
In the light of our results, we conclude that dual-colour ETV6/AML1 interphase 
FISH is a simple, efficient and relatively quick method o f screening for the t(12;21) 
translocation among adult patients with ALL. The translocation appears to occur 
over a larger age range than previously suspected and may be more prognostically 
heterogeneous in adults than in children. An added advantage in using these probes 
is in the extra genetic information they provide about patients who do not have the 
fusion gene.
The reliability of the technique is underlined by the remarkable agreement between 
the results it produced and those obtained with the other methods employed. 
Although occasional ‘false positives’ do occur, they are easily distinguishable from 
true positivity by the small proportions of cells they involve. Thus confidence can be 
placed in the exclusive use of interphase FISH for determining ETV6/AML1 fusion.
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Table III .l Patients grouped by successful FISH analysis.
FISH STUDIES SAMPLE PATIENTS IMMUNO CC
Total F L AN >200n <200n BM PB M+B Tr NT C PreB T O N U A N F
BCR 193 0 4 5 8 176 138 38 158 12 6 163 13 81 35 27 7 2 24 104 37 35
MLL 193 4 4 5 6 174 157 17 157 11 6 162 12 81 34 27 9 1 22 104 36 34
ETV6 193 6 4 15 6 162 124 38 145 11 6 154 8 73 34 25 9 1 20 94 36 32
MP 83 5 27 3 0 48 39 7 2 43 5 19 7 12 2 1 7 27 21
BCR; BCR/ABL 
F: Fail
<200n: less than 200 nuclei analysed 
Tr: patient within UKALLXII trial 
N: null ALL
ETV6: ETV6//AML1
L  tested elsewhere
M: Bone marrow
NT: Patient treated independently
U: No immunophenotype available
MR: Multiprobe-I 
AN: analysed in study 
B: Peripheral blood 
C: CDlO+CommonALL 
A: Abnormal clone identified
D Not done : Inadi
>200n: at least 200 nuclei analysed 
M+B: Bone marrow and peripheral blood 
T: T-ALL O: Other
N: 20 normal metaphases analysed
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Table III.2 Ph positive cases
Case UIN Clinical Treatment
Features and outcome
1 143
Age
43
Sex WBC 
M 12
Immuno
c-ALL
BMT Outcome 
EFS 8mo
2 104 37 M 4.6 c-ALL BM relapse 5mo
3 146 42 M 19.4 c-ALL EFS 8mo
4 98 20 M 330 Pre-B BM Relapse 7 mo
5 132 47 F 2 c-ALL Died in CR 3 mo
6 176 50 F
7 74 41 F 2.2 Other ALL Alio 1st CR EFS 29 mo
8 129 23 F 2.1 c-ALL EFS 16mo
9 88 26 M 6.5 Pre-B A llo ls,CR BM Relapse 15 mo
10 155 22 F 2.9 c-ALL EFS 5mo
FISH Results BCR/ABL G-Banded
no of signals (% of abnormal nuclei) PCR Karyotype
F BCR- B MLL ETV6 AML1
97 m-BCR 46,XY,t(9;22Xq34;ql 1 )[7]/
46,XY[5]
12.3 m-BCR ela2 46,XY,t(9;22Xq34;qll)[7]/
46,XY[5]
31 M-BCR 46,XY,t(9;22Xq34;qll)[12]/
46,XY[6]
78 m-BCR 46,XY,t(9;22Xq34;qll)[18]/
46,XY[1]
91 m-BCR ela2 46,XX,t(9;22Xq34;pll)[30]
80 M-BCR 46„XX,t(9;22)(q34 ;ql 1)[27]/
46,XX[6]
8 m-BCR b3a2 45,XX,X9;22Xq34;qll),
add(3Xq27),-10,+mar[5]/
46,XX[2]
12 m-BCR 46,XX,X9;22Xq34;qll),
add(14)(ql2)[4]/
46,XX[6]
50 m-BCR ela2 45,XY,-7,t(9;22Xq34;ql 1), 10,
+mar[9]
70 M-BCR 3 3 4 57,XX,+X,t(9;22Xq34;ql 1),
(28%) (28%) (28%) +13,+15,+15,+17,+18,+19,
+19,?del(19Xpl3pl3),+21,+21, 
+der(22)t(9;22Xq34;ql l)[cp8]/ 
70,dem,+X,+1 ,+2,+4,+5 ,+6,
+6,+8,+10,+11,+12,+14,+14,
-15,+17,-21 ,+22/[cp8]72,idem,+1, 
+2,+2,+4,+5,+6,+8,+8,+ 
der(9)t(9;22Xq34;qll),+10,
+11,+12,+13+14,- 
15,+18,+20[cp8]
46,XX[24]
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11 118 34 F 28.2 c-ALL MUD 2nd CR BM Relapse 8 mo
12 117 35 M 8 Alio 1st CR EFS 17 mo
13 148 41 F 64.7 EFS 8 mo
14 31 46 M 277 c-ALL MUD 2nd CR BM Relapse 4 mo
15 125 24 F 43.3 Pre-B BM Relapse 7 mo
16 108 33 F 24.7 c-ALL Alio 1st CR EFS 19 mo
17 91 21 M 38 T-ALL BM Relapse 10 mo
18 113 43 F 350 c-ALL MUD 1st CR Died in CR 14 m
19 71 41 F 4.6 Alio 1st CR Died in CR 6mo
20 175 88 F
21 174 29 M
22 39 55 M 17.4 Died in CR 7 mo
23 144 26 M 152.5 BM Relapse 6 mo
[mmuno:Immunophenotype 
EFS: Event free survival in months
Alio: Allogeneic transplant CR: Complete remission 
; BM: Bone marrow F: BCR/ABL fusion signal
ETV6: copy number o f  ETV6
75 m-BCR
85 m-BCR 1
(87%)
86 m-BCR
87
94
90
93
80
80
53
M-BCR
m-BCR
M-BCR
M-BCR
M-BCR
m-BCR
M-BCR
m-BCR 3(11%)
4(32%)
47,XX,t(9;22Xq34;qll), 
+i(17XqlO),inc[6]/idem,-7, der22 
,t(7;22Xql 1 2;ql l)t(9;22),inc[27]/ 
46,XX[6]
46,X Y,del(3)(p 13),del(7Xp 13), 
t(9;22)(q34;q 11 ),del(l l)(q l3)[8]/ 
46,XY[23]
44,X,-X.add(lXp36.3), 
add(3Xp2.3),-7,-9, 
t(9;22Xq34;ql l),+mar[15]/45,X,- 
X,idem,+der(22)t(9;22)[3]/ 
46,XX[2]
b3a2 46,XY,t(9,22Xq34;q 11 )[3]/
45,idem,del(9)(p22), 
dic(20;22)(q 11 ;p 11 )[27]
45,XX,der(9)t(9;22Xq34;q 11) 
der(9;22Xq 10;q 10),der(22)t(9;22)
44,XX,-7,der(9)t(9;22Xq34;ql 1), 
add(9Xpl)
46,XY,t(2;9;22Xpl?2;q34;ql 1), 
-5,del(l 1 Xq ?14),+mar[15]/ 
46,XY[3]
46,XY,t(l;9;22Xp36;q34;ql 1)[7] 
46,XX[ 1 ] 
e la2  Fail 46,XX[15]
Fail
Fail
11-15 M-BCR
70 M-BCR
46,XY[30]
46,X Y,del( 13)(q 12q 14)[20]
BM T: Bone marrow transplant 
BCR-B: BCR Breakpoint 
AM L1: copy number o f  AML1
MUD: Matched unrelated transplant 
MLL: copy number o f  MLL signals
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Table III.3 Vysis BCR/ABL LS ES probe.
Case UIN LS probe FISH ES probe FISH
PCR G-Banded karyotype
A 74
F%
8
BCR
Breakpoint
M-BCR
F% 
No ES 
5
F% 
With ES 
10 b3a2 45,XX,t(9;22)(q34;ql l),add(3)(q27),-10,+mar[5]/ 46,XX[2]
B 39 11 M-BCR 1.5 4.5 46 XY[30]
c 129 12 m-BCR 1.4 11 46,XX,t(9;22)(q34;q 1 l),add(14)(ql2)[4] /46,XX[6]
D 104 12.3 m-BCR 1.5 6.5 ela2 46,X Y,t(9;22)(q34;q 11)[7]/ 46,XY[5]
E 136 4.6 4 0 Neg 46,XY,del(9)(p21)[ 12]/46,XY[8]
F 11 4.7 5 0 NS 51 ,X Y,+21 ,+mar 1 ,+mar2,+mar3 ,+dmin,inc(cp4)
G 56 5 4 0 Neg 46,XY,-17,+mar[3]/47,idem,+mar2[5]/46,XY[3]
H 85 5 4 0 Neg Fail 46,XY[13]
I
J
133
167
5
5
3.5
6
0
0 NS
46,Y,t(X; 10)(?q 11 ;?p 11 )[6]/46,idem,del(6)(q21)[ 1 ]/45,idem,der( 17)t( 17;21)( ?p 11 ;ql 1 ),-21 [3]/ 
45,idem,der( 17)t( 17;21)(?p 11 ;ql 1 ),-21 ,del(6)(q?)[2]
46,XY[3]
Fail
K 84 5.5 6 0 664-180 ,inc[6]/46,XY[4]
L 147 6.6 4.5 0 Neg 46,XY[40]
M 103 1.5 2.1 0.8 ela2 Fail
N 53 3.75 4 0.6 b2a2 45 ,XX,-7,?t(9;22)(q34;q 11 ),?der( 16)t( 1; 16),+?der( 16)t( 1; 16),-18(1) 
46,XX(19)
ES:extra signal ¥ .BCR/ABL fusion signal Neg: Negative NS: No sample
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Table III.4 Cases with abnormal findings by single colour MLL probe
Clinical Features Treatment and outcome FISH
24 135
Sex
F
Age
50
WBC
15.1
Immuno
Pre-B
BMT
No
Outcome in months 
EFS 10 mo
Results
MLL CN 
3 (50%)
G-Banded Karyotype
46,XX,t(4 ;11 )(q21 ;q23)[5]/47,idem,+X[4]/
25 66 F 35 132 Pre-B No BM relapse 7 mo 3 (57%)
48,idem,+X,+der(4)t(4;l 1)[2]/
46,XX[4]
46,XX,t(4; 11 )(q21 ;q23),i(7)(q 10),dd( 12)(p 13)[ 16]/
26 34 M 30 192 Pre-B MUD 1st CR EFS 48 mo 3 (39%)
46,XX[1]
46,XY,t(4;l 1 )(q21 ;q23)[ 12]/
27
28
169
105
M
F
19
32 78 c-ALL No Died in CR 2 mo
3 (50%) 
1 (32%)
46,XY[5]
46,XY,der(7)9q210[3]/46,XY,add(7)(q21 ),del( 19)(p 11 p 13)[ 15]/ 
46,XY[2]
48,XX,+X,+5,i(6)(p 10),+7,-10,del( 11 )(q23),
der( 14)t( 14;?)(q23:?),-15,-17,+2mar[ 18]/ 
46,XX[2]
BM: Bone marrow BMT: Bone marrow transplant CR: Complete remission
EFS: Event free survival MLL CN: Number o f  copies o f MLL signal NA: Not applicable
Table III.5 Cases with abnormal findings by dual-colour MLL probe
Case UIN Clinical Features Treatment and outcome FISH results G-Banded Karyotype
Age Sex WBC Immuno BMT Outcome MLL SP ETV6
29 161 24 F 191 cALL No EFS 3 mo 82% 1(88%) 51 ,XX,+X,t(4; 1 l)(q21 ;q23), 
+der(4)t(4; 11 ),+6,+7,+13 [4]/ 
46,XX[11]
30 156 16 F 255 Pre-B No EFS 5 mo 94% 46,XX,t(4; 11 )(q21 ;q23)[4]/ 
46,idem,add( 14)(q?32)-18,+mar[3]/ 
46,XX[1]
31 140 46 M 930 Other Alio 1st CR Died in CR 5 mo 94% 46,XY,t( 11; 19)(q23 ;p 13)[ 10]
Alio: Allogeneic transplant BM: Bone marrow BMT: Bone marrow transplant CR: Complete remission
EFS: Event free survival MLL SP: % o f Split MLL signals ETV6: % of nuclei showing single ETV6 signal
125
Table III.6 Single colour versus dual-colour MLL probe
Case  Interphase FISH Findings__________________
Single colour probe Dual-colour probe Multiprobe®-!
IS 2S 3S 4S Split 1FS 2FS 3FS 4FS Overall 11
A 139 0 95 5 0 0 0 97.5 1.5 1 NA 48,XX,+8,del(9)(p?21),+? 14[ 13] 
46,XX[2]
B 138 0 92.6 7.3 0 0 0 100 0 0 NA 47,XY,+X[30]
C 175 0 92.6 7.3 0 0 2 96 2 0 NM Fail
D 45 0 53.5 63.3 0 0 0 53 47 0 Fail 3 Fail
E 87 0 91.5 0 8.5 1 0.5 82 3.5 13 Tt 4 46,X Y,del(6)(q 12)[ 10]
F 135 0 82 18 0 64 0 36 0 0 NA 46,XX,t(4; 11 )(q21 ;q23)[5]/47,idem, 
+X[4]/48,idem,+X,+der(4)t(4; 11 )[2 
46,XX[4]
G 66 0 43 57 0 87 0 27 0 0 NA 46,XX,t(4; 11 )(q21 ;q23),i(7)(q 10), 
del( 12)(p 13)[ 16]/
46,XX[1]
H 34 0 61 39 0 93 0 7 0 0 NA 46,XY,t(4;ll)(q21;q23)[12]/
46,XY[5]
I 169 0 50 50 0 96 0 4 0 0 NA 46,XY,add(7)(q21 )[3 ]/46,XY, 
add(7)(q21 ),del( 19)(p 11 p 13)[ 15]/ 
46,XY[21
Not applicable NM: No material S: signal FS .Fusion signal Tt: Near triploidy (>70 chromosome)
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Table III.7 t(12;21) positive cases.
Case UIN Clinical Features Outcome Interphase FISH results G-Banded Karyotype
(months)
Age Sex WBC Immuno OS EFS FS ETV6 AML1 MLL BCR ABL
32 44 15 M 3.2 cALL 24 31 1(79%) 0 1 Fail 46,XY[12]
33 131 15 M 3 CALL 15 15 1(50%) 0 3 4 3 4 90,XX YY,-5,-9,-12,del(12)(pl 1),
(50%) (50%) (50%) del(l 2)(pl 1,)+13 [cp 15]/
46,XY[5]
34 26 16 F 8.3 cALL 29 29 1(64%) 1 1 Fail 46,XX[15]
35 100 25 F 5.1 cALL 11 18 1(67%) 1 1 45,X,-X,add(3)(q 12),del(6)(q? 16),
add(9)(q?),add(12)(pl 1)[18]/
45,idem,-del(6)(q? 16),
der(6)del(6q? 16)rdup(6)(pter-q 12)[2]
36 82 28 M 3.1 cALL 27 27 1(82%) 1 1 47,XY,add(8)(p 1 ?),?add(9)(p?),del(9)(p
?),
add(12)(p?),+21 [ 13]/46,idem,-Y[ 11 ]
46,XY[3]
37 151 43 M 240 cALL 6 6 1(94%) 1 3 Fail 46,XY[9]
38 145 50 M 9.7 cALL 9 9 1(33%) 3 3-4 3-4 4 3 70,inc[33]/
2(51%) (90%) (90%) 46,XY[31
Imm Immunophenotype 
OS overall survival in months 
MLL: Number o f copies o f MLL
EFS Event free survival in months 
ETV6: Number o f copies o f ETV6 
BCR: Number o f copies o f BCR
FS Fusion signals: number o f  signals (% o f abnormal cells) 
AML1 :Number o f copies oiAMLI 
ABL: Number o f copies o f ABL
Table III.8 Abnormal BCR, ABL, MLL, ETV6, AML1 copy number
Interphase FISH_______________________________________________ G-banded karyotype
39 105
BC
R
2 2
MLL
1
ETV6
2
AM L1 M-i
Overall
2
Individual centromeres
9 11 12 13/ 14/ 
21 22
NA 48,XX,+X,+5,i(6)(pl0),+7,-10,del(ll)(q23),
40 96 2 2 2 1(96%) 2 NA
der( 14)t( 14;?)(q23;?),-15,-17,+2mar[ 18]/46,XX[2] 
46,XY,del(12)(p?ll~pl3),del( 13)(q 12q 14)[20]/46,XY[l ]
41 37 2 2 2 1(60%) 2 NA 46,XY,del(5)(ql3q35),add(10)(pl3~15),del(12)(pll)[6]/
42 116 2 2 2 1(19%) 2 NA
46,XY[17
45,XX,del(6)(ql 3q21 ),-7,add(12)(pl ?)[ 12]/46,XX[26]
43 75 2 2 2 1(68%) 2 NA 45,XX,dic(9; 12)(pl ?;pl ?),der( 19)
44 154 2 2 2 1(68%) 2 NA
t(l;19)(q23;pl3)[2]/46,XX[4]
45,XX,dic(9;12)(pl?;pl?),del(17)(pl?)[20]
45 168 2 2 2 1(97%) 3(100%) NA 47,XX,t(8;14)(ql?l;q32),del(12)(pl2pl3),+21c
46 43 2 2 2 1(56%) 3(56%) NA 47,XY,del(12)(p?),+21 [ 12]/46,XY[l 4]
47 112 2 2 2 2 3(80%) NA 46-47, XX, del(6)(q21 q25),del( 13)(q 14q22),+21 ,inc[cp]
48 80 2 2 2 2 4(42%) NA 56,XY,+X,+Y,+4,+8,+l 0,+l 4,+17,+l 8,+21,+21 [ 11 ]/
49 89 2 2 2 4(55%) NA
46,XY[9]
61 ,XY,+X,+Y,+4,+5,+6,+8,+l 0,+l 4,+l 7,+l 8,+l 8,+20,
50 60 2 2 3 3(33%) 3(33%) NA
+21,+21,+22[18]/46,XY[7]
54-61 ,XY,+X,+Y,+1 ,add( 1 )(p 13),+add( 1 ),+4,+7,
51 158 4 2 3 2 2 NA
der(9)t(8;9)(q? 13 ;p? 13),+11 ,+12,+13,+14,add( 14)(q32), 
+17,+19,+20,+21,-22,-22,+mars,inc[cpl5]/46,XY[l] 
59-60,XX,+X,+l ,+5,+6,+8,+8,+l 0,+l 4,+l 8,+l 8,+l 9,+20,
52 173 2 2 3 2 2 NA
i(21 )(q 10),+22[cp4]/46,XX[ 1 ] 
52,inc
53 30 2 2 2 2 4(83%) NA 5 3 ,+4,i nc[cp4]/46,XX[2]
54 50 4 3 3-4 3(44%) 4(86%) NA 85-87,XXYY,+mar,inc[4]/46,XY[2]
55 84 4 3 3-4
4(48%)
1(17%) 3(19%) NA 64-180,inc[6]/46,XY[4]
56 15 2 3 2
3(7%)
2
4(58%)
2 NA 46,XY,der(9')t(9';9)(p22;q22),der( 19)t( 1; 19)(q23 ;p 13)[4]
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57 68 2 3 2 2 2 NA
58 123 2 3 2 2 2 NA
59 164 2 3 2 2 2 NA
60 19 2 2 2 2 1(21%) Ho 2
61 120 2 2 2 2 3(35%) HeL 2
62 110 2 2 2 2 3(12%) HeL 2
63 85 2 2 2 2 3(45%) HeH 2
64 21 3 4 3 2 3(10%) HeH 3 3 2
4(43%)
65 12 3 2 3 3(41%) 4(41%) Tr 2 4 F
66 171 2 2 2 2 4(72%) HeH 2
67 87 4 4 4 4(13%) 4(13%) Tt 4 4
68 124 2 2 2 1(18%) 2 NA
69 93 2 1 2 2 2 NM
70 126 3 2 2 1(15%) 2 NM
71 40 2 2 2 0(85%) 2 NA
72 72 3 2 2 2 2 NM
73 45 1 1 3 2 2 NM 3
74 159 2 2 2 2 5(77%) HeH 2
75 11 2 2 2 6(33%) 2 NA
8(31%)
76 101 2 2 2 2 4(55%) NA
ABL : copies o f ABL signal
NA: Not applicable
Tt: (near triploidy >70 chromosomes)
13/21 :Number o f copies o f D Z131 /D Z211 
HeL: Low Hyperdiploid (47-50 chromosomes)
BCR  : copies o f BCR  signal 
NM: No material 
ETV6: Number o f copies o f ETV6 
NA: Not applicable
HeH: High Hyperdiploid (51-65 chromosomes)
46,XY,i(9)(q 10),i( 17)(q 10)[ 15]
45,X,-Y,add(3)(q21 q23),del(6)(q 1 ?3q2? 1 ),i(9)(q 10), 
add( 14)(q32),i( 18)(ql 0)[5]/45,idem,add( 12)(p 13),+l 8,- 
i( 18)(q 10)[2]/46,XY[2]
46,XX,add(2)(p),add(3)(p),-5,-6,add(7)(q),i(9)(ql0),
-13,add( 14),der( 14; 17),+4xmar
3 Fail 46,XY[15]
5 Fail
5 Fail
5 Fail 46,XY[13]
5/6 6 46,XX[20]
6 5 Fail
5 Fail
6 8 46,XY,del(6)(ql 2)[ 10]
46,XX,?del(9)(q21q33)[4]/46,XX[6]
46,XX[20]
Fail
46,XY,inc[68]
Fail
Fail
4 46,XY[20] 
50,XY,+21,+marl,+mar2,+mar3,+ldmin,inc[cp4]
46,X Y,del(7)(p 1 ?5),t(8;22)(q 1 ? 1 ;q 13),dup(21)(q)
9: number o f  copies o f DZ91 14/22: number o f copies o f DZ141/DZ221
HeH: High hyperdiploidy (51-60 chromosomes)
AML1: Number o f copies o iA M L l  12: Number o f  copies o f DZ121
NM: Insufficient material Ho: Hypodiploid (40-45 chromosomes)
Tr: Near Triploid (66-80 chromosomes) Tt: Near Tetraploid (>80 chromosomes)
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Finding on interphase
• •  BCR
•  •  ABL
•  •  BCR/ABL fusion
Findings on metaphase
Fig 111:1 BCR/ABL positive Hyperdiploid ALL
(case 21 table 111:2 UIN 174)
9 centromere
BCR
ABL
BCR/ABL
AML1 ES 
der(12)t(12;21)
AML1 
N 21
ETV6/AML1 fusion  
der(21)t(12;21)
Fig 111:3 ETV6/AML1 fusion positive near tetraploid ALL
(case 33 table 111:7 UIN 131) 132
TEL/AML1 probe
Fig 111:4 dup(21)(q) presenting as amplified
Chapter IV 
Interphase FISH in the accurate diagnosis of 
aneuploidy in adult ALL
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IV: 1 Abstract
FISH was used to complement cytogenetic analysis on diagnostic bone marrow or 
blood from 193 adult patients with ALL. Interphase FISH was carried out to search 
for aneuploidy in 77 cases with a failed or normal cytogenetic analysis, using a 
novel device for all chromosome centromeres (Multiprobe®-I system). Complete or 
partial analysis was possible in 48 cases and revealed abnormalities in 12 (24%) 
cases. These were high hyperdiploidy (>50 chromosomes) in 5 cases, low 
hyperdiploidy (47-50 chromosomes) in 4 cases, hypodiploidy (45 chromosomes) in 
two cases, and near triploidy (>70 chromosomes) in one case. By combining 
cytogenetic analysis and interphase FISH the overall incidences of the abnormalities 
in the group thus become hypodiploidy 17/193=9%, low hyperdiploidy 17/193=9%, 
high hyperdiploidy 18/193=9%, near triploidy 6/193=3%.
The overall incidence of aneuploidy detected in this study was 30%. Of which one 
third were hidden, detectable only in the non-dividing population.
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IV: 2 Introduction
The prognostic significance o f chromosomal number for classification of ALL 
patients was demonstrated in 1978, when an improved prognosis was found in 
children with ALL and a karyotype o f >50 chromosomes (Seeker-Walker 1978). 
Chromosomal number or ploidy remains an important prognostic feature in ALL. 
Loss o f chromosomes known as hypodiploidy is generally associated with poor 
prognosis. It has been reported that the prognosis worsens as the chromosome 
number declines (Heerema 1999). Near haploidy (23-29 chromosomes) has the 
worst outcome with median survival o f 11 months (Gibbons 1991; Harrison 2004). 
A poor outcome is also associated with less than 45 chromosomes in childhood ALL 
(Heerema 1999), and loss o f chromosome 7 in adults (Wetzler 1999). In contrast 
chromosomal gain, particularly high hyperdiploidy is associated with a better 
prognosis in both children and adults (Jackson 1990; Seeker-Walker 1997). Within 
the hyperdiploidy groups gains of specific chromosomes are related to the clinical 
course of disease, the combination o f trisomies for chromosomes 4 and 10 predicts 
good prognosis (Harris 1992), and the presence of trisomies for chromosomes 4 and 
18 in high hyperdiplody has been found to predict five year survival of 96% 
(Moorman 2003) whereas the presence o f trisomy 5 confers poorer outcome within 
the high hyperdiploidy group in children (Heerema 2000). Low hyperdiploidy (47- 
50 chromosomes) appears to predict improved outcomes in adults (Secker-Walker
1997).
Unlike chromosomal translocations, associated with the production of chimeric 
RNA, which can be traced using PCR based methods, detection o f numerical
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changes cannot be carried out using this molecular technique. Alternative methods, 
such as the measurement of DNA index or FISH are the most appropriate tests. 
Measurement o f DNA index has limitations, since individual chromosomal gains are 
not identified, nor is it sensitive enough to detect all cases o f low hyperdiploidy, or 
single chromosome gains or losses. FISH using probes directed to the alpha satellite 
regions of the individual chromosome centromeres has been used extensively to 
determine chromosomal gains and losses in interphase cells (Jenkins 1992; 
Kibbelaar 1993; Tosi 1994; Ritterbach 1998).
By using selected centromeric probes to detect the chromosomes most commonly 
present within hyperdiploid clones it can be applied at presentation (Ritterbach
1998). The combination of two or three probes has also been described in the 
detection o f minimal residual disease, when a hyperdiploid clone was identified at 
diagnosis (Heerema 1993; Kasprzyk and Seeker-Walker 1997).
In this section o f the study interphase FISH using centromeric probes, either as the 
total chromosome complement together in the Multiprobe-I device or individually / 
in pairs has been carried out to evaluate this procedure in the detection of 
chromosomal gains or losses in adult ALL.
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IV: 3 Materials and Methods
IV: 3: 1 Patients and controls
O f the 193 patients in this study, in 82 initial cytogenetic analysis failed or showed 
only normal metaphases. Diagnostic samples were available from 77 o f these 
patients, bone marrow (n=63), peripheral blood (n=9) and both (n=5). These 
included 69 entered to the current UKALLXII treatment trial and eight treated 
independently.
Five bone marrow samples were selected as normal controls as described in Chapter 
11:1, and an additional three from adults with ALL with pseudodiploid karyotypes 
(structural chromosomal abnormalities but only 46 chromosome). Positive controls 
were two adults with ALL and hyperdiploidy seen by conventional cytogenetics.
IV: 3: 2 Probes for FISH
Multiprobe®-1 device (Cytocell):
This device allows the simultaneous detection o f centromeres from 24 individual 
chromosomes in a single hybridisation on one slide, using directly labelled 
centromeric probes. (Details of probes used in the kit are presented in Chapter 11:4). 
Other probes:
Probes for BCR/ABL, MLL and TEL/AML 1, and wcp were applied to the same 
samples used in interphase FISH studies on cases presented in this section as 
detailed in Chapter 11:4).
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IV: 3: 3 Methods o f  Analysis
Details of cytogenetic analysis, immunophenotyping, FISH and equipment used for 
analysis are presented in Chapter III: 3: 3.
Interphase FISH  
Multiprobe®-1 device (Cytocell):
One hundred nuclei were scored for each individual centromeric probe. The 
hybridisation efficiency of the five control samples, ranged from 47-94%. The 
proportion of nuclei with two signals was also variable ranging from 83-98% as 
detailed in (Tables 11.2 and II.3). Samples were only included in the study if a 
successful result was achieved on a minimum of 10 probes. Those probes that failed 
most frequently were those for chromosomes 1, 20, 4, 14/22, X, and 13/21 as 
detailed in (Table II.4).
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IV: 4 Study results
Samples were available from 77 patients. In 29 cases, 10 o f which had a normal 
karyotype and 19 with a failed cytogenetic result, material was inadequate for testing 
with Multiprobe-I. In the remaining 48 cases, 28 with a normal karyotype, and 20 
with a failed cytogenetic result a successful FISH result was obtained.
These were common-ALL (n=19), pre-B ALL (n=7), T-ALL (n=12), Null ALL 
(n=l), and “other” (n=2). Immunophenotyping was not available for the remaining 
seven patients.
Aneuploid cases
In 36 cases, two signals were observed for all chromosomes tested with Multiprobe- 
1, indicating a normal diploid number o f chromosomes. In 12 cases the gain or loss 
o f signals implicating the gain or loss o f whole chromosomes. The abnormal results 
from Multiprobe-I are shown in Table VI. 1.
In two cases (A-B) there was loss o f one centromeric signal for chromosomes 9 and 
13/21 respectively (case B had a single copy o f AML1 making monosomy 21 more 
likely), the absence of metaphases prevented further detailed studies in these cases. 
In both cases, a number o f probes failed to hybridise, thus losses or gains o f other 
chromosomes were difficult to rule out. Thus the verity of these chromosomal losses 
is in question. In cases C and D, with apparent gain o f chromosome 8 only, the 
successful hybridisation of other probes supported this positive finding as a true 
result. Two further cases (E-F) showed five signals on analysis o f centromere 13/21, 
the associated gain o f an AML1 signal in both cases supported the conclusion o f an
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extra copy of chromosome 21. However the presence o f further gains could not be 
ruled out due to poor quality of the results from other wells.
There were two cases with evidence o f a high hyperdiploid clone (modal number 
>50) (G & H) with gains of centromeric signals corresponding to chromosomal 
gains commonly found in high hyperdiploidy.
In two cases (I & J), there was a combination o f trisomies and tetrasomies for 
chromosomes within abnormal clones, giving modal numbers o f 59-61 in case I, and 
63-72 in case J.
Cases K & L were unique in that the chromosomal gains were associated with 
apparent chromosomal losses. In case K interphase FISH showed the presence o f 
t(9;22) in addition to a hyperdiploid clone and an apparent monosomy of 
chromosome 7, In case L with apparent monosomies for chromosomes 6 and 13 in 
addition to tetrasomy X, a small number o f metaphases were sequentially hybridized 
with combinations o f wcps to fully characterise the karyotype of these patient as 
detailed in Chapter V.
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IV: 5 Discussion
Cytogenetic findings in adults identify prognostic subgroups, o f which some o f the 
most significant structural abnormalities and can be detected by PCR. Numerical 
chromosomal changes on the other hand can only be detected by conventional 
cytogenetics and cannot be detected by many molecular procedures. Since 
karyotypic analysis is often difficult in ALL, and chromosome morphology is 
notoriously poor in hyperdiploid clones, an alternative method to detect numerical 
changes is needed. Measurement of the DNA index has its limitations. It will only 
provide information on total DNA content. Details o f any specific gains or losses o f 
individual chromosomes remain unknown.
FISH using centromeric probes is a highly reliable and sensitive method that allows 
enumeration o f individual chromosomes. Previous studies comparing interphase 
FISH using centromere probes and DNA index showed that FISH is the more 
sensitive technique (Ritterbach 1998). A number o f previous studies have utilised a 
selected number o f centromeric probes as surrogate markers for hyperdiploidy 
(Kasprzyk and Seeker-Walker 1997; Ritterbach 1998). The use o f selective probes 
means that abnormality detection is limited to the chromosomes for which the 
probes are being applied. The combined testing for all chromosomes in one test is 
thus an attractive alternative allowing detection o f hyperdiploid as well as 
hypodiploid clones, and identifying isolated gains or losses o f one or a few 
chromosomes.
In this study a series o f adult ALL patients were studied for numerical chromosomal 
abnormalities, using Multiprobe-I. This device is designed to allow testing for all
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chromosomes in one hybridisation. In using this technique several problems were 
encountered. For a single hybridisation all probes must be calibrated to the same 
conditions. When probes are attached to a single slide this is the responsibility o f the 
manufacturers. There were problems with the availability o f the kits, as well as cross 
hybridisation, which made analysis impossible for chromosomes 5/19, and to a 
lesser degree, 13/21 and 14/22. Smaller probes, in particular for chromosome 20 
centromere, frequently failed due to incomplete hybridisation at conditions adequate 
for the other probes. The combination o f these difficulties meant that in every case at 
least one probe (that for 5/19) gave an inconclusive result and in many cases up to 
one third of probes gave inadequate results.
However centromeric probes for the chromosomes most commonly involved in 
hyperdiploidy (6/10/17/18) (Moorman 1996; Raimondi 1996), as well as the 
chromosomes of specific interest in adults, namely 7 and 8 (Wetzler 1999) were 
robust and reliable in standard hybridisation / washing processes and produced a 
high success rate.
In addition to probe factors, success was related to availability and quality o f patient 
material. Testing for all 24 probes requires a total of 50 pi o f high cell density 
sample, which was not available in a high proportion o f patients. This applied in 
particular in those in which the initial cytogenetic analysis had failed. In some cases 
the quality o f cells was poor, therefore only a small proportion o f nuclei hybridised 
efficiently, yielding too few cells for successful analysis.
Despite these technical difficulties, analysis was possible on 48 patients and within 
this group 12 cases with abnormalities were found. O f particular interest in nine of
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these cases, the first indications o f a hidden hyperdiploid clone came from the 
detection of additional signals with specific probes on screening for structural 
abnormalities. The most common finding was o f an extra copy of AML1, present in 
seven cases, five o f which showed classical high hyperdiploidy. This observation 
reflects the known high incidence o f trisomy 21 in high hyperdiploidy (Moorman 
1996; Raimondi 1996). Extra copies of BCR, ABL, ETV6 and MLL, indicating 
trisomies of chromosomes 22, 9, 12 and 11 respectively were also present in some of 
these cases.
Three cases were not revealed by specific probes. They were cases with isolated 
trisomy 8, for which no specific probe was applied, and one case with loss of one 
chromosome 9 centromere signal. This case was o f interest in that the initial 
cytogenetic analysis had shown only normal metaphases. Interphase FISH however 
confirmed the presence o f a small clone o f BCR/ABL positive cells accounting for 
11-15% of nuclei, without loss o f the second ABL signal. The additional finding of 
the loss of one chromosome 9 centromere in 17% nuclei suggested the presence o f a 
further abnormality in addition to the Ph translocation. This hypothesis could not be 
confirmed due to the lack of metaphases showing BCR/ABL fusion or a single 
chromosome 9 centromere signal.
A similar situation was observed in two further cases with apparent monosomies, 
these were shown to result from unbalanced translocations with loss of centromeric 
regions rather than whole chromosomes (as detailed in Chapter V). This emphasises 
that the interpretation o f hypodiploidy from the use o f centromeric probes must be 
undertaken with caution, especially in cases with no metaphases to substantiate the
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findings.
In conclusion the utilisation of the Multiprobe-I offers an exciting alternative 
method o f testing for numerical chromosomal abnormalities in ALL. Multiprobe-I is 
very compact and user-friendly, especially when large numbers o f samples are being 
tested. It is much more convenient and quicker than carrying out individual or paired 
centromeric probe. Although the method has some limitations in the amount of 
material required and difficulties o f complete analysis, a number of cases with 
hidden abnormalities were detected. Even in cases with very scant material, the 
Multiprobe-I provided useful information albeit from a limited selection of probes. 
The highest came from combining this information with results from tests for BCR /  
ABL /  MLL /  ETV6 and AML1, which covered the detection o f most major numerical 
abnormalities.
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Table IV .l Abnorm al M ultiprobe-I results
UIN CC Number of signals for each centromere on Multiprobe-I
1 2 3 4 6 7
(% of nuclei showing abnormal copy number) 
8 9 10 11 12 13/21 14/22 15 16 17 18 20 X Y
A 39 N F 2 2 F F 2 2 1
(17)
F F F 4 F 2 F 2 2 F 1 ]
B 19 F F 2 F 2 2 2 2 2 2 F 2 3
(36)
F 2 2 2 2 F 1 l
C 152 F 2 2 2 2 2 2 3
(47)
2 2 2 2 4 4 2 2 2 2 F I 1
D 147 N 2 2 2 2 2 2 3
(20)
2 2 2 2 F F 2 2 2 2 2 2 NA
E 110 F F 2 2 F F 2 F 2 F F 2 5
(48)
F 2 F F 2 F 1 1
F 120 F F 2 2 F F F 2 2 2 2 2 5
(IS)
F F 2 F 2 2 1 1
G 159 N 3
(36)
2 2 3
(55)
3
(55)
2 4
(56)
2 3
(51)
2 2 4 5(37) 2 2 3
(39)
4
(42)
2 F NA
H 85 F 2 2 2 3
(25)
F F 2 2 3
(60)
2 2 5
(43)
4 F 2 3
(43)
3
(42)
2 2
(50)
2
(50)
I 21 N 3
(24)
2 2 3
(30)
3 
(31)
4 
(24)
2 3
(39)
3
(40)
3
(40)
2 2 5
(24)
6
(25)
5(38)
6(22)
3(11) F 3
(38)
3
(32)
4
(40)
2 NA
J 12 F F 4
(56)
3
(19)
4
(55)
F 3 
(15)
4
(53)
3 
(18)
4
(53)
3 
(22)
4
(46)
3
(56)
3
(56)
F F 6
(27)
F 3(25)
4(45)
3(22)
4(37)
3 
(25)
4
(40)
3
(18)
4 
(42)
4
(33)
2
(50)
2
(24)
K 174 F 3
(29)
3
(34)
4
(33)
3
(23)
2 1
(40)
3
(31)
3
(36)
3
(26)
3
(31)
2 5 
(20)
6 
(19)
4 3(32) 3(27) 3
(24)
3
(26)
F 2
(35)
1
L 171 F F 2 2 3
(56)
1
(80)
2 3
(51)
2 3
(55)
2 2 5(79) 4 2 2 3
(44}
3
(46)
2 4
<55)
NA
UIN: Unique identification number CC: Conventional Cytogenetics N : Normal Karyotype= 20 normal metaphases F: Fail NA: Not Applicable
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Chapter V 
Karyotype characterisation in ALL by 
complementary FISH techniques
147
V: 1 Abstract
A series o f FISH techniques were used to complement cytogenetic analysis in the 
identification o f undefined (marker) chromosomes in 29 adult patients with ALL. 
Interphase FISH results from a range o f specific probes, BCR/ABL, ETV6/AML1 and 
MLL, in addition to centromeric probes, was already available. In 15 patients 
metaphase analysis provided additional information with these probes. By 
complementary metaphase FISH analysis with wcps hybridised in a sequential 
manner, the marker chromosomes were accurately identified, as simple (5 cases) or 
complex. This study indicated that sequential metaphase FISH analysis is a highly 
informative approach for the accurate characterisation o f karyotypes in ALL and 
provides a useful alternative to other multicolour FISH techniques.
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V: 2 Introduction
The identification of numerical and structural chromosomal abnormalities by 
cytogenetic analysis continues to be the gold standard approach both for diagnosis 
and assigning likely outcome o f patients as well as the recognition of new recurrent 
chromosomal abnormalities of prognostic significance. It provides the starting point 
for molecular studies, leading to identification o f genes involved in 
leukaemogenesis. In ALL the poor quality o f metaphases often precludes the 
accurate characterization of complex karyotypes by conventional chromosomal 
analysis alone. Molecular cytogenetic techniques have greatly improved the 
accuracy of detection of important cytogenetic changes, as demonstrated in Chapters 
III and IV and has allowed the identification o f a number o f cryptic chromosomal 
abnormalities in ALL (Romana 1994; Clark 2000).
The use of multiplex FISH (M-FISH), and spectral karyotyping (SKY) analysis has 
facilitated the accurate definition o f complex karyotypes in AML (Tosi 1999), CML 
(Harrison 2000) and ALL (Mathew 2001).
A number of studies in haematologic malignancies such as AML (Grimwade 1998), 
myelodysplasia (Ohyashiki 1992), and lymphoma (Offit 1991) have shown a 
correlation between complex karyotypes and poor outcome.
In ALL the effect o f complex karyotypes on outcome remains unclear, although 
there is some evidence that it is similarly poor (Jarosova 2003).
We have demonstrated that it is possible to completely unravel the make up of 
highly complex karyotypes in patients with ALL by serial hybridisation of probes to 
the same metaphase in a methodical and painstaking manner. Locus specific, alpha-
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satellite and whole chromosome paints are hybridised serially to a single or a small 
number of metaphases. This method allows the identification all chromosomes 
within the metaphase in sequence. Digital images are captured at every step and then 
superimposed to produce a complete picture of the metaphase (Pinson 2000).
Using this sequential metaphase FISH approach in combination with interphase 
studies, I analysed a series o f 29 ALL patients with incompletely defined 
karyotypes. The combined techniques allowed characterisation o f complex 
karyotypes in fifteen patients, providing insight into the impact o f karyotype 
complexity in ALL.
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V: 3 Materials and Methods
V: 3: 1 Patients and controls
Among 193 patients in this study, 111 had an abnormal karyotype by conventional 
cytogenetic analysis. Fixed cells from diagnostic bone marrow or peripheral blood 
samples were available from 24 cases with unidentified marker chromosomes and 
incomplete karyotypes for further FISH studies. An additional three cases with 
complete cytogenetic analysis and two cases with a failed cytogenetic result but 
unexpected interphase FISH findings were also analysed.
V: 3 :2  Probes for FISH
Details of all probes used are presented in Chapter 11:4:1).
Specific probes: Commercial probes for BCR/ABL, MLL and ETV6/AML1 (Vysis, 
Downers IL, USA) were used in interphase FISH studies.
Centromere specific probes: Multiprobe®-I (Cytocell) or single indirectly labelled 
alpha satellite probes (Oncor) were used for chromosome enumeration.
Whole chromosome painting probes: Digoxigenin or biotin labelled wcps were used. 
(Star*FISH, Cambio)
V: 3: 3 Methods o f  Analysis
Details of cytogenetic analysis, FISH preparation and analysis are presented in 
Chapter II.
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FISH:
All probes were hybridized according to manufacturers’ instructions. As detailed in 
Chapter II.
Interphase FISH
All 29 cases had been tested by interphase FISH for BCR/ABL, MLL and 
ETV6/AML1. The cases with failed or normal cytogenetics were also studied by 
Multiprobe-I to enumerate chromosomes, as previously described in Chapters II and 
III.
Metaphase FISH:
Slides, from 27 patients, which had been previously hybridized with dual-colour 
probes, had metaphases available, for serial hybridization with wcps. Abnormalities 
detected by conventional cytogenetic analysis, such as apparently deleted 
chromosomes, or by interphase FISH with specific probes, such as loss of one signal 
for BCR, ABL, ETV6, AML1 or MLL directed the choice o f initial wcp to be used. 
Images of metaphase(s) showing the relevant abnormality with the specific probe 
were captured. In the next step, two or three wcps specific for the chromosomes o f 
interest were applied using a mixture o f biotin (green) and Cy3 (red) labeled probes, 
combined as 50% biotin: 50% Cy3 (yellow). Images o f the same metaphase(s) as 
captured with the specific probes were also captured following hybridization with 
wcp. The findings from this step were used to direct the next wcp selection, and so 
on. After each hybridisation step, a new image o f the same metaphase(s) was 
captured. The images were then digitally merged to produce a composite image o f 
the metaphase as it would have appeared had the wcps been all applied
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simultaneously. These steps were repeated until either the whole chromosome 
marker(s) was elucidated or the material became too friable to proceed with further 
testing. Up to six hybridisations with wcps were carried out.
In two cases in which initial cytogenetic analysis had failed to produce a result, there 
were very few metaphases. Interphase FISH showed loss o f one or more centromeric 
signal, suggestive of the presence o f hidden monosomies. Wcp for the apparently 
lost chromosome(s) was applied to a slide with only interphase nuclei. Greater than 
the expected two distinct areas of signal seen on interphase nuclei, suggested an 
underlying translocation. Wcp was applied to the slide with the metaphase(s) to 
confirm the presence of derived chromosomes.
Multicolour-FISH (M-FISH/24-colour FISH):
Another investigator in our laboratory (R.Jalali) carried out M-FISH in four cases, 
using the 24-colour probe kit (SpectraVysion™, Vysis, U.K.). This allows 
simultaneous detections of all 24 chromosomes in a single hybridisation and allowed 
direct comparison with sequential FISH.
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V: 4 Study Results
O f the 29 cases selected for further studies, sufficient material was available for 
further studies on only 15 of them. The details o f these cases are presented in (Table
V . l ) .
V: 4: 1 Simple marker chromosomes:
In five cases the unidentified marker chromosome was derived entirely from one 
chromosome (cases 1-5)
Case 1:
Karyotype by CA: 46 XY,del(7)(pl?5),t(8;22)(ql?l;ql3), -21,+mar
Karyotype after FISH: 46,XY,del(7Xpl?5),t(8;22)(ql?l;ql3),dup(21)(q?)
FISH with locus specific probes in case 1 showed four copies o f AML1 in sequence 
along the marker chromosome. This indicated that wcp 21 was the choice of wcp to 
apply, FISH with this paint showed the marker chromosome to be composed solely 
of chromosome 21 material (Fig III: 4).
Case 2:
Karyotype by CA: 46 XY,-17,+mar/47,XY,-17,+marl,+mar2
Karyotype after FISH: 46 XY,r(17)/47,XY,r(17),+r(17)
Cytogenetic analysis in case 2 showed two cell populations with loss o f one 
chromosome 17, and one or two unidentified ring chromosomes. FISH with 
centromeric probe for chromosome 17 showed two populations o f interphase cells. 
In the majority o f nuclei, one normal and two smaller signals were seen, and in a 
smaller proportion o f nuclei one normal and one smaller signal were seen, 
supporting the presence o f one or two derived chromosome 17 (Fig V: 1).
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Metaphase FISH confirmed the ringed chromosome as the site o f the smaller signals. 
Case 3:
Karyotype by CA: 45,XY,-7,t(9;22)(q34;q 11 ),-10,+mar
Karyotype after FISH: 45,XY,-7, t(9;22)(q34;ql l),del(10)(q?)
In case 3 the karyotype showed a t(9;22)(q34;ql 1), apparent monosomy of 
chromosomes 7 and 10, in addition to a marker chromosome. Interphase FISH 
showed BCR/ABL fusion. Metaphase FISH painting with wcp7 and wcp 10 
confirmed the monosomy 7 and revealed the marker chromosome to be del(10)(q?) 
(Fig V: 2).
Case 4:
Karyotype by CA: 46,XY,t(2;9;22)(pl?2;q34;ql l),-5,del(ll)(ql4),+m ar
Karyotype after FISH: 46,XY,t(2;9;22)(pl?2;q34;ql 1 ),del(5)(q?),
del(ll)(q21q23)
Cytogenetic analysis in the fourth case showed a complex Ph chromosome, a 
del(l lq), monosomy of chromosome 5, and a marker chromosome. Interphase FISH 
confirmed the BCR/ABL fusion, and two normal MLL signals. Sequential metaphase 
FISH was carried out in a stepwise manner wcp 22 was applied first, followed by 
wcp 9 and wcp 2 together. The third hybridisation was wcp 5, applied to the same 
metaphase. This confirmed t(2;9;22) and identified the marker chromosome as a 
del(5)(q?) (Fig V: 3).
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Case 5:
Karyotype by CA:
47,XY,add(8)(pl?),?add(9)(p?),del(9)(p?),add(12)(p?),+21/46,idem,-Y 
Karyotype after FISH:
47,XY,del(8)(p?l),?add(9)(p?),del(9)(p?),t(12;21)(pl3;q22),+21/ 46,idem,-Y 
Cytogenetic analysis in case 5 showed abnormalities of chromosomes 8, 9 and 12 
plus an extra copy o f chromosome 21. Interphase FISH showed ETV6/AML1 fusion. 
Metaphase FISH with wcp8, wcpl2 and wcp21 confirmed both t(12;21) and +21 in 
addition to del(8q)(Fig V: 4).
V: 4: 2 Complex marker chromosomes:
In nine cases (cases 6-15) the unidentified chromosome was shown to be the product 
of translocations involving between two to five chromosomes.
Case 6:
Karyotype by CA: 46,XX,add(2)(q3?7),-8,add(9)(p2),+mar
Karyotype after FISH: 46,XX,der(2)t(2;8)(q?;?),del(8)(q),
der(9)del(9)(p?)t(2;9)(?;?)
In case 6 cytogenetic analysis showed abnormalities o f chromosomes 2 and 9, 
monosomy for chromosome 8 and a marker chromosome. FISH with wcp 2 and wcp 
8, followed by wcp 9 showed three derived chromosomes; a der(2)t(2;8), del(8)(q) 
and der(9)del(9)(p?)t(2;9) (Fig V: 5).
Case 7:
Karyotype by CA: 46,XY,der(7)(q21)/46,XY,der(7)(q21),del(19)(pllpl3)
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Karyotype after FISH: 46,XY, der(7)t(4;7)(p?;q?)/46,XY,der(7)t(4;7)(p?;q?),
t(ll;19)(q23;p?)
Cytogenetics in case 7 revealed abnormalities o f chromosomes 7 and 19. Interphase 
FISH showed three signals with single-colour MLL probe. Metaphase FISH showed 
splitting of the probe between two chromosomes confirming a rearrangement of 
MLL. wcpl 1 with wcp 19, wcp 4 with wcp7 were used in sequence and revealed the 
MLL rearrangement to result from t(l 1; 19) with der(7)t(4;7) (Fig V: 6).
Case 8:
Karyotype by CA: 47,XY,deI(3)(q22),del(6)(ql3),-8,t(l I;14)(ql3;q32),
+ m arl,+m ar2
Karyotype after FISH: 47,XY,+3,del(3),del(6),der(8)t(8;3;8;19),t(l I;14)(ql3;q32) 
Cytogenetic analysis in case 8 showed monosomy 8, deletions o f chromosomes 3 
and 6, and two marker chromosomes. FISH with wcp3, wcp6 and wcp8, followed by 
alpha satellite probe to chromosome 8 centromere in one metaphase, confirmed the 
del(3) and del(6), and showed the marl to be an extra copy o f chromosome 3, the 
mar2 was a derived chromosome 8 with insertion o f chromosome 3 material (Fig V: 
7a, 7b). Further testing with wcp22, followed by wcp land wcp 19, identified the 
second marker chromosome as a der(8)t(8;3;8;19) (Fig V: 7c).
Case 9:
Karyotype by CA: 46,XX,add(2)(p?),add(3)(p?),-5,-6,add(7)(q?),i(9)(ql0),
-13,add(14),der(14;17),+m arl,+m ar2,+m ar3,+m ar4
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Karyotype after FISH: 46,XX,add(2)(p?),deI(3)(p?),der(5)ins(5;3)(?;??),
der(5)t(?;5)(?; ?),del(6q),add(7)(?q),i(9)(q 10), 
der(13)t(2; 13)(?; ?),der(17)t(14; 17)(?; ?)
The karyotype in case 9 was highly complex, with apparent losses of chromosomes 
5, 6, and 13, abnormalities o f chromosomes 2, 3, 7, 9, 14 and 17 in addition to four 
marker chromosomes. Interphase FISH showed three copies of ABL consistent with 
the cytogenetically identified i(9)(q 10). Metaphase FISH with wcp3, wcp5 and 
wcp 14, followed by wcp7 and wcp 17 was undertaken. Results from wcp7 were 
inconclusive, however the other tests confirmed add(2) and add(3), and showed four 
derived chromosomes; der(2)t(2;13), der(5)ins(3;5), der(5)t(?;5), der(?)t(7;?), del(6) 
and confirmed der( 17)t( 17; 14) (Fig V: 8). Results from M-FISH of this case were 
concordant in part and parallel examination o f metaphases from both techniques 
provided more detailed information. The der(5) was identified as der(5)ins(5;3), the 
der(17) identified as der(17)t(17;14), as well as defining a del(5), a der(7)t(7;22), a 
der( 14)t( 14;6),and a der( 14)t( 14;5).
By M-FISH a small marker was described as der(2)t(2:22). A marker o f similar size 
appeared to be a der(2)t(2;13) by sequential FISH.
Case 10:
Karyotype by CA: 46,XX,der(5)t(l ;5)(q23;q35)/45,XX,-2,add(4)(p?),-5,-8,-ll,
add(12)(pl),del(12)(plpl),+marl,+mar2,+mar3,+mar4 
Karyotype after FISH 46,XX,der(5)t(l;5)(q23;q35)/ 45,XX,der(5)t(l;5),
der(2)t(2;5)(?;?),der(2)t(12;?;5;2)(?;?;?;?),
der(4)ins(4;5)(?;??),-5,der(8)t(8;12),-12,der(12)t(5;12)
158
Cytogenetic analysis o f case 10 showed a complex karyotype with two populations 
of abnormal cells, one with an isolated der(5)t(l;5), the second showing losses of 
chromosomes 2, 5, 8, possibly 11, abnormalities o f chromosomes 4 and 12 with four 
marker chromosomes. Interphase FISH showed two normal copies o f MLL. One 
slide was hybridised in five sequential steps, with wcpl and wcp5, followed by 
wcp2 and wcp8, then wcp4 and wcp 12, followed by wcp 11 and wcp 17 and finally 
w cpl9. All but the last experiment were successful, and two abnormal clones were 
identified, one with isolated der(5)t(l;5) (Fig V: 9a). The second clone with five 
derived chromosomes der(2)t(2;5), der(?2)t(12;?5;2), der(4)ins(4;5), der(8)t(8;12), 
and der(12)t(5;12) (Fig V: 9b), M-FISH of this case confirmed the findings in the 
first clone but no metaphases showing the complex clone were observed.
Case 11:
Karyotype by CA: 45,X,X,add(3)(ql2),del(6)(q?16),add(9)(q?),
add(12)(pll)/45,idem,del(6)(q?16),
der(6)del(6)(q?16)rdup(6)(pter-ql2)
Karyotype after FISH: 45,X,-X,der(3)t(3;21),r(6),der(9)t(9;3),
der(12,)t(9;3;21;12), der(12)t(12;21)
Cytogenetics showed abnormalities o f chromosomes 3, 6, 9 and 12. Interphase FISH 
detected an ETV6/AML1 fusion signal in all nuclei, which on metaphase FISH 
analysis appeared to be localized on the marker chromosome. The karyotype 
established by M-FISH was: 46,XX,der(3)t(3;21),r(6),der(9)t(9;3), 
der( 12)t(9;3;21; 12),der( 12)t( 12;21) (FigV: 10a).
Sequential FISH with wcp2 and 12, showed the q arm of the marker chromosome to
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contain material from both chromosomes (Fig V: 10b), Attempts to re-hybridise this 
metaphase to wcp3 and 6 failed.
Case 12:
Karyotype by CA: 46,XX,ins(l ;?)(q21 ;?),del(6)(ql4)/47,idem,+mar
Karyotype after FISH: 46,XX,ins(l;?)(q21;?),del(6)(ql4)/
47,add(l),del(6)(q),der(?)ins(?;6)
Sequential FISH was incomplete; abnormalities o f chromosomes 2 and 6 in 
association with a marker chromosome were identified by cytogenetic analysis. 
Metaphase FISH with wcpl and wcp6 showed add(l) and confirmed del(6). The 
marker chromosome appeared to have an insertion of material from chromosome 6 
into the q arm; further hybridization to identify the origins of this marker was 
unsuccessful (Fig V: 11).
Case 13:
Karyotype by CA: 46,XY,deI(13)(ql2ql4)
Karyotype after FISH: 46,XY,der(9)?ins(9;22)(q34;qllqll),del(13)(q?),
ins(14;13)(q?;q?),del(22)(q?)
The only abnormality detected by cytogenetic analysis was a deleted chromosome 
13. Interphase FISH showed a BCR/ABL fusion, and metaphase FISH with 
BCR/ABL locus specific probe and chromosome 9 alpha satellite centromeric probe 
showed the fusion signal to be located on the long arm o f chromosome 9 (Fig III: 2). 
Additional testing with wcpl3 and 14 revealed a der(14)ins(14;13) in addition to the 
del(13)(q) (Fig V: 12).
M-FISH confirmed these abnormalities.
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Case 14:
Karyotype by CA: Fail
Karyotype after FISH: 45,XY,der(3)t(3;7),-7,t(9;22)(q34;qll)/64,idem,+X,
+l,+2,+3,der(3)t(3;7),+der(3)t(3;7),+4,+5,+7,+8,+9,
+10,+ll,+15,+16,+17,+18,+19,+21,+der(22)t(9;22)
This case failed cytogenetic analysis. Hyperdiploidy was detected by interphase 
FISH. The chromosomal gains were associated with apparent monosomy 7. Wcps 
showed the presence o f four signals for chromosome 7 in interphase nuclei and one 
metaphase. Sequential FISH on three metaphases with 3-6 hybridisation rounds per 
metaphase was used to further define the karyotype. Due to the paucity o f 
metaphases, the initial step in the identification o f partner chromosomes was to use 
wcp applied to interphase nuclei (as described in section V:3:3). The metaphases 
were analysed using BCR/ABL probe and whole chromosome paint for 
chromosomes 1, 3, 4, 5, 7, 8, 9, 11, 14 and 22. By combining the interphase FISH 
results with those o f the metaphase wcp the karyotype was defined as: 
45,XY,der(3)t(3;7),-7,t(9;22)(q34;qll)/64,idem,+X,+l,+2,+3,der(3)t(3;7),
+der(3)t(3 ;7),+4,+5 ,+7,+8,+9,+l 0,+11,+15,+16,+17,+18,+19,+21 ,+der(22)t(9;22). 
(Fig V: 13)
Case 15:
Karyotype by CA: Fail
Karyotype after FISH: 54,+der(X)(X;13)x2,+4,+6,+der(?)t(?;6), +8,+10,
+der(13)t(6;13),+17,+18,+der(?)t(?;6)(?;?)
A hyperdiploid clone with gains o f chromosomes X, 4, 8, 10, 17, 18, 21 and
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apparent monosomies for 6 and 13 were detected by interphase FISH.
Sequential FISH experiments on two metaphases and a number o f interphase cells 
using whole chromosome paints for chromosomes X, 1, 4, 6, 9, 11 and 13 was 
carried out (Fig V: 14a) and revealed two der(X)t(X;13) chromosomes,
der(13)t(6;13), and one derived chromosome containing chromosome 6 material 
defining the karyotype as: 54,+der(X)(X;13)x2,+4,+6,+der(?)t(?;6),+8,+10,
+der( 13)t(6; 13),+17,+18 (Fig V: 14b).
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V: 5 Discussion
A combination o f interphase and metaphase FISH in a serial manner was carried out 
in 15 cases with incompletely characterised karyotypes, in an attempt to fully 
identify marker or unidentified chromosomes. The group was heterogeneous in 
terms o f karyotype complexity. Despite the fact that analysis was dictated by the 
availability o f material for further studies, a number of common features were found. 
Sequential FISH revealed that in a high proportion o f the cases with suspected 
partial or total loss o f a chromosome, from cytogenetic analysis or FISH with 
centromeric probes, hidden and occasionally complex translocation were found. This 
confirms the known higher incidence o f structural rather than numerical 
chromosomal changes in ALL. A similar observation has been described in patients 
with dic(9;20) who present as monosomy 20 (Clark 2000). This observation is 
important when interpreting apparent monosomy detected by interphase FISH, in the 
absence of metaphase analysis.
These studies also showed a pattern of involvement of certain chromosomes in these 
complex translocations. Chromosomes 3, 5, 8 and 12 were involved in three cases 
each, and chromosomes 2, 7, 9, 13, 21 and 17 involved in two cases each. 
Abnormalities involving chromosomes 3 and 5 have not been commonly described 
in ALL (Chen 1992; Mitelman 1995; Mitelman 2004). Chromosome 5 abnormalities 
reported in ALL were usually in the form of deletions o f the long or short arm and 
inversion of the p arm del(5p), del(5q), and inv(5p). Monosomy 5 and del(5q) have 
been associated with a poor outcome in AML (Grimwade 1998). A translocation 
t(l ;5)(q23;q33) has been previously reported in three cases o f ALL, all three patients
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showed chemotherapy resistant disease and short survival, (Barriga 1996). 
Abnormalities o f chromosome 8 are often seen in AML (Grimwade 1998). In ALL 
trisomy 8 has been associated with poor outcome (Wetzler 1999).
Chromosome 12 abnormalities in ALL frequently involve 12pl 1-13 in balanced 
translocations and deletions (Mitelman 1995; Mitelman 2004). The well known 
t( 12;21 )(p 13:q22) in childhood ALL and dic(9;12)(pl3:pl 1), including other 
abnormalities of (12p), are associated with a more favourable outcome in ALL 
(Behrendt 1995; Harbott 1997; Seeker-Walker 1997).
The effect of highly complex karyotypic abnormalities on outcome in ALL remains 
unclear and is likely to depend on the primary chromosomal changes. In this small 
series, five o f the 15 cases had evidence of hidden abnormalities, associated with a 
poor prognosis, four had BCR/ABL fusion and one had an MLL rearrangement. 
However half the patients with complex chromosomal abnormalities without 
BCR/ABL fusion or MLL rearrangement had disease relapse within one year o f 
presentation.
The availability of revolutionary new multicolour FISH techniques including M- 
FISH, makes it possible to investigate all 24 chromosomes (22 autosomes, X and Y) 
in a single hybridisation. However the success o f M-FISH is dependent on the 
number and quality of abnormal metaphases. The complexity o f the probe mixture, 
including 24 chromosome paints, puts enormous dependence on computer software 
to identify the origin of chromosomal segments. Well spread chromosomes with 
minimum overlaping is essential to prevent interaction between pseudocolours. In 
our small series, four cases were tested by both M-FISH and sequential FISH. The
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findings were identical in one case with abnormalities o f only three chromosomes. 
In two cases with more than four chromosomes involved in complex translocations, 
there was less correlation between the two approaches. The sequential approach was 
more accurate as it was certain which chromosome wcp had been applied. M-FISH 
showed interference between signals in poor quality metaphases in these cases.
Each technique has its limitations. In cases with adequate metaphases, M-FISH 
allowed complete clarification of karyotypes with more than three chromosomes 
involved in abnormalities, while sequential FISH became technically more difficult 
with successive hybridisations. However, the application o f sequential FISH 
provided greater information on a larger number o f translocations and identified 
derived chromosomes with greater accuracy.
In five cases with simpler karyoytpes and two cases with failed cytogenetics due to 
very poor quality metaphases, sequential FISH provided detailed information from a 
small number of metaphases, which had already been utilized in interphase 
screening tests. M-FISH was not applicable to these cases.
In ALL where metaphase quality and quantity may preclude adequate M-FISH 
analysis, we have shown that sequential FISH with locus specific, alpha satellite and 
whole chromosome paints applied to interphase cells and to limited numbers of poor 
quality metaphases, can be highly informative in the characterization of complex 
karyotypes.
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Further analysis o f karyotypes using this highly sensitive sequential interphase and 
metaphase FISH approach will assist in determining the significance of karyotype 
complexity in ALL.
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Table V .l M arker chrom osom es identified by FISH
Interphase FISH
101 46,XY,del(7)(p 1 ?5),
t(8;22)(q 1 ? 1 ;q 13),-21 ,+mar
56 46,XY,-17,+mar[3]/47,X Y,-17,
+marl+mar2[5]/46,XY[3]
88 45,XY,-7,t(9;22)(q34;q 11),
-10,+mar[9]
91 46,XY,t(2;9;22)(pl ?2;q34;q 11),
-5,del(l lql4),+mar[l 5]/46,XY[3]
82 47,XY,add(8)(p 1 ?),?add(9)(p?),
del(9)(p?),add( 12)(p?),+21 [ 13]/ 
46.idem,-Y[l 1]/46,XY[3]
107 46,XX,add(2)(q3?7),-8,
add(9)(p2),+mar[20]
BCR/ABL 
F ABL 
N
N
N
N
MLL ETV6/AMLJ 
F AML1 
2 N 4
2 N
2 N
2 N
N
169 46,XY,der(7)(q21 )[3]/
46,idem,del(19)(pl lpl3)[15] 
46,XY[2]
86 47,XY,del(3)(q22),del(6)(q 13),-J
t( 11; 18)(q 13 ;q23),+mar 1 ,+mar2
N
N
3 N
2 N
164 46,XX,add(2)(p?),add(3)(p?),
-5,-6,add(7)(q?),i(9)(q 10),-13, 
add(14),der(14;17), 
+marl,+mar2,+mar3,+mar4
N 3 2 N
(50%)
Centromere
Metaphase FISH NCI
46,XY,del(7)(p 1 ?5),t(8;22)(q 1 ? 1 ;q 13), 
dup(21)(q?)
D17Zx4 46 XY,r(17) /
47,XY,r(17),+r(17)
45,XY,-7,t(9;22)(q34;ql 1), 
del(10)(q?)
46,XY,t(2;9;22)(pl?2;q34;ql 1), 
del(5)(q?),del(ll)(q21q23)
47,XY,del(8)(pl ?),?add(9)(p?), 
del(9)(p?),t(12;21)(pl3;q22),+21/
46,idem,-Y
46,XX,der(2)t(2;8)(q ?;?), 
del(8)(q?),
der(9)del(9)(p?)t(2;9)(q?;?)
46,XY,der(7)t(4;7)(p?;q?)/
46,XY,der(7)t(4;7)(p?;q?),
t(ll;19)(q23;pl3)
D8Zlx2 47,XY,+3,del(3)(q22),del(6)(ql3), 
der(8)t(8;3;8;19)(?;?;?;?),
t( 11; 14)(q 13 ;q32)
46,XX,add(2)(p?),del(3)(p?), 
der(5)ins(5;3)(?;??),der(5)t(?;5)( ?;?),del( 
6)(q?),add(7)(?q), 
i(9)(ql0),der(13)t(2;13)(?;?), 
der(17)t(14;17)(?;?)
4-5
EFS 22+ 
No CR 
BMR 15 
DICR 11 
EFS 27+
EFS 20+
Uk
EFS 26+
Uk
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10 33 46,XX,der(5)t( 1 ;5)(q23;q35[7])/ N
45,XX,-2,add(4)(p?),-5,-8,-11, 
add( 12)(p 1 ),del( 12)(p 1 p 1),
+marl ,+mar2,+mar3 ,+mar4[4]/46,X 
X[8]
11 100 45,X,-X,add(3)(q 12),del(6)(q? 16), N
add(9)(q),add( 12)(pl 1)[ 18]/45,idem, 
del(6)(q? 16),der(6)del(6)(q? 16) 
rdup(6)(pter-q 12)[2]
N 46,XX,der(5)t(l;5)(q23;q35)/
45,XX,der(5)t(l;5),der(2)t(2;5)(?;?),der(2
)t(12;?;5;2)(?;?;?;?),
der(4)ins(4;5)(?;??),-5,
der(8)t(8; 12),+l 2,der(l 2)t(5; 12)(?; ?)
45,X,-X,der(3)t(3;21)(ql?q22),r(6), 
der(9)t(9;3)(q2?q 1 ?), 
der(12)t(9;3;21;12)(ql ?;q2 ?pl3), 
t(12;21)(pl3;q22)
12 119 46,XX,ins( 1 ;?)(q21;?)
,del(6)(ql4)[3]/
47,idem+mar[4]
13 144 46,XY,del( 13)(q 12q 14)[20]
14 171 Fail
N
15 174 Fail N 2
N 46,XX,ins(l;?)q21;??),del(6)(ql4)
47,idem,der(?)ins(?;6)(?;??)
N 46,XY,
der(9)ins(9;22)(q34;ql lq l 1), 
ins(14;13)(q?;q?)
N 3(11%) HeH 45,XY,der(3)t(3;7)(?;?),-7,
4(32%) Multiprobe-I t(9;22)(q34;qll)/
64,idem,+X,+1 ,+2,+3, 
der(3)t(3;7),+der(3)t(3;7),
+4,+5,+7,+8,+9,+10,
+11,+15,+16,+17,+18,+19,
+21 ,+der(22)t(9;22)
N 4(72%) HeH 54,+der(X)(X;13)(?;?)x2,+4,+6,+8,
Multiprobe-I +10,+der(l 3)t(6; 13),+17,+18,
___________________________ +der(?)t(?;6)(?;?)_______________
F: fusion signal
NCI: No o f chromosomes involved 
CR: complete remission
ABL: copy no o f ABL MLL : copy no o f MLL
HeH: high hyperdiploidy (51-65 chromosomes)
BMR: bone marrow relapse DICR: died in CR
AML1: copy no o iA M L l
EFS: event free survival (presentation to relapse/death/last visit) 
Uk: unknown
BMR 11
BMR 11
BMR 7
BMR 6
Uk
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17 centromere probe
Fig V:1 derived chromosome 17 marker
(case 1 table V:1 UIN:56)
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V:2 Monosomy 7, and del(10)(q) in Ph positive ALL
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+ del(8)
▲ der(12)t(12;21)
A der(21)t(12:21)
A Normal chromosome 8
W CP 8 WCP 12 WCP 21
Fig V:4 t(12;21) and del(8)
(case 5 table V:1 UIN:82) 172
der(2)t(2;8) 
▲ del(8)
A  der(9)t(2;9)
W CP 8 W CP 9
Fig V:5 Three markers
(case 7 table V:1 UIN:107) 173
9 ,
*
«
%
f t
A der(7)t(4;7)
A der(ll)t(ll;19) 
* der(19)t(ll:19)
WCP 4 WCP7 W C P11 W C P 19
Fig V:6 Hidden t(ll;19) and der(4)t(4;7)
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Fig V:7 Complex marker derived from chromosomes 3, 8 and 19
(case 8 table V:1 UIN:86)
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Fig V:9 Five markers detected by sequential FISH
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Fig V:10b Variant t(12;21) M-FISH
(case 11 table V : 1 UIN:100)
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Fig V:14a Sequential Interphase FISH after failed cytogenetics
(case 15 table V:1 UIN:174)
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Fig V:14b Sequential Interphase FISH after failed cytogenetics
(case 15 table V:1 UIN:174)
Chapter VI 
Interphase FISH screening is useful in risk 
assessment for adult patients with ALL
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VI: 1 Abstract
Multiplex interphase FISH for MLL gene rearrangements, BCR/ABL and 
ETV6/AML1 fusions in addition to interphase FISH tests for hidden numerical 
chromosomal changes, was carried out on a series o f adult patients with ALL. 
Complete follow up information was available for 159 patients, in whom the impact 
of cytogenetic abnormalities including additional information from FISH studies 
could be assessed in relation to outcome.
Twenty cases (12.4%) with t(9;22)(ql l;q34) , six cases (3.7%) with translocations 
involving MLL, seven cases (4.4%) with t( 12 ;21 )(p 13:q22), nine cases (5.6%) with 
other ETV6 rearrangements and seven cases with hidden numerical chromosomal 
abnormalities were detected by FISH.
The detection o f these abnormalities by cytogenetic studies and / or FISH ensured all 
patients were accurately identified and allowed prognostic classification of patients. 
Patients with t(9;22), MLL or ETV6 rearrangements showed a poor prognosis when 
compared with patients with normal karyotypes. The only group with a good 
outcome detected in this study was high hyperdiploidy, in which no high-risk 
structural abnormalities were detected.
Using a simple combination o f cytogenetics, FISH results, and presentation white 
cell counts we identified three prognostic groups differing in EFS and OS.
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VI: 2 Introduction
ALL may be viewed as a spectrum of diseases, ranging from chemotherapy sensitive 
disease in which patients have long-term survival, to extremely resistant disease 
associated with short survival times.
With the use of intensive chemotherapy, it has become possible to identify several 
factors influencing treatment outcomes, including sex, age, immunophenotype, 
WBC count, response to induction treatment, cytogenetics at presentation and the 
detection of minimal residual disease at various points during treatment (Hoelzer 
1988; Boucheix 1994; GFCH 1996; Seeker-Walker 1997; Mortuza 2002). Another 
factor that may influence outcome is the use of high dose treatment with 
transplantation as consolidation chemotherapy, a question that is being addressed by 
the current MRC U.K. adult ALL treatment trial (UKALL XII). It is hoped that in 
the future our ability to distinguish risk groups at presentation will allow a more 
individualised approach to patient treatment.
Both numerical and structural chromosomal abnormalities are commonly detected in 
leukaemic blasts; and their presence allows the identification o f groups with 
significantly different outcomes. In the previous adult ALL trial UKALLXa, from a 
review of 350 patients, 232 patients had abnormal clones. Using a hierarchical 
method for classification significantly poorer outcomes were seen in patients with 
t(9;22), t(4;l 1) or other 1 lq  abnormalities, and hypodiploidy (<46 chromosomes). A 
somewhat better outcome was noted in patients with 12p abnormalities or 
hyperdiploidy (50-60 chromosomes) (Secker-Walker 1997). Similar results were 
seen in a French study o f 443 adult ALL patients (GFCH 1996) confirming the poor
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outcome associated with t(9;22) and 11 q23 abnormalities. An additional group of 
patients with hypodiploidy (30-39 chromosomes) and associated triploidy, were 
identified as poor risk, while an improved outcome was seen in patients with near 
tetraploidy in addition to those with high hyperdiploidy. More recently, CALGB 
have published the findings from cytogenetic analysis o f 256 patients who were 
diagnosed since 1984. The high risk o f trisomy 8 and monosomy 7 were described 
as well as the possible good outcome seen in association with 12p abnormalities 
(Wetzler 1999); This is the only study presenting long term follow up o f patients, 
over 10 years in some cases.
Due to the low incidence of many o f the described chromosomal changes, firm 
conclusions on their influence on prognosis are difficult to reach. For example, the 
good outcomes observed in patients with 12p abnormalities from the UKALLXa 
study represented only 13/350 patients, similarly the good outcome associated with 
near tetraploidy was based on 9/443 patients. The poor outcome described in 
association with trisomy 8 and monosomy 7 was found in 23/256 and 14/256 
patients respectively, only 11 and 5 of whom were Ph negative.
It is important in the design of risk-adapted treatment protocols in ALL that 
adequate cytogenetic information is available for all patients. However, due to 
difficulties o f cytogenetic analysis in ALL; up to 25% o f cases fail in large multi­
centre series (Seeker-Walker 1997; Wetzler 1999) a proportion of the chromosomal 
abnormalities may be cytogenetically undetectable (as they are present in a non­
dividing population of cells or produce only subtle chromosomal change) molecular 
methods are increasingly being used to complement conventional cytogenetics
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(Devaraj 1995; Scurto 1998).
The application of FISH allows chromosomal abnormalities to be identified in 
interphase and metaphase cells on a cell-by-cell basis. Using locus specific probes 
for gene rearrangements and chromosome specific alpha satellite centromeric probes 
(Romana 1993; Kasprzyk and Seeker-Walker 1997) it is possible to rapidly assess 
large numbers of cells and identify patients with gene rearrangements or alteration in 
chromosome number, even in the absence o f adequate metaphases for complete 
karyotypic analysis. Unlike RT-PCR with specific primers, the use o f multiplex 
FISH will also detect: abnormalities arising from alternative breakpoints within the 
BCR and ABL or ETV6 and AML1 loci; other abnormalities involving these genes; 
and cases of hidden aneuploidy. With the availability o f commercial FISH probes, it 
has become possible to undertake screening for the chromosomal abnormalities of 
prognostic significance which have influence on the predicted outcome in patients 
with ALL (Ritterbach 1998; Avet-Loiseau 1999).
This study evaluates interphase FISH for the detection o f BCR/ABL, ETV6/AML1 
and MLL rearrangements, as well as aneuploidy and the impact of these 
abnormalities on outcome in adult ALL.
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VI: 3 Materials and methods
VI: 3: 1 Patients
Diagnostic bone marrow (148 samples) and peripheral blood (11 samples) were 
available from 159 adults with ALL presenting between February 1993 and April 
2000. Patient details are given in Chapter II. All patients were entered to the current 
UK Medical Research Council adult ALL treatment trial (UKALLXII). The criteria 
for entry are age > 15 years; newly diagnosed ALL; excluding mature B-cell ALL. 
The trial was designed to evaluate the efficacy o f bone marrow transplantation or 
peripheral blood stem cell transplantation in the treatment o f adult ALL. Patients 
with matched related donors receive an allogeneic transplant, while those without 
donors are randomly assigned to receive chemotherapy or an autologous transplant. 
In patients randomly allocated to receive chemotherapy, conventional maintenance 
therapy is given for 2 years. They also receive 24 Gy cranial irradiation. In a 
modification to the initial protocol, the trial is now assessing the effect o f ABL 
tyrosine kinase inhibitor ST1 571 (Imatinib) on maintaining remission after 
chemotherapy as well as after any transplant procedure for patients with Ph positive 
ALL. Following allogeneic or autologous transplants patients receive no 
maintenance therapy, except Imatinib for Ph positive patients.
Although the trial continues to recruit, data up to May 2000 have been published 
(Durrant 2000). Patient data are shown in (Table VI. 1).
Clinical details, treatment and outcome data were available for 159 patients within 
the UKALL XII trial and form the basis o f this study. O f these patients 55 had 
undergone a transplant procedure in first complete remission. In 39 patients this was
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allogeneic, while in 12 patients it was autologous. There were three matched 
unrelated donor (MUD) and one syngeneic transplant. A further five allogeneic 
transplants, five MUD and one autologous transplant were undertaken at relapse.
For FISH studies nine bone marrow samples were selected as controls from adult 
patients with normal karyotypes and non-malignant hematological disease, as 
previously described in Chapter II.I.
VI: 3: 2 Probes for FISH
Details o f all probes used are presented in Chapter 11:4:1).
Specific probes:
Commercial probes for BCRJABL, MLL and ETV6L/AML1 were used in interphase 
FISH studies.
Centromere specific probes:
Multiprobe®-I (Cytocell) or single indirectly labelled alpha satellite probes (Oncor) 
were used for chromosome number assessment.
VI: 3: 3 Methods o f  analysis
Details of cytogenetic analysis, immunophenotyping and equipment used for FISH 
analysis are presented in Chapter III: 2: 3.
FISH:
All probes were hybridized according to manufacturers’ instructions, as detailed in 
Chapter 11:5.
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Interphase FISH
All cases were tested by interphase FISH for BCR/ABL, MLL and ETV6/AML1.
Cases with failed or normal cytogenetics results were also studied by the 
Multiprobe-I system for chromosome enumeration.
Statistical analysis:
Statistical analysis was undertaken using SPSS software.
Differences between chromosomal subgroups in terms o f age and white blood count 
were tested by the chi-squared test.
Two end points were studied, the time to death from any cause (overall survival) and 
the time to relapse or death in remission (event free survival). Univariate analysis of 
several possible confounders on these end points were then examined using the 
Kaplan Meier and Log rank test. Confounders with significant influence were then 
entered in a multivariate cox regression model.
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VI: 4 Results
Cytogenetic and FISH results
Samples from 159 patients were tested; an abnormal clone was detected in 100 
cases, only normal metaphases were found in 34 cases. In the remaining 25 cases, 
conventional cytogenetics failed to produce a result. Interphase FISH screening for 
BCR/ABL, MLL, ETV6/AML1 abnormalities was successful in all 159 patients. In 17 
of those with a failed cytogenetic result screening for aneuploidy was also 
successful.
Hierarchical classification
The features of patients according to cytogenetic group, including those with 
established structural abnormalities (45 patients) or numerical abnormalities (38 
patients) are shown in (Table VI:2).
Structural Abnormalities:
The subgroup of patients with Ph chromosome was the largest, having 20 cases 
(12.4%), three of which were only detected by FISH. Additional chromosomal 
abnormalities were seen in 13 cases, including a complex Ph translocation (2 cases), 
an additional Ph (2 cases), monosomy 7 (4 cases), or chromosomal gains resulting in 
low or high hyperdiploidy (one case each). Ph positive patients tended to be older 
(mean age 36y compared to 28y for the group as a whole) (p=0.05), but did not have 
higher WBC’s (mean 17.4 compared to 9.7 for the group as a whole) (p=0.72), 
although the majority were o f the pre-B/C-ALL immunophenotype the difference 
was not statistically significant.
Six patients had 1 lq23 abnormalities, including five with t(4; 11) one with t(l 1; 19).
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Additional chromosomal abnormalities were present in four cases; high 
hyperdiploidy in two and i(7)(ql0) in one. Patients with 11 q23 abnormalities were 
more likely to have WBC > 100x109/l (p=0.0001), and five of the six had a pre-B 
immunophenotype.
Seven patients had the cryptic t(12;21) detected by FISH, in four cases cytogenetics 
had failed and in the remaining three cases 12p abnormalities were found by 
conventional cytogenetics, with deletion 12p in one and additional material on 12p 
in two cases. The patients ranged in age from 15-50 years, all seven expressed the c- 
ALL phenotype.
Twelve patients showed 12p abnormalities without evidence of the ETV6/AML 
rearrangement. Abnormalities were detected by conventional cytogenetics in eight of 
these, deletions of 12p were present in three cases, translocations involving 12p were 
found in four cases, two of which showed the dicentric, dic(9; 12)(p 11 ;p 11). In one 
case additional material was present on 12p. In a further four cases the presence of 
the abnormal 12p was only detected by FISH as loss of one (three cases) or both 
(one case) copies o f ETV6, without cytogenetically visible deletions of chromosome 
arm, 12p. Patients with 12p abnormalities were younger (/?=0.01).
Numerical abnormalities:
Nine patients were classified as hypodiploid, in which cytogenetics showed 45 
chromosomes in seven cases and 38 chromosomes in one previously published case 
(Harrison 2004). Although cytogenetic analysis showed only 15 normal metaphases 
in one patient Multiprobe-I revealed an isolated monosomy 21 (case B table IV: 1). 
In all but one case there were associated structural abnormalities, all but one
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expressed the c-ALL phenotype.
Low hyperdiploidy, with chromosome counts o f 47-49 was found in 15 patients, 
seven having 47 chromosomes by cytogenetic analysis. Three patients with failed 
cytogenetic results were shown by Multiprobe-I to have low hyperdiploidy, with 
isolated trisomy 21 in two cases (cases E and F, table IV: 1) and trisomy 8 in the 
third (case C, table IV: 1). Isolated trisomy 8 was found by Multiprobe-I in a further 
case with normal cytogenetics (case D, table IV: 1). Additional structural 
abnormalities were present in seven cases. There was no association with age group, 
immunophenotype, or WBC.
Fourteen patients showed high hyperdiploidy, ten were younger than 20 years, all 
had WBC <20x109/l and in ten, blasts expressed a c-ALL phenotype.
A total of 42 patients were classified as normal (defined as normal karyotype, or 
failed conventional cytogenetics, and negative FISH for gene rearrangements and 
where possible for chromosomal abnormalities); 31 had normal cytogenetic results, 
eleven had failed cytogenetic results. Multiprobe-I testing was negative in seven of 
those with failed cytogenetics and 20 o f those with normal karyotypes. These 
patients with normal results accounted for 46% of patients with T-ALL 
immunophenotype.
In view of the description of trisomy 8 as an isolated high risk factor (Wetzler 1999), 
patients with trisomy eight were examined separately. Among eleven patients with 
trisomy 8 it was the sole chromosomal abnormality in two cases, associated with low 
(three cases) or high (five cases) hyperdiplody in eight cases. In two cases with 
normal and one with failed cytogenetics, trisomy 8 was detected by FISH screening
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with Multiprobe-I. It was the sole abnormality in two cases and associated with high 
hyperdiploidy in one. In six cases the numerical abnormalities were associated with 
structural abnormalities, half o f which were undefined marker chromosomes. 
Patients with trisomy 8 had WBC ranging from 2-20 x l0 9/l.
Influence o f cytogenetic /  FISH defined hierarchical classification on outcome:
The mean event-free survival for the 159 patients on UKALLLXII was 3.5 years 
(95% Cl 2.9-4). Overall disease-free survival at three years was 45.6% and at five 
years was 33.5%.
Patient groups with structural or numerical chromosomal abnormalities were 
compared with the group of patients with normal cytogenetics and FISH results. 
Survival curves are shown in figures VI: 1 and VI :2. The Ph positive patients showed 
unfavourable outcomes when compared to patients classified as normal (p=0.03 for 
EFS, and /?=0.01 for OS). The patients with 1 lq23 abnormalities were difficult to 
assess due to small numbers.
O f interest, we found that in contrast to some previous studies, patients with 12p 
abnormalities showed a tendency to shorter event free survival (£>=0.05). This result 
persisted when the seven patients with t(12;21) were added in the analysis (p=0.08). 
Despite the small numbers, the nine patients with FISH evidence of ETV6 deletion 
showed statistically significant shortened event free survival (£7=0.01).
Patients with hypodiploidy or low hyperdiploidy showed no significant difference in 
survival from the group as a whole.
Patients with high hyperdiploidy showed a trend for improved survival comparable
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to that seen in the normal group
Patients with trisomy 8 had EFS and OS similar to those of the patient group as a 
whole, but shorter than the normal group.
Prognostic groups by combination o f cytogenetics, FISH and WBC
Previously described factors with an impact on OS or EFS which influence death or 
freedom from relapse; in childhood and / or adult ALL were studied among our 
patient series, these included:
Male sex, WBC above 100xl09/l,
B-lineage immunophenotype,
Slow early responders (time to complete remission o f more than 28 days) 
Cytogenetic and / or FISH evidence o f the presence of the unfavourable 
abnormalities: t(9;22), llq23  abnormalities, trisomy for chromosome 8,
hypodiploidy, or the favourable markers: including normal cytogenetics, high 
hyperdiploidy, 12p abnormalities, t(12;21).
The effect o f treatment received (i.e. the use o f chemotherapy versus transplant 
procedure of any type in first remission) was also studied.
Tables VI :2 and VI :3 show results o f univariate analyses o f the above factors on end 
points studied. Variables adversely influencing outcome were found to be: age over 
42 years, WBC over 100xl09/l, cytogenetic / FISH finding o f t(9;22), MLL 
rearrangement, or ETV6 abnormalities. On the other hand, patients with normal 
cytogenetics / FISH or high hyperdiploidy showed improved outcome. Using a 
combination o f cytogenetic findings, FISH and WBC it was possible to define three
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distinct risk groups, allowing better definition o f those groups with better outcome. 
Survial curves are shown in figures VI :3 and VI :4.
High Risk group (n=35): Patients with t(9;22), MLL gene rearrangements, and ETV6 
abnormalities (excluding those with t(12;21)
Low risk group (n=52): Patients with high hyperdiploidy, normal cytogenetics / 
FISH; WBC<100x109/1.
Intermediate risk group (n=72): Patients not classified into the other two groups.
The identification of these groups has led to a clear separation in the Kaplan Meier 
survival curves.
There is more than five fold difference in survival for the low risk compared to the 
high-risk group (Median survival and event free survival o f 60 & 61 months 
compared to 11 & 13 months respectively, /?=003 & p=006).
Multivariate analysis: For EFS, analysis of 159 cases identified age o f >42 years as 
the most significant factor relating to poor outcome (p=0.01), after adjusting for age, 
the risk grouping system remained a significant factor (p=0.02), patient sex, disease 
immunophenotype, time to achieve complete remission and treatment protocol were 
not related to outcome.
For OS, analysis of 159 cases identified age o f >42 years as the most significant 
factor related to poor outcome (p=0.003), after adjusting for age the risk grouping 
system remained a significant factor (p=0.013). Patient sex, disease 
immunophenotype, time to achieve remission and treatment protocol were not 
related to outcome.
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VI: 5 Discussion
Over the decades a number of factors related to presenting features have been 
described in adult ALL that influence treatment outcome and survival. 
Immunophenotype, total WBC and time to achieve complete remission have all been 
found to affect prognosis. The strongest predictor of outcome however remains the 
presence of distinct chromosomal abnormalities at presentation.
A number of these factors are currently incorporated into treatment algorithms in 
childhood ALL, with more intensive therapy reserved for patients with high WBC, 
high risk cytogenetic features or failure to rapidly clear bone marrow o f blast 
infiltration. The uniformly poor outcome in adults with ALL has thus far limited 
such an approach for this patient group.
The patients presented in this study are being treated within the ongoing UKALLXII 
trial; follow up time is variable in the majority o f these patients, ranging from 1-8 
years. Based on karyotypic information for 134 patients with follow up details, (Fig 
VI: 1&2) it was apparent that Ph positive patients continue to do poorly with event 
free survival rates of <20%, compared to 57% at three years in patients with normal 
karyotypes. However, the previously described improved outcome for patients with 
t(12;21) was not apparent in this group, with event free survival rates o f <20% at 3 
years. Similarly trisomy 8 did not appear to associate with poorer outcome (43% 
EFS at 3 years). A new finding in this study was the poor outcome found in the 
subgroup with ETV6 deletions and 12p abnormalities, this is contrary to previous 
studies of childhood ALL (Rubnitz 1997). Patients with high hyperdiploidy and no 
high-risk structural abnormalities were the only group to do better than those with
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normal cytogenetics, with survival rates exceeding 60% at 3 years.
It was clear from this study of 159 patients that the application o f interphase FISH 
testing carried out as a routine screening approach was effective in the accurate 
detection of poor prognosis patients. This was demonstrated by the identification of 
three patients with hidden BCRJABL, and nine patients with ETV6 abnormalities. 
However it was equally effective in the detection o f eight patient with good outcome 
identified from negative FISH results, despite failed cytogenetics.
In addition to the direct effect of chromosome abnormalities detected by 
conventional cytogenetics or FISH, we have shown that by using a simple ranking 
system dependent on cytogenetics / FISH and total WBC at presentation, it is 
possible to identify three subgroups with significantly different event-free and 
overall survival. The results were based on relatively small numbers, thus this risk 
grouping needs to be confirmed by application to large patient groups. It appears to 
hold promise due to its simplicity and the strength of its influence on outcome, 
exceeding that of individual factors, including time to remission. It may assist in 
treatment option decisions, particularly for the group o f patients identified as low 
risk.
Cytogenetic analysis is routinely undertaken on all cases o f ALL as a requirement 
for patients entered into clinical treatment trials. In both children and adults the 
cytogenetic results influence treatment choices, especially induction chemotherapy, 
and in adults, the option of allogeneic bone marrow or stem cell transplantation.
With the recent advances in modes of treatment targeting clone specific products, 
such as the ABL tyrosine kinase inhibitors ST1 571 (Imatinib) (Goldman 2000;
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Ottmann and Hoelzer 2002; Wassmann 2002; Wassmann 2003), which has been 
used for the treatment of Ph positive ALL patients in UKALLXII since June 2002, it 
has become essential that every effort be made to provide complete cytogenetic 
information for all adults presenting with ALL.
The proven superior sensitivity o f FISH confirms that this approach is the best 
technique to use as an adjunct to conventional cytogenetics to rapidly and accurately 
identify patients with high and low-risk abnormalities at the time of diagnosis. FISH 
provides speed and reliability in the detection not only o f gene rearrangements, but 
also aneuploidy. Screening for BCR/ABL fusion was successful in 176/180 (99%) of 
samples tested in our laboratory. The success rates for MLL and ETV6/AML1 were 
99% and 97% respectively. The use o f directly cultured bone marrow for the 
preparation of interphase nuclei or cytospin preparations (Horton 2000) means that 
FISH results can be available within 24 hours. The systematic use of FISH, as a 
screening tool for t(9;22)(q34;ql 1), t( 12;21 )(p 13q22), MLL rearrangements and high 
hyperdiploidy in all adult patients with ALL, not only provides more accurate 
information on the incidences of these abnormalities, but helps to make more precise 
assessment o f long term outcome in these patients.
In combination with cytogenetics and WBC, FISH screening may provide sufficient 
diagnostic information to allow the introduction of risk adjusted treatment strategies 
in adults similar to those already in place for children.
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Table VI: 1 D ata from  M R C  U K A L L  X II Trial
Data as of May 2000 MRC
Registered 707
Early deaths (<84 days) 56
Early relapse 8
No CR but alive 8
Treated < 13 weeks 19
Allogeneic BMT 206
MUDT 40
Eligible for randomization 370
Randomized 161
Elected ABT 21
Elected chemotherapy 108
Unknown 80
CR: Complete remission BMT: Bone marrow transplant
MUDT: Matched unrelated donot transplant 
ABT: Autologous bone marrow transplant
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Table V I:2 Clinical outcom e by cytogenetic groups
t(9;22) llq 2 3  t(12;21) Abn 12p +8* Ho (34-45) HeL (47-49) HeH (50-60) Norm
N % N % N % N % N % N % N % N % N %
Total 159 20 12.6 6 3.7 7 4.4 12 8 11 7 9 6 15 9 14 9 42 26
Sex
Male 95 11 12 4 4 5 5 7 7 5 5 6 6 9 9 10 11 25 26
Female 64 9 14 2 3 2 3 5 8 6 9 3 5 6 9 4 6 17 27
Age
15-19 38 0 0 1 3 3 8 0 0 6 16 2 5 5 13 10 26 7 18
20-29 45 8 18 1 2 2 4 8 18 1 2 1 2 3 7 0 0 13 29
30-39 27 3 11 2 7 0 0 0 0 1 4 1 4 2 7 1 4 10 37
40-49 36 8 22 1 3 1 3 3 8 1 3 4 11 4 11 1 3 9 25
50-55 13 1 8 1 8 1 8 1 8 2 15 1 8 1 8 2 15 3 23
WBC
<10 77 8 10 0 0 6 8 4 5 8 10 4 5 10 13 12 16 21 27
10-49 43 6 14 1 2 0 0 4 9 3 7 4 9 3 7 2 5 14 33
50-99 13 1 8 0 0 0 0 3 23 0 0 0 0 2 15 0 0 2 15
>100 26 4 15 5 19 1 4 1 4 0 0 1 4 0 0 0 0 5 19
Immno
C-ALL 73 10 14 0 0 7 10 3 4 7 10 8 11 7 10 10 14 17 23
Pre-B 33 3 9 5 15 0 0 5 15 3 9 0 0 2 6 2 6 10 3
Null 1 0 0 0 0 0 0 1 100
T-ALL 24 0 0 0 0 2 8 0 0 2 8 11 46
Mixed 1 0 0 0 0 1 100
Other 6 1 17 1 17 0 0 0 2 33 1 17
*EFS Med mo 26 13 6 28 12 24 27 26 45 58
+EFS 3Y (%) 46 0 30 NA 28 41 37 NA 53 57
♦EFSMed mo: Median event free survival in months +EFS 3 Y (%): (%)3-year event free survival
NA: follow up less than 3 years +8* these patients are also included in the HeL or HeH groups
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Table VI:3 Effects of risk factors on event free and overall survival
Event free survival Overall survival
Category No Med mo P RR (95% Cl) No Med mo P RR
Risk Group Low 52 60 0.003 0.6 (0.3-1.2) 52 61 0.006 0.6 (0.3-1.2)
Intermediate 72 26 1 71 36 1
High 35 11 1.7 (0.9-3.34) 35 13 2.0 (1.0-4.2)
Age <42 y 118 27 0.02 0.4 (0.2-0.8) 117 40 0.002 0.3 (0.2-0.7)
>42 y 41 15 1 41 15 1
Sex Male 95 24 0.42 1 95 34 0.66 1
Female 64 60 0.9 (0.6-1.8) 63 35 0.9 (0.5-1.7)
WBC <100 xl09/l 134 28 0.008 1 133 47 0.004 1
>100 x 109/l 25 9 0.5 (0.1-2.0) 25 13 0.5 (0.2-0.9)
Immuno B-type 106 24 0.06 1 106 34 0.27 1
T-type 24 51 0.6(1.6-2.9) 24 50 0.7 (0.2-2.8)
Time to CR <28 days 67 28 0.15 0.7 (0.4-1.3) 66 38 0.55 1.0 (0.5-1.7)
>28 days 63 20 1 63 34 1
Treatment BMT 55 44 0.83 1.6 (0.9-2.9) 52 48 0.64 1.0 (0.5-1.8)
Chemo 93 28 1 93 34 1
No: number Med mo :median in months BMT bone marrow transplant
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Chapter VII 
Conclusions
VII: 1 FISH improves cytogenetic success rate in adult 
ALL
FISH analysis for the BCR/ABL fusion was successful in 176 (99%) cases and 
detected a Ph translocation in 23 cases (13%) of which six cases were not detected 
by cytogenetic analysis, as described in Chapter III. This demonstrates that these 
patients would not have been identified if cytogenetics alone had been relied on.
In sixteen of 153 (6.5%) Ph negative patients, gains of BCR and/or ABL signals were 
identified, in a number of cases this finding led to the identification of hidden 
numerical chromosomal abnormalities. Overall FISH detected alterations invoving 
the BCR and or ABL genes in 22% of patients.
FISH with the MLL probe was successful in 174 cases, with an MLL rearrangement 
found in seven patients (4%). The MLL probe independently detected all cases o f 
t(4;l I)(q21;q23) seen by cytogenetic analysis, as well as the two cases with the 
cytogenetically subtle t(l 1; 19)(q23 ;p 13) one o f which had been described as 
add(19). Two cases were identified with MLL rearrangements, which had been 
reported as deletions of 1 lq23. Although FISH did not detect any 1 lq23 abnormality 
that had not been seen by cytogenetics, the involvement of MLL was confirmed in 
all cases. These observations confirm the advantages of FISH in identifying 
abnormalities of llq23  involving MLL, including translocations with all 
chromosomal partners, as well as MLL deletions. This may be significant in adults as 
the outcome in children with ALL with all MLL gene rearrangements is the same as 
that for patients with t(4;l 1).
Seven o f 162 (4.3%) cases tested were found to be positive for the ETV6/AML1
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fusion. This incidence in adults is much lower than that of 25% reported in 
childhood B-lineage ALL. A similar incidence was previously published from 
results of RT-PCR,(Aguiar 1996). Our series included one FISH positive case that 
was RT-PCR negative, suggesting that FISH provides a more accurate method of 
screening for this abnormality including detection of cases with variant breakpoints 
not seen in the routine RT-PCR process. Two of our positive cases were 45 and 50 
years old respectively, representing the oldest ETV6/AML1 fusion positive patients 
reported.
Outcome of adults with t(12;21) has not previously been reported. Our study, 
although only covering a short period of follow up suggested these were not 
dissimilar to overall poor outcome results for adults. Losses or gains o f ETV6 and/or 
AML1 signals were identified in 31 o f 155 (20%) negative patients. In total 
interphase FISH detected abnormalities involving the ETV6 and or AML1 genes in 
23.5% of cases.
FISH using the Multiprobe-I for aneuploidy was successful in 48 cases, including 28 
cases with a normal karyotype, and 20 with failed cytogenetics. A clone with a 
numerical chromosomal abnormality was detected in twelve (25%) cases.
High hyperdiploidy o f >50 chromosomes was found in five cases. The hyperdiploid 
clone was associated with apparent losses of chromosome 6 and 13 in one case and 
of chromosome 7 in another. Further studies using wcp helped to elucidate complex 
chromosomal abnormalities in both cases. Low hyperdiploidy of 47-50 
chromosomes was found in four cases, with isolated trisomy 21 and trisomy 8 in two 
cases each. A further two cases showed hypodiploidy of 45 chromosomes and one
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case showed near triploidy >70 chromosomes. The overall incidence of numerical 
chromosomal abnormalities detected in this study was 30.5%. One third o f these 
cases were only detected by the application of FISH.
Metaphase FISH, including sequential FISH, was utilised to complement 
cytogenetic analysis in the identification of marker chromosomes in 29 patients. 
Marker chromosomes were identified in 15 cases. The marker chromosome was 
simple in five cases and complex in 10 cases. Patients with highly complex 
karyotype had a shortened survival.
Overall the combination of FISH techniques in this study provided additional 
cytogenetic information in 36/176 (20%) cases. Alterations in karyotype were, as 
expected, seen in significantly more cases with a failed cytogenetic result 15/35 
(43%), than those with a successful cytogenetic analysis 21/141(15%). The changes 
altered prognostic expectation in 23 cases, five with a Philadelphia chromosome, 
one with t(ll;19 ) and nine with ETV6 abnormalities. In this study patients with 
ETV6 rearangements fared very poorly. O f equal importance was the finding of 
normal FISH results among a group of eight patients with failed cytogenetics and a 
good outcome.
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VII: 2 Results of FISH can distinguish groups with 
differing prognosis
The detection of chromosomal abnormalities by cytogenetic studies or by FISH 
allowed prognostic classification of patients. A poor prognosis was observed in 
patients with t(9;22), MLL or ETV6 rearrangements as compared to patients with a 
normal result from karyotype and FISH studies together. The EFS rate was <20%, 
compared to 57% in the normal cases. The previously described good outcome o f 
children with t(12;21) was not apparent in this group of adults with EFS of <20% at 
3 years. A poor outcome was seen in the subgroup with ETV6 deletions and 12p 
abnormalities, a finding contrary to previous studies in childhood ALL.
Patients with high hyperdiploidy without evidence of high-risk structural 
abnormalities continue to do well, with survival rates exceeding 60% at 3 years. 
Whereas patients with trisomy 8 do not appear to have a poorer outcome than those 
with normal karyotypes (43% EFS at 3 years), contrary to previous reports.
Using a combination of cytogenetics, FISH, and presentation white cell count we 
distinguished three distinct prognostic groups:
High Risk group
Unfavourable outcome comprised patients with t(9;22), MLL gene rearrangements, 
and ETV6 abnormalities. These patients fared poorly (p=0.003, and j9=0.006 for 
event free and overall survival, respectively)
Low risk group
Favourable outcome included patients with high hyperdiploidy, and those with a
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normal result from cytogenetics and FISH with presentation WBC<100xl09/l. 
Intermediate risk group
Patients without the poor outcome cytogenetics, or normal cytogenetics and FISH, 
but with high WBC showed an intermediate outcome. They fared less well than the 
favourable group (p=0.05, andp=0.02 for EFS and survival, respectively).
During the follow up period of the study compared to the low risk group, the 
probability of an event occurring in the high-risk group was increased almost 
threefold (2.933 1.4-6.1 95% Cl), for the intermediate risk group the probability was 
increased by a factor of 1.7 (0.87-3.22 95% Cl).
When compared to the low risk group the likelihood of death was increased by over 
threefold (3.53 1.51-8.2 95% Cl) in the high-risk group, with a doubling in the 
probability of death (2.3 1-4.75 95% Cl) in the intermediate risk group.
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VII: 3 FISH screening should be incorporated into the 
diagnostic workup for adults with ALL.
In the current and previous trials for the treatment of AML in the UK (AML 12 and 
AML 15), the role of cytogenetics was integral to the prognostic classification of 
patients at presentation and assisted in the choice of post remission induction 
chemotherapy. Patients within the good prognosis category being treated with high 
dose chemotherapy and stem cell / bone marrow transplantation only in second 
remission.
The results from this study suggest that a similar approach could be taken for adults 
with ALL. Using the simple combination of presentation WBC, cytogenetic and 
FISH results, a subgroup of low risk patients with considerably better overall 
outcomes was identified. For this subgroup treatment strategies that do not include 
high dose therapy in first remission should be considered. For this approach to be 
implemented, FISH screening for the structural abnormalities involving BCR/ABL, 
MLL, ETV6/AML1 and screening for high hyperdiploidy must be incorporated to the 
disgnostic workup for these patients. We have shown that these tests can be 
undertaken rapidly and reliably using commercially available probes on small 
amounts of patient material, providing results within days o f patient presentation. 
Thus clinicians can make rapid decisions regarding treatment options.
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